{"text": "The first - line treatment for this subtype of breast cancers is the HER2 monoclonal antibody trastuzumab .In combination with cytotoxic chemotherapy , trastuzumab has revolutionized treatment and clinical outcome for patients whose breast tumors express high levels of the HER2 protein .", "label": "", "metadata": {}, "score": "15.967509"}
{"text": "Evaluation of monoclonal humanized anti - HER2 antibody , trastuzumab , in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2 : A phase II trial of the Gynecologic Oncology Group .", "label": "", "metadata": {}, "score": "16.596004"}
{"text": "Since 2005 , major progresses have been made in the neoadjuvant treatment of HER2-positive breast cancer .Trastuzumab introduction associated with chemotherapy has been the first major step leading to the improvement of the complete pathological response rate and , like in the adjuvant studies , better survivals .", "label": "", "metadata": {}, "score": "18.30873"}
{"text": "Numerous new agents have been developed that target specific molecules on cancer cells , including the monoclonal antibody trastuzumab , which targets Her2/neu and has been very beneficial in the treatment of breast cancer .", "label": "", "metadata": {}, "score": "18.833046"}
{"text": "Approximately 15 - 25 % of breast cancers overexpress HER2 , and tend to grow faster and more aggressively than tumors not overexpressing HER2 .Trastuzumab is an antibody used in the treatment of breast cancers that will be more completely explored in Part Two , which discusses antibody targeted therapies .", "label": "", "metadata": {}, "score": "19.794926"}
{"text": "Moreover , they stated that despite the higher rates of cardiac events , 12 months of adjuvant trastuzmab should remain the standard of care .Sorscher ( 2013 ) stated that trastuzumab is a monoclonal antibody targeting HER-2 ; and HER-2 over - expression has been described in gallbladder cancer and in cholangiocarcinoma .", "label": "", "metadata": {}, "score": "19.829279"}
{"text": "If successful , this type of strategy could be used to lighten or to reinforce future neoadjuvant treatments .Conclusion .Trastuzumab ( Herceptin ) has been a breakthrough in the treatment of HER2-positive breast cancer .", "label": "", "metadata": {}, "score": "20.723068"}
{"text": "The design of future prospective clinical trials in HER2-positive breast cancer should ideally be guided by predictive biomarkers .However , this significantly increases the complexity of randomised studies since a variety of mechanisms of resistance may exist in a patient population , and in reality , it is likely to take years before trastuzumab resistance biomarker - directed treatment approaches may be integrated into routine clinical practice .", "label": "", "metadata": {}, "score": "21.496162"}
{"text": "Despite this notable success , 70 % of patients with HER2-positive breast cancers demonstrate intrinsic or secondary resistance to trastuzumab [ 4 ] , highlighting the importance of developing new therapies for this disease .", "label": "", "metadata": {}, "score": "21.609055"}
{"text": "Trastuzumab resistance poses a significant challenge in the treatment of HER2-positive breast cancer .Substantial research has been dedicated to elucidating mechanisms of trastuzumab resistance , as well as developing a myriad of novel anti - HER2 therapeutic agents with promising clinical activity .", "label": "", "metadata": {}, "score": "22.5178"}
{"text": "The trastuzumab monoclonal antibody seeks out and binds to the specific HER2 or HER2/neu receptors on the surface of HER2 over - expressing breast cancer cells and directly inhibits tumor cell growth .", "label": "", "metadata": {}, "score": "22.537857"}
{"text": "The introduction of the humanized monoclonal antibody trastuzumab dramatically improved DFS and OS in this subgroup .As the majority of patients with metastatic disease ultimately develop resistance to trastuzumab , a need exists for more effective targeted therapies .", "label": "", "metadata": {}, "score": "22.561146"}
{"text": "Because of the infrequency of HER2 over - expression , and the absence of improved outcomes in patients with non - small cell lung cancer who were treated with trastuzumab plus chemotherapy in other studies , neither regimen tested will be advanced to a Phase III clinical trial .", "label": "", "metadata": {}, "score": "22.734196"}
{"text": "Multi - center co - operative group clinical trials are required to assess novel therapies to maximize patient resources in this uncommon tumor .Fleming et al ( 2010 ) evaluated the effectiveness of single - agent trastuzumab against advanced or recurrent HER2-positive endometrial carcinoma ( EC ) , and explored predictors for HER2 amplification .", "label": "", "metadata": {}, "score": "22.821209"}
{"text": "Furthermore , combinations of trastuzumab and drugs targeting the downstream pathway were described .The authors concluded that dual blockade is likely to represent a substantial advance for patients with HER2-positive breast cancer .", "label": "", "metadata": {}, "score": "23.206667"}
{"text": "The authors concluded that 2 years of adjuvant trastuzumab is not more effective than is 1 year of treatment for patients with HER2-positive early breast cancer .", "label": "", "metadata": {}, "score": "23.335052"}
{"text": "It is administered intravenously and is believed to work by targeting a different part of the HER - protein than trastuzumab , resulting in further reduction in growth and survival of HER2-positive breast cancer cells .", "label": "", "metadata": {}, "score": "23.351803"}
{"text": "Trastuzumab , an anti - HER2 monoclonal antibody , improves outcome in women with early and metastatic breast cancer .Resistance to trastuzumab involves the phosphoinositide 3-kinase / mammalian target of rapamycin ( PI3K / mTOR ) pathway , truncation of the Her2 receptor or lack of immune response .", "label": "", "metadata": {}, "score": "24.103712"}
{"text": "In addition , a large proportion of HER2-positive patients relapsing with metastatic disease in the future will have received adjuvant trastuzumab or even lapatinib therapy , indicating that new treatment paradigms will be required for this group of patients .", "label": "", "metadata": {}, "score": "24.123383"}
{"text": "Combining HER2-targeted therapies or combining therapies targeted against mediators of resistance with trastuzumab has shown success in preclinical models of trastuzumab - na\u00efve and resistant breast cancer .", "label": "", "metadata": {}, "score": "24.241365"}
{"text": "The development of trastuzumab represents a major advance in the treatment of breast cancer .Subsets of patients who acquire resistance to trastuzumab now have multiple therapeutic regimens available to further prolong progression - free survival .", "label": "", "metadata": {}, "score": "24.332209"}
{"text": "The authors believed this to be the first demonstration of Her-2/neu amplification in a malignant skin adnexal tumor .In analogy to breast carcinoma , these findings suggested the applicability of trastuzumab for patients with metastatic adnexal carcinomas demonstrating Her-2/neu amplification .", "label": "", "metadata": {}, "score": "24.358814"}
{"text": "Therefore , routine testing for HER2 over - expression or HER2 amplification would not be of benefit in this patient population .These results also imply that anti - HER2 therapy with trastuzumab is highly unlikely to provide benefit for patients with metastatic melanoma .", "label": "", "metadata": {}, "score": "24.868475"}
{"text": "Preclinical studies have demonstrated the enhanced efficacy of this agent compared to unconjugated trastuzumab in both trastuzumab - sensitive as well as in trastuzumab - resistant HER2-overexpressing tumour models [ 50 , 51 ] .", "label": "", "metadata": {}, "score": "24.932137"}
{"text": "The selection was limited to neoadjuvant randomised clinical trials that include HER2 + breast cancer .Trials investigating trastuzumab as the only HER2 agent were excluded from the review as we wished to focus on the neoadjuvant trials introducing novel therapies for early breast cancer .", "label": "", "metadata": {}, "score": "25.639378"}
{"text": "Two FISH kits for HER2 are now available : PathVysion from Visis ; and Inform , developed by Oncor and now marketed by Ventana .Tumors that are candidates for trastuzumab therapy can be detected at the DNA level by FISH assays because there is a high correlation between over - expression of the HER2 protein and amplification of the gene that codes for it .", "label": "", "metadata": {}, "score": "25.692802"}
{"text": "There is now strong evidence of differential response to trastuzumab in ER - positive versus ER - negative HER2-overexpressing breast cancer .Increased HER2 signaling has been well documented in models of acquired resistance to ER - targeted therapies , with current efforts focused on testing anti - HER2 strategies against tamoxifen - resistant disease [ 28 , 165 , 166 ] .", "label": "", "metadata": {}, "score": "25.924534"}
{"text": "The combination was well tolerated , and importantly , the incidence of cardiac dysfunction was minimal [ 46 ] .Further support for the potential development of this chemotherapy - free anti - HER2 combination was derived from the recently completed phase II NeoSphere study , which evaluated the efficacy of preoperative pertuzumab , trastuzumab , or their combination , with or without docetaxel in HER2-positive early - stage breast cancer .", "label": "", "metadata": {}, "score": "26.041595"}
{"text": "However , only the PathVysion FISH test has been approved by the FDA for selecting patients with metastatic breast cancer for trastuzumab therapy .FISH assays of HER2 gene amplification have been found to have a high correlation with immunochemical antibody assays for HER2 over - expression .", "label": "", "metadata": {}, "score": "26.315956"}
{"text": "A potential treatment strategy is to simultaneously block ER and HER2 , avoiding chemotherapy , in ER - positive / HER2-positive cancers .Again , molecular profiling will be critical for identifying those individuals who will benefit from such an approach versus patients who should continue to be treated with trastuzumab plus chemotherapy or another combination of HER2-targeted therapies .", "label": "", "metadata": {}, "score": "26.33928"}
{"text": "In one initial trial of adjuvant trastuzumab in 42 patients with early stage invasive operable HER2-positive breast cancer , 23 received chemotherapy plus trastuzumab and 19 received chemotherapy alone [ 54 ] .", "label": "", "metadata": {}, "score": "26.450298"}
{"text": "Preliminary results of a randomised phase II study ( TDM4450 g ) of T - DM1 versus trastuzumab plus docetaxel ( TH ) in the first - line treatment of HER2-positive metastatic breast cancer patients were recently released .", "label": "", "metadata": {}, "score": "26.47719"}
{"text": "There was no clinically significant short - term cardiotoxicity in patients treated with trastuzumab and doxorubicin .The authors concluded that despite intensive chemotherapy plus trastuzumab for patients with HER2-positive disease , the outcome for all patients was poor , with no significant difference between the HER2-positive and HER2-negative groups .", "label": "", "metadata": {}, "score": "26.71857"}
{"text": "They stated that definitive assessment of trastuzumab 's potential role in treating osteosarcoma would require a randomized study of patients with HER2-positive disease .", "label": "", "metadata": {}, "score": "26.722298"}
{"text": "A recently published phase II , open - label study evaluated the efficacy and tolerability of neratinib monotherapy in two cohorts of patients with HER2-positive metastatic breast cancer : those with and those without prior trastuzumab treatment .", "label": "", "metadata": {}, "score": "27.054459"}
{"text": "Taken together , our results indicate that kinases regulating mitosis and immune functions convey distinct prognostic information that varies by clinical subtype ... .Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer .", "label": "", "metadata": {}, "score": "27.280006"}
{"text": "Continuing strategies to overcome trastuzumab resistance include the development of a class of agents known as trifunctional , bispecific antibodies .MM-111 is an antibody targeting both the HER2/HER3 heterodimer and the HER3 ligand , heregulin , and is currently being evaluated in combination with trastuzumab in HER2-overexpressing metastatic breast cancer patients with prior trastuzumab exposure ( NCT01097460 ) [ 81 ] .", "label": "", "metadata": {}, "score": "27.554047"}
{"text": "In addition to reduced drug - target interactions possibly due to epitope masking , sustained activation of HER2 in the presence of trastuzumab treatment has been reported .", "label": "", "metadata": {}, "score": "27.763025"}
{"text": "Trastuzumab .Several randomized trials have evaluated , in the neoadjuvant setting , the role of trastuzumab ( Herceptin , Roche laboratory ) , a recombinant humanized monoclonal antibody that targets HER2 receptor .", "label": "", "metadata": {}, "score": "27.771837"}
{"text": "It is an immunohistochemical antibody assay designed for the detection of HER2 over - expression of HER2/neu protein using specific antibodies , and localizes over - expressed protein in cells or tissues .", "label": "", "metadata": {}, "score": "27.938206"}
{"text": "In addition , complete or partial remission of patients treated with neoadjuvant trastuzumab was correlated with tumor infiltration of immune cells and higher in vitro ADCC activity in lysis assays [ 108 ] .", "label": "", "metadata": {}, "score": "27.973984"}
{"text": "Research published during the past decade has identified multiple molecular mechanisms contributing to trastuzumab resistance .In addition , recent studies have suggested novel combinations of drugs that will benefit patients who have shown disease progression on prior trastuzumab treatment , including combinations of HER2-directed drugs and drugs targeted against the molecular drivers of resistance .", "label": "", "metadata": {}, "score": "28.15572"}
{"text": "Efficacy results from the ToGA trial : A phase III study of trastuzumab added to standard chemotherapy ( CT ) in first - line human epidermal growth factor receptor 2 ( HER2)-positive advanced gastric cancer ( GC ) .", "label": "", "metadata": {}, "score": "28.279507"}
{"text": "About 20 percent of breast cancers have increased amounts of the HER2 protein .\" This research provided the background to combine two targeted drugs - trastuzumab and Perjeta with docetaxel to slow disease progression in breast cancer .", "label": "", "metadata": {}, "score": "28.423618"}
{"text": "Although an increased number of NK cells and ADCC were documented , these did not correlate with clinical response .Another study failed to show benefit from the addition of IL-12 to trastuzumab in the majority of the 12 patients with HER2-positive breast cancer [ 113 ] .", "label": "", "metadata": {}, "score": "28.44574"}
{"text": "Future studies will have to address how to best select the optimal therapeutic strategy for each patient .Molecular profiling using cutting - edge genomic and proteomic approaches will allow for individualized approaches to be implemented and will help to establish a molecular signature predicting trastuzumab resistance .", "label": "", "metadata": {}, "score": "28.62047"}
{"text": "The use of trastuzumab is considered as standard of care both in early and metastatic HER2 over - expressing breast cancer .Numerous clinical trials have confirmed that trastuzumab improves overall survival ( OS ) in metastatic breast cancers [ 11 - 13 ] .", "label": "", "metadata": {}, "score": "28.62247"}
{"text": "In addition , a subset of patients with early - stage or metastatic disease may eventually acquire resistance to trastuzumab , as is the case with many molecularly targeted cancer therapies .", "label": "", "metadata": {}, "score": "28.727373"}
{"text": "In a multi - center , phase II clinical study , Clamon and colleagues ( 2005 ) determined whether trastuzumab would effect responses in patients with non - small cell lung carcinoma who had tumors that over - expressed HER2 .", "label": "", "metadata": {}, "score": "28.93378"}
{"text": "They note that , in general , cisplatin or carboplatin and etoposide are recommended as primary treatment .The NCCN Compendium has no recommendation for use of trastuzumab ( Herceptin ) for small cell lung cancer or neuroendocrine tumors .", "label": "", "metadata": {}, "score": "28.97242"}
{"text": "Patients with HER2-positive tumors were also randomized to receive trastuzumab or not .In the 512 eligible patients for efficacy , the pCR rate was significantly higher after neoadjuvant EDC ( 23.8 % versus 15.2 % , . )", "label": "", "metadata": {}, "score": "29.160603"}
{"text": "Neither HER2 over - expression nor HER2 amplification appeared to be associated with progression - free survival or OS .The authors concluded that trastuzumab as a single agent did not exhibit activity against endometrial carcinomas with HER2 over - expression or HER2 amplification , although full planned accrual of women with HER2 amplified tumors was not achieved due to slow recruitment .", "label": "", "metadata": {}, "score": "29.242924"}
{"text": "Trastuzumab achieved significant regression of human HER2-overexpressing tumor xenografts as monotherapy or in combination with cytotoxic chemotherapeutic agents [ 36 - 38 ] .", "label": "", "metadata": {}, "score": "29.320404"}
{"text": "The clinical support for combining HER2-targeted agents and the potential molecular mechanisms of synergy between these agents are discussed below .In addition , we review rationale and strategies for combined blockade of critical pathways mediating resistance and trastuzumab .", "label": "", "metadata": {}, "score": "29.523077"}
{"text": "It is also being evaluated in early - stage disease both in the neoadjuvant and adjuvant settings ( NCT01008150 and NCT00878709 ) .These data warrant further investigations to clarify the utility of this anti - HER2 combination .", "label": "", "metadata": {}, "score": "29.610802"}
{"text": "J Clin Oncol 2002 , 20 : 719 - 726 .PubMed View Article .Eiermann W , International Herceptin Study Group : Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer : pivotal trial data .", "label": "", "metadata": {}, "score": "29.709652"}
{"text": "Recently , trastuzumab has emerged as the first targeted drug to improve OS when combined with chemotherapy in advanced HER2-positive gastric cancer .Primary and secondary resistance to trastuzumab has become a major problem and new strategies to overcome this resistance are needed .", "label": "", "metadata": {}, "score": "29.878063"}
{"text": "A preclinical study employing a large - scale functional RNA interference screen detected PTEN as the main modulator of trastuzumab sensitivity in a HER2-overexpressing breast cancer cell line .", "label": "", "metadata": {}, "score": "29.977863"}
{"text": "The prevalence of HER2 over - expression / amplification in various tumor types raises the possibility of using trastuzumab to antagonize the abnormal function of over - expressed HER2 receptors in HER2-positive tumors other than breast .", "label": "", "metadata": {}, "score": "30.152401"}
{"text": "The anti - tumor activity with the significant reduction in the risk of progression or death , as reflected upon the increase of 6.1 months in median PFS , indicates that pertuzumab may provide an avenue for achieving additional benefit for patients with HER2(+ ) .", "label": "", "metadata": {}, "score": "30.264984"}
{"text": "The dual anti - HER2 combination of pertuzumab and trastuzumab has been evaluated without chemotherapy in the open - label , phase II BO17929 study conducted on HER2-positive metastatic breast cancer patients with prior trastuzumab failure , yielding extremely promising results .", "label": "", "metadata": {}, "score": "30.379732"}
{"text": "In this paper , we will discuss proposed mechanisms of trastuzumab resistance , including epitope masking , cross signaling from other cell surface receptors , hyperactive downstream signaling , and failure to induce antibody - dependent cellular cytotoxicity .", "label": "", "metadata": {}, "score": "30.533293"}
{"text": "It has demonstrated activity in trastuzumab - resistant HER2-overexpressing cell lines as well as promising clinical activity in phase I development [ 61 ] .", "label": "", "metadata": {}, "score": "30.612675"}
{"text": "With the emergence of several novel HER2-directed agents , recent therapeutic advancements have been remarkable compared to the limited progress following the initial regulatory approval of trastuzumab more than a decade ago .", "label": "", "metadata": {}, "score": "30.635971"}
{"text": "A high percentage of advanced HER2-positive gastric cancer patients who progress on trastuzumab therapy are candidates for second - line therapy .An UpToDate review on \" Treatment protocols for colorectal cancer \" ( Brenner et al , 2013 ) does not mention the use of ado - trastuzumab or trastuzumab as a therapeutic option .", "label": "", "metadata": {}, "score": "30.65004"}
{"text": "Although the study did not evaluate the effect of treatment on survival , prior studies have shown that pCR correlates with improved disease outcomes in patients treated with trastuzumab and chemotherapy .", "label": "", "metadata": {}, "score": "30.905071"}
{"text": "There was no limit on prior therapy although total prior doxorubicin dose was limited to 320 mg / m(2 ) .Tumors were required to have HER2 over - expression ( 2 + or 3 + immunohistochemical staining ) or HER2 amplification ( FISH HER2/CEP 17 ratio greater than 2.0 ) .", "label": "", "metadata": {}, "score": "31.001972"}
{"text": "At least three HSP90 inhibitors have undergone clinical investigation in HER2-positive breast cancer , and to date , all have been evaluated in combination with trastuzumab .", "label": "", "metadata": {}, "score": "31.022972"}
{"text": "These include HER2 -amplified breast cancer cell lines that display primary resistance , meaning they do not undergo growth inhibition upon trastuzumab treatment despite lack of prior trastuzumab exposure .", "label": "", "metadata": {}, "score": "31.135252"}
{"text": "The combination treatment with trastuzumab and pertuzumab has shown strongly enhanced antitumor activity in xenograft models with reduction in the levels of HER proteins [ 56 ] .", "label": "", "metadata": {}, "score": "31.164423"}
{"text": "109 - 119 , 2012 .View at Google Scholar . A. Valachis , D. Mauri , N. P. Polyzos , et al . , \" Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer : a systematic review and meta - analysis , \" Breast , vol .", "label": "", "metadata": {}, "score": "31.299906"}
{"text": "R. Nahta , M. C. Hung , and F. J. Esteva , \" The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells , \" Cancer Research , vol .", "label": "", "metadata": {}, "score": "31.32318"}
{"text": "As the examples of trastuzumab for breast cancer and gefitinib for lung cancer treatment illustrate , knowledge of the appropriate patient population for a novel targeted therapy can make the difference between a blockbuster drug and a drug that never makes it to market [ 62 - 66 ] .", "label": "", "metadata": {}, "score": "31.405052"}
{"text": "Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer : a 4-year follow - up of a randomised controlled trial .", "label": "", "metadata": {}, "score": "31.454203"}
{"text": "In HER2-positive breast cancer , randomized studies with and without anthracyclines have demonstrated the essential role of anti - HER2 therapies in obtaining increased pathological complete response rates and good long - term results .", "label": "", "metadata": {}, "score": "31.482738"}
{"text": "The investigators concluded that this randomized trial investigating anti - HER2 therapy in advanced gastric cancer showed that herceptin plus chemotherapy is superior to chemotherapy alone .", "label": "", "metadata": {}, "score": "31.486492"}
{"text": "This was the first systematic review / pooled analysis to synthesize all available data evaluating the safety and effectiveness of intra - thecal ( IT ) administration of trastuzumab for the treatment of MC in HER2-positive breast cancer patients .", "label": "", "metadata": {}, "score": "31.695595"}
{"text": "These data warrant further investigation of simultaneous HER1/EGFR TKI inhibition and HER1/HER2 dimerization inhibition for colorectal cancer therapy .El - Sahwi et al ( 2010 ) evaluated pertuzumab activity separately or in combination with trastuzumab against primary uterine serous papillary adenocarcinoma ( USPC ) cell lines expressing different levels of HER2/neu .", "label": "", "metadata": {}, "score": "31.805527"}
{"text": "These findings confirmed the efficacy of dual anti - HER2 blockade in the context of a chemotherapy - free regimen associated with minimal toxicities .Table 1 : Pertinent clinical trials of novel HER2-directed therapies in HER2-positive breast cancer .", "label": "", "metadata": {}, "score": "31.895927"}
{"text": "Steric Hindrance of Receptor - Antibody Interaction .The binding between trastuzumab and HER2 may be disrupted by the membrane - associated glycoprotein mucin-4 ( MUC4 ) , as evidenced by the overexpression of MUC4 in a trastuzumab - resistant breast cancer cell line and subsequent restoration of trastuzumab binding through MUC4 siRNA knockdown [ 28 ] .", "label": "", "metadata": {}, "score": "31.910536"}
{"text": "The phase III TH3RESA trial compared third line treatment ( including trastuzumab and lapatinib ) of metastatic or unresectable locally advanced or recurrent HER2 positive breast cancer with T - DM1 to the treatment of the physician 's choice .", "label": "", "metadata": {}, "score": "31.91486"}
{"text": "In the future , these studies may lead to a reduction in overtreatment with chemotherapy , as they may identify patients with excellent response to targeted therapy alone that can be evaluated in a future chemotherapy - sparing study .", "label": "", "metadata": {}, "score": "31.969357"}
{"text": "In a randomized controlled phase II clinical trial , Krug et al ( 2005 ) examined whether combined trastuzumab with weekly taxanes would improve outcomes over standard chemotherapy in patients with advanced non - small cell lung cancer .", "label": "", "metadata": {}, "score": "32.01519"}
{"text": "T - DM1 is the first and only HER2-directed ADC in clinical development and combines the intracellular delivery of a microtubule - depolymerisation agent , DM1 , a maytansine derivative , with the antitumour activity of trastuzumab .", "label": "", "metadata": {}, "score": "32.029396"}
{"text": "In this clinical trial , overall response rates were 43 % with trastuzumab and chemotherapy , compared to only 28 % in women treated with chemotherapy alone .", "label": "", "metadata": {}, "score": "32.040237"}
{"text": "The traditional model of conducting initial trials in metastatic breast cancer patients with refractory disease following standard therapy has been disappointing , as it demands a lot of effort and requires a long time before the drug reaches adjuvant registration .", "label": "", "metadata": {}, "score": "32.07989"}
{"text": "J Clin Oncol .Lara PN Jr , Laptalo L , Longmate J , et al . ; California Cancer Consortium .Trastuzumab plus docetaxel in HER2/neu - positive non - small - cell lung cancer : A California Cancer Consortium screening and phase II trial .", "label": "", "metadata": {}, "score": "32.087654"}
{"text": "Among 96 evaluable patients with newly diagnosed metastatic osteosarcoma , 41 had tumors that were HER2-positive by immunohistochemistry .All patients received chemotherapy with cisplatin , doxorubicin , methotrexate , ifosfamide , and etoposide .", "label": "", "metadata": {}, "score": "32.099823"}
{"text": "Trastuzumab can also induce responses in patients with HER2 over - expressing metastatic breast cancers who have failed to respond to chemotherapy .In a trial of 222 women who had failed 1 or 2 prior chemotherapy regimens , 14 % of women treated with trastuzumab alone had objective tumor responses with tumor shrinkage of 50 % or more .", "label": "", "metadata": {}, "score": "32.14958"}
{"text": "An UpToDate review on \" Ampullary carcinoma : Treatment and prognosis \" ( Ryan et al , 2015 ) does not mention the use of trastuzumab as a therapeutic option .", "label": "", "metadata": {}, "score": "32.221916"}
{"text": "The development of novel targeted therapies has changed the practices in metastatic settings .New standards of care include trastuzumab plus pertuzumab plus docetaxel in first line treatment and TDM-1 for trastuzumab - resistant patients .", "label": "", "metadata": {}, "score": "32.229015"}
{"text": "Two NCI cooperative group trials , NSABP B-31 and NCCTG N9831 , showed that amongst 3752 women with HER2-overexpressing breast cancer who received adjuvant chemotherapy , and radio- or endocrine therapy as appropriate , those who also received trastuzumab were significantly less likely to have disease progression .", "label": "", "metadata": {}, "score": "32.245552"}
{"text": "Novel Chemotherapy - Free Anti - HER2 Combinations .Rational combinations of novel anti - HER2 therapies are of particular interest not only because of their ability to overcome trastuzumab resistance through their concurrent blockade of multiple HER2 family members , but also for their potential to offer chemotherapy - free therapeutic options that are relatively less toxic .", "label": "", "metadata": {}, "score": "32.39399"}
{"text": "The standard of care is 1 year of adjuvant trastuzumab , but the optimum duration of treatment is unknown .The HERA trial was an international , multi - center , randomized , open - label , phase III clinical trial comparing treatment with trastuzumab for 1 and 2 years with observation after standard neoadjuvant chemotherapy , adjuvant chemotherapy , or both in 5,102 patients with HER2-positive early breast cancer .", "label": "", "metadata": {}, "score": "32.46131"}
{"text": "The authors concluded that these findings suggested that drugs that specifically target Her2/neu are not likely to be useful for the treatment of metastatic melanoma or as adjuvant therapy for melanoma patients at high risk for recurrence .", "label": "", "metadata": {}, "score": "32.476524"}
{"text": "The authors concluded that further studies in clinical samples are needed to confirm these findings and the interest of combining anti - HER2 and anti - HER3 therapeutic antibodies .", "label": "", "metadata": {}, "score": "32.48606"}
{"text": "This paper summarizes existing preclinical and clinical evidence on the mechanisms of trastuzumab action and resistance and provides an up - to - date overview of novel HER2-directed therapies in clinical development .", "label": "", "metadata": {}, "score": "32.489426"}
{"text": "Neoadjuvant systemic therapy is frequently used option for the systemic treatment for breast cancer .Inclusion in the regimen of targeted drugs ( e.g. , trastuzumab and pertuzumab ) significantly improves outcomes in HER2-positive breast cancer patients ( Semiglazov et al , 2013 ) .", "label": "", "metadata": {}, "score": "32.565216"}
{"text": "Trial Study Team . 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer ( HERA ) : An open - label , randomised controlled trial .", "label": "", "metadata": {}, "score": "32.604393"}
{"text": "We previously reviewed the data suggesting that the pathologic complete response rates to trastuzumab - based treatment are lower in patients with the highest ER expression levels in HER2-positive breast cancer [ 167 ] .", "label": "", "metadata": {}, "score": "32.69846"}
{"text": "Latif et al concluded that \" [ t[]e role of trastuzumab in these tumours remains untested at present . \" The investigators reported , however , that patients with 3 + HER2/neu expression did well in contrast to historical data suggesting potential benefit for trastuzumab in this rare subset of non - small cell lung cancer .", "label": "", "metadata": {}, "score": "32.772953"}
{"text": "The authors concluded that IT administration seems to represent a safe and in some cases effective option for the treatment of HER2-positive breast cancer patients with leptomeningeal involvement .", "label": "", "metadata": {}, "score": "32.831017"}
{"text": "The development of even more robust chemotherapy - free anti - HER2 combinations , driven by a clearer understanding of basic scientific mechanisms , is highly anticipated to improve HER2-directed therapeutic strategies in the future .", "label": "", "metadata": {}, "score": "32.841892"}
{"text": "ML 22229 , Eudract no .2009 - 013410 - 26 , NCT01142778 ) aiming at confirming the role of early PET to differentiate the excellent responders to HER2 neoadjuvant trastuzumab - based therapy from the less responders who are then randomized to additional neoadjuvant bevacizumab [ 64 ] .", "label": "", "metadata": {}, "score": "32.909134"}
{"text": "Three randomised studies in the neoadjuvant setting have evaluated the additional of trastuzumab to standard therapy ( Table 2 ) .Interestingly , both of these studies administered anthracycline chemotherapy concurrently with trastuzumab and did not report a high rate of observed cardiac toxicity .", "label": "", "metadata": {}, "score": "32.92306"}
{"text": "Of potential translational importance , the HER3 surrobodies showed stronger antitumor activity combined with trastuzumab versus pertuzumab and trastuzumab combined and were as effective in combination with lapatinib as was trastuzumab plus lapatinib against HER2-overexpressing breast xenografts .", "label": "", "metadata": {}, "score": "33.115276"}
{"text": "The role of trastuzumab in abrogating the PI3K / Akt signaling pathway has been addressed in two preclinical studies , where treatment of HER2-gene - amplified breast cancer cells with trastuzumab caused growth inhibition through PTEN upregulation and downregulation of PI3 K activity and Akt function [ 12 , 13 ] .", "label": "", "metadata": {}, "score": "33.123688"}
{"text": "The limited information in the node - negative group did not allow for a separate analysis of this group .In these studies , the likelihood of congestive heart failure in women receiving standard combination chemotherapy and trastuzumab was increased by 3 % to 4 % .", "label": "", "metadata": {}, "score": "33.12529"}
{"text": "The pathologic complete response rate for the trastuzumab group was 65 % , compared to 26 % in the chemotherapy alone group .The 4-year followup of NSABP B-31 and NCCTG N9831 trials showed sustained significant reduction in disease - free survival for patients treated with trastuzumab [ 55 ] .", "label": "", "metadata": {}, "score": "33.167053"}
{"text": "The authors concluded that addition of pertuzumab to carboplatin - based chemotherapy did not substantially prolong PFS in unselected patients with platinum - sensitive ovarian cancer .", "label": "", "metadata": {}, "score": "33.337112"}
{"text": "Adjuvant trastuzumab was administered only in patients randomized to receive trastuzumab preoperatively for one year ( excepted for 7 % of patients ) .There was a 41 % reduction in risk of recurrence , progression , or death with addition of trastuzumab . , although 19 ( 16 % ) patients with HER2-positive disease assigned to chemotherapy alone crossed over to receive adjuvant trastuzumab [ 8 ] .", "label": "", "metadata": {}, "score": "33.422287"}
{"text": "Kumler et al ( 2014 ) stated that HER2 is over - expressed in 15 to 20 % of all breast cancers .Treatment with trastuzumab has led to an improved outcome and prolonged survival of HER2-positive breast cancer patients and today the drug is established as standard of care in both the adjuvant and metastatic settings .", "label": "", "metadata": {}, "score": "33.446632"}
{"text": "C. L. Vogel , M. A. Cobleigh , D. Tripathy et al . , \" Efficacy and safety of trastuzumab as a single agent in first - line treatment of HER2-overexpressing metastatic breast cancer , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "33.4707"}
{"text": "Intended for patients who have not received prior treatment for metastatic breast cancer with an anti - HER2 therapy or chemotherapy , Perjeta is combined with trastuzumab , another anti - HER2 therapy , and docetaxel , a type of chemotherapy .", "label": "", "metadata": {}, "score": "33.53807"}
{"text": "With the emergence of new anti HER2 therapies like lapatinib ( Tyverb ) , pertuzumab ( Tarjeta ) and TDM1 ( Kacyla ) , dual HER2 blockade , still associated with chemotherapy , has proven to be superior .", "label": "", "metadata": {}, "score": "33.56857"}
{"text": "Preclinical studies have shown a synergism between trastuzumab and anti - PD1 antibodies [ 82 ] .Other monoclonal antibody ( mAb)-based therapies are being investigated including anti CD73 .", "label": "", "metadata": {}, "score": "33.59733"}
{"text": "In a recent meta - analysis , Valachis et al .studied the overall effect of neoadjuvant trastuzumab on BCS [ 35 ] .Breast - conserving surgery is scarcely described even in the randomized studies and the number of patients who underwent BCS was available in only four trials [ 35 ] .", "label": "", "metadata": {}, "score": "33.600193"}
{"text": "The study compared 1 or 2 years of trastuzumab given every 3 weeks with observation in women with HER2-positive and either node - negative or node - positive breast cancer who had completed locoregional therapy ( surgery with or without radiotherapy ) and at least 4 cycles of neoadjuvant or adjuvant chemotherapy .", "label": "", "metadata": {}, "score": "33.68724"}
{"text": "We will also discuss data supporting therapeutic combinations of trastuzumab with agents targeted against molecules implicated in trastuzumab resistance .Finally , we will examine the major issues that need to be addressed in order to translate these combinations from the bench to the clinic .", "label": "", "metadata": {}, "score": "33.748566"}
{"text": "Inhibition of Angiogenesis .Mechanisms of Trastuzumab Resistance .Understanding the mechanisms behind trastuzumab resistance is a critical step towards the development of novel anti - HER2 strategies .", "label": "", "metadata": {}, "score": "33.860718"}
{"text": "Interestingly , a promising pCR rate of 17.8 % was achieved with dual anti - HER2 blockade in the absence of chemotherapy , further highlighting the potential of combining two anti - HER2 agents with different mechanisms of action [ 48 ] .", "label": "", "metadata": {}, "score": "33.892593"}
{"text": "In another study , Herceptin therapy was administered weekly for 1 year .Four years into the study , 85 % of women with early - stage HER-2 positive breast cancer who received trastuzumab were free of recurrence , compared with 67 % of women who did not receive the drug .", "label": "", "metadata": {}, "score": "33.898468"}
{"text": "Multiple therapeutic approaches are now available for treating HER2-positive breast cancer .Molecular profiling of individual tumors may allow for rational selection of the optimal therapeutic strategy .", "label": "", "metadata": {}, "score": "33.93026"}
{"text": "In addition , a randomised phase II study has been planned to evaluate the efficacy of lapatinib versus trastuzumab in combination with first - line chemotherapy in metastatic patients whose tumours display concomitant overexpression of HER2 and p95HER2 ( NCT01137994 ) .", "label": "", "metadata": {}, "score": "34.061726"}
{"text": "Thus , cross - activation mechanisms that sustain trastuzumab resistance may be overcome by cotreatment with pertuzumab .In addition , trastuzumab has been shown to block cleavage of the extracellular domain ( ECD ) of HER2 , suppressing formation of constitutively active p95HER2 [ 47 ] .", "label": "", "metadata": {}, "score": "34.07948"}
{"text": "Combined treatment with trastuzumab and lapatinib in trastuzumab - na\u00efve HER2-overexpressing breast cancer cell lines showed synergistic inhibition of proliferation [ 131 ] .", "label": "", "metadata": {}, "score": "34.116066"}
{"text": "We previously showed that combining trastuzumab and pertuzumab in HER2-positive BT474 cells resulted in synergistic inhibition of proliferation , increased apoptosis , disruption of HER2-HER3 dimerization , and reduced Akt phosphorylation [ 154 ] .", "label": "", "metadata": {}, "score": "34.175438"}
{"text": "Verma and colleagues ( 2012 ) randomly assigned patients with HER2-positive advanced breast cancer , who had previously been treated with trastuzumab and a taxane , to T - DM1 or lapatinib plus capecitabine .", "label": "", "metadata": {}, "score": "34.187935"}
{"text": "Analysis of treatment sequencing may also be warranted , as one study demonstrated that chemotherapy followed by IGF - IR inhibition blocked growth of breast cancer cells , whereas inhibiting IGF - IR first actually suppressed chemotherapy - induced apoptosis [ 162 ] .", "label": "", "metadata": {}, "score": "34.21479"}
{"text": "Further to this , a three - arm randomised phase III study ( MARIANNE , NCT01120184 ) is underway to evaluate T - DM1 alone and T - DM1 combined with pertuzumab versus the reference arm of trastuzumab plus taxane in previously untreated patients with HER2-positive metastatic breast cancer .", "label": "", "metadata": {}, "score": "34.24071"}
{"text": "Trastuzumab - resistant cells retained sensitivity to pertuzumab and showed evidence of partial disruption of IGF - IR / HER2 dimerization in resistant cells [ 86 ] .", "label": "", "metadata": {}, "score": "34.28273"}
{"text": "Limited experience is available with angiogenesis inhibitors , apoptosis inhibitors and COX-2 inhibitors .As yet , targeted therapies are proven to be safe often in combination with chemo - radiation , but modestly effective for esophageal cancer .", "label": "", "metadata": {}, "score": "34.33297"}
{"text": "T cell infiltration is predictive for the efficacy of trastuzumab [ 73 - 76 ] .Biomarker studies have shown that PD-1 + TILs are associated with poor prognosis in HER2 positive breast cancer [ 77 , 78 ] and preliminary data also suggest a relationship between PD - L1 expression on tumor cells and objective response to anti PD-1 therapy [ 79 ] .", "label": "", "metadata": {}, "score": "34.64009"}
{"text": "Slamon D , Leyland - Jones B , Shak S , et al .Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 .", "label": "", "metadata": {}, "score": "34.647804"}
{"text": "Additional studies should examine HER2-positive breast tumors for HER2 kinase domain mutations and differential response to HER2-targeted reversible TKI lapatinib versus irreversible inhibitors .", "label": "", "metadata": {}, "score": "34.658997"}
{"text": "Bookman et al ( 2003 ) reported on the results of a Gynecology Oncology Group Phase II study of trastuzumab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with 2+/3 + HER2 expression .", "label": "", "metadata": {}, "score": "34.661137"}
{"text": "Zinner RG , Glisson BS , Fossella FV , et al .Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing , untreated , advanced non - small cell lung cancer : Report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease .", "label": "", "metadata": {}, "score": "34.679398"}
{"text": "As a result , a new pathway to accelerate the clinical development of emerging therapies is sorely needed .The identification of the central role of the human epidermal growth factor receptor 2 ( HER2 ) protein in the pathogenesis of HER2-overexpressing breast cancer is one of the greatest successes of modern oncology .", "label": "", "metadata": {}, "score": "34.806732"}
{"text": "Neratinib .Neratinib is an oral irreversible pan - HER inhibitor .Preclinical data on breast cancer cell lines suggest that it could overcome both primary and acquired trastuzumab resistance in HER2 positive breast cancer cell lines [ 43 ] .", "label": "", "metadata": {}, "score": "34.840088"}
{"text": "Serum markers offer a noninvasive method for predicting probability of responding to trastuzumab .Ultimately , creating a molecular signature of trastuzumab response or trastuzumab resistance may allow the best HER2-targeted therapy or combination of therapies to be selected .", "label": "", "metadata": {}, "score": "34.882385"}
{"text": "Loibl et al . reported the pCR ( noninvasive residuals in breast and lymph nodes ) and resistance rates in 153 patients included in the GeparQuattro study and then received neoadjuvant trastuzumab according to p95 expression in immunohistochemistry [ 50 ] .", "label": "", "metadata": {}, "score": "34.96113"}
{"text": "Another HSP90 inhibitor , AUY922 , is currently being evaluated in combination with trastuzumab in patients with trastuzumab - refractory HER2-positive metastatic breast cancer in a phase I / II study ( NCT01271920 ) .", "label": "", "metadata": {}, "score": "35.095665"}
{"text": "The effectiveness of pertuzumab and trastuzumab in conjunction with chemotherapy is currently being evaluated in the adjuvant setting .Zagouri et al ( 2013 ) carried out the first systematic review according to Preferred Reporting Items for Systematic Reviews and Meta - Analyses guidelines to synthesize all available data of pertuzumab in breast cancer .", "label": "", "metadata": {}, "score": "35.17463"}
{"text": "Similarly , favorable response rates have been achieved in patients with metastatic disease when trastuzumab was given as a single agent [ 56 - 58 ] or in combination with chemotherapeutic agents [ 59 - 61 ] .", "label": "", "metadata": {}, "score": "35.177856"}
{"text": "Using currently available models , potential mechanisms of trastuzumab resistance that have been identified include epitope masking , truncated HER2 , cross - signaling or compensatory signaling by other cell surface receptors , altered downstream signaling , and impaired immune function .", "label": "", "metadata": {}, "score": "35.17958"}
{"text": "This includes the development of antibody - drug conjugates , dual HER2 inhibition strategies , inhibition of PI3K / mTOR pathway and development of modulators of immune checkpoints .", "label": "", "metadata": {}, "score": "35.359474"}
{"text": "Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer .N Engl J Med .Romond EH , Perez EA , Bryant J , et al .", "label": "", "metadata": {}, "score": "35.37766"}
{"text": "Ebb D , Meyers P , Grier H , et al .Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression : A report from the children 's oncology group .", "label": "", "metadata": {}, "score": "35.426964"}
{"text": "Antibody - drug conjugates : T - DM1 .Trastuzumab emtansine ( T - DM1 ) is an antibody - drug conjugate and is composed of trastuzumab covalently linked to maytansine , a cytotoxic agent [ 61 ] .", "label": "", "metadata": {}, "score": "35.50187"}
{"text": "Even in the absence of targeted therapy against the HER2 signalling axis , HER2 + breast cancer demonstrates a higher rate of pCR to traditional neoadjuvant chemotherapy [ 9 ] .", "label": "", "metadata": {}, "score": "35.554436"}
{"text": "Future studies can improve upon these models by treating orthotopic xenografts of trastuzumab - sensitive cells until acquired resistant tumors emerge , and then isolating these tumors or their counterparts which retain sensitivity , and culturing these ex vivo .", "label": "", "metadata": {}, "score": "35.66962"}
{"text": "This assay may be of benefit for the treatment of metastatic , recurrent , or treatment - refractory unresectable locally advanced breast cancer .\" The HER2/neu is over - expressed / amplified in a range of other tumor types including ovarian , bladder , pancreatic , salivary gland , endometrial and non - small - cell lung cancer ( Scholl et al , 2001 ) .", "label": "", "metadata": {}, "score": "35.683987"}
{"text": "Other FDA - approved drugs used to treat HER2-positive breast cancer include trastuzumab ( 1998 ) , lapatinib ( 2007 ) and pertuzumab ( 2012 ) .", "label": "", "metadata": {}, "score": "35.780247"}
{"text": "After stratification based on the results of HER2 immunohistochemistry , chemotherapy - naive patients were randomized to receive trastuzumab plus docetaxel or trastuzumab plus paclitaxel .", "label": "", "metadata": {}, "score": "35.803635"}
{"text": "Pivot and associates ( 2013 ) noted that since 2005 , 12 months of adjuvant trastuzumab has been the standard treatment for patients with HER2-positive early - stage breast cancer .", "label": "", "metadata": {}, "score": "35.86415"}
{"text": "Trastuzumab , 10 mg .ICD-10 codes covered if selection criteria are met : .C50.011 - C50.929 .Malignant neoplasm of breast [ HER2-positive previously treated with trastuzumab ] [ not covered for HER2-negative breast cancer ] .", "label": "", "metadata": {}, "score": "35.904484"}
{"text": "These differences can be explained by various inclusion criteria , different type , and different duration of the regimens .Nonetheless , all the studies showed a higher pCR rate when trastuzumab was combined with chemotherapy compared to chemotherapy alone ( Table 1 ) .", "label": "", "metadata": {}, "score": "35.961246"}
{"text": "The finding of this case study needs to be validated by well - designed studies .Moreover , the NCCN 's clinical practice guideline on \" Hepatobiliary cancers \" ( Version 1.2014 ) does not mention the use of trastuzumab , pertuzumab , or ado - trastuzumab emtansine as a therapeutic option .", "label": "", "metadata": {}, "score": "36.093414"}
{"text": "We report updated results from our primary analysis to establish the long - term benefit of trastuzumab - containing neoadjuvant therapy ... .Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced , inflammatory , or early HER2-positive breast cancer ( NeoSphere ) : a randomised multicentre , open - label , phase 2 trial .", "label": "", "metadata": {}, "score": "36.139137"}
{"text": "The drug can also cause severe life - threatening birth defects , and pregnancy status should be verified prior to starting Kadcyla treatment .Pazo Cid and Anton ( 2013 ) stated that trastuzumab has emerged as the first targeted drug to improve OS when combined with chemotherapy in advanced HER2-positive gastric cancer .", "label": "", "metadata": {}, "score": "36.224113"}
{"text": "The authors concluded that T - DM1 has been shown to be a very promising agent for the targeted delivery of chemotherapy and anti - HER2 monoclonal antibody therapy for patients with HER2-positive MBC .", "label": "", "metadata": {}, "score": "36.224533"}
{"text": "The superiority of the pertuzumab - trastuzumab arm either in first - line metastatic setting or in the neoadjuvant setting leads to the initiation of the ongoing adjuvant trial with pertuzumab ( NCT01358877 ) .", "label": "", "metadata": {}, "score": "36.419167"}
{"text": "135 - 144 , 2012 .View at Google Scholar .V. Guarneri , A. Frassoldati , A. Bottini , et al . , \" Preoperative chemotherapy plus trastuzumab , lapatinib , or both in human epidermal growth factor receptor 2-positive operable breast cancer : results of the randomized phase II CHER - LOB study , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "36.474506"}
{"text": "Trastuzumab - associated cardiac events at 8 years of median follow - up in the Herceptin Adjuvant trial ( BIG 1 - 01 ) .To document the rate and outcome of trastuzumab - associated cardiac dysfunction in patients following 1 or 2 years of adjuvant therapy ... .", "label": "", "metadata": {}, "score": "36.529823"}
{"text": "Finally , HER2-positive cells that become \" coated \" in trastuzumab will be recognized by specific immune cells , causing antibody - dependent cellular cytotoxicity ( ADCC ) , or lysis of the antibody - bound cells [ 52 , 53 ] .", "label": "", "metadata": {}, "score": "36.559986"}
{"text": "The anti - tumor effects induced by Erb - hcAb on some cell lines were more potent than those observed for either Herceptin or 2C4 .", "label": "", "metadata": {}, "score": "36.565254"}
{"text": "Barginear MF , John V , Budman DR .Trastuzumab - DM1 : A clinical update of the novel antibody - drug conjugate for HER2-overexpressing breast cancer .", "label": "", "metadata": {}, "score": "36.63313"}
{"text": "In both this study and IDEAL-1 , single agent therapy with gefitinib produced radiographic response in 12%-18 % and improved symptoms in 40%-43 % of patients with advanced NSCLC who had failed chemotherapy .", "label": "", "metadata": {}, "score": "36.835796"}
{"text": "Lewis R , Bagnall AM , Forbes C , et al .The clinical effectiveness of trastuzumab for breast cancer : A systematic review .Health Technol Assess .", "label": "", "metadata": {}, "score": "36.897926"}
{"text": "ARRY-334543 , a reversible pan - HER TKI which has demonstrated significant preclinical activity in HER2-overexpressing tumour models and synergism with trastuzumab and docetaxel [ 64 ] , is currently being evaluated in early phase studies in advanced solid tumours ( NCT00710736 ) .", "label": "", "metadata": {}, "score": "36.94232"}
{"text": "Because it was recognized that constitutive HER2 signaling can drive breast tumor development and progression , strategies were developed to therapeutically target HER2 activity .The first successful approach began with the development of a mouse monoclonal antibody ( mAb ) [ 30 ] called 4D5 , which targets an extracellular epitope of the HER2 protein [ 31 ] .", "label": "", "metadata": {}, "score": "36.98855"}
{"text": "In addition , combination approaches that are currently being tested against trastuzumab - refractory cancers may enhance ADCC .For example , treatment with a combination of HER2-targeted antibodies that targeted distinct epitopes was shown to induce a greater level of ADCC in vitro than when cells were treated with trastuzumab alone [ 115 ] .", "label": "", "metadata": {}, "score": "37.090866"}
{"text": "Biomarkers for Response .Many studies reported different biomarkers for the prediction of the pCR after neoadjuvant chemotherapy in HER2-positive breast cancer .Nonetheless , no biomarker is clearly validated so far .", "label": "", "metadata": {}, "score": "37.16426"}
{"text": "Severe cardiotoxicity developed in 0.5 % of the women who were treated with trastuzumab .Fluorescent in situ hybridization ( FISH ) assays have also been validated for use in the selection of candidates for trastuzumab therapy .", "label": "", "metadata": {}, "score": "37.425514"}
{"text": "These investigators performed a non - inferiority trial of a shorter exposure of 6 months versus the standard 12 months of trastuzumab for patients with early breast cancer .", "label": "", "metadata": {}, "score": "37.431496"}
{"text": "\" Our study also supports investigation of novel targeted agents for breast cancer in the neoadjuvant setting , when tumors have not yet acquired resistance to therapy and when chances of clinical benefit are highest .", "label": "", "metadata": {}, "score": "37.444748"}
{"text": "2014 Aug 12 [ Epub ahead of print].Ado - Trastuzumab Emtansine ( Kadcyla ) : .Mathew J , Perez EA .Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer : A review .", "label": "", "metadata": {}, "score": "37.535374"}
{"text": "For pre - operative chemo - radiation , only 2 of 10 randomized trials showed advanced survival compared to surgery alone , and , therefore , more phase III trials and , consequently , meta - analyses are needed .", "label": "", "metadata": {}, "score": "37.65293"}
{"text": "Another ongoing phase III trial , MARIANNE ( NCT01120184 ) , compares single - agent T - DM1 to T - DM1 combined with pertuzumab to trastuzumab plus a taxane in first line treatment of metastatic breast cancer .", "label": "", "metadata": {}, "score": "37.671528"}
{"text": "Langer CJ , Stephenson P , Thor A , et al . ; Eastern Cooperative Oncology Group Study 2598 .Trastuzumab in the treatment of advanced non - small - cell lung cancer : Is there a role ?", "label": "", "metadata": {}, "score": "37.703484"}
{"text": "Chemotherapy for advanced gastric cancer .Cochrane Database Syst Rev. 2010;(3):CD004064 .Nash JW , Barrett TL , Kies M , et al .Metastatic hidradenocarcinoma with demonstration of Her-2/neu gene amplification by fluorescence in situ hybridization : Potential treatment implications .", "label": "", "metadata": {}, "score": "37.726982"}
{"text": "HER3 knockdown in BxPC-3 cells led to resistance to pertuzumab therapy .Pertuzumab treatment of HER3-expressing pancreatic cancer cells increased HER3 at the cell membrane , whereas the anti - HER3 monoclonal antibody 9F7-F11 down - regulated it .", "label": "", "metadata": {}, "score": "37.74276"}
{"text": "It is to be used in combination with trastuzumab and other chemotherapy prior to surgery and , depending upon the treatment regimen used , may be followed by chemotherapy after surgery .", "label": "", "metadata": {}, "score": "37.830757"}
{"text": "Cancer Control .Fornier M , Esteva FJ , Seidman AD .Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer .Semin Oncol .", "label": "", "metadata": {}, "score": "37.832664"}
{"text": "Disruption of dimerization by pertuzumab has been associated with reduced HER2 phosphorylation and growth inhibition of BT474 and MCF7 xenograft tumors [ 148 ] .A phase I trial tested trastuzumab plus pertuzumab in a trastuzumab - refractory population of 11 patients and showed a favorable response rate of 18 % with median time to progression of 6 months [ 150 ] .", "label": "", "metadata": {}, "score": "37.97669"}
{"text": "Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced , inflammatory , or early HER2-positive breast cancer ( NeoSphere ) : a randomised multicentre , open - label , phase 2 trial .", "label": "", "metadata": {}, "score": "37.999023"}
{"text": "Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced , inflammatory , or early HER2-positive breast cancer ( NeoSphere ) : A randomised multicentre , open - label , phase 2 trial .", "label": "", "metadata": {}, "score": "37.999023"}
{"text": "Krop IE , LoRusso P , Miller KD , et al .A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab , lapatinib , an anthracycline , a taxane , and capecitabine .", "label": "", "metadata": {}, "score": "38.02038"}
{"text": "It should be noted that there is even less evidence regarding the correlation between the extent of residual breast cancer burden following neoadjuvant targeted therapy ( with or without chemotherapy ) and survival [ 12 , 29 ] .", "label": "", "metadata": {}, "score": "38.055992"}
{"text": "These researchers therefore examined Her2/neu expression in a very large cohort of melanoma specimens in order to determine the value of exploring trastuzumab therapy for melanoma patients .", "label": "", "metadata": {}, "score": "38.066513"}
{"text": "Trastuzumab ( Herceptin ) , Ado - Trastuzumab ( Kadcyla ) and Pertuzumab ( Perjeta ) .For individuals with breast cancer who are HER2-positive with no distant metastatic disease , up to 1 year of Herceptin is considered medically necessary for adjuvant treatment .", "label": "", "metadata": {}, "score": "38.089256"}
{"text": "The past decade of research into HER2-overexpressing breast cancer has provided significant insight into the mechanisms by which HER2 signaling drives tumor progression , as well as potential mechanisms by which cancer cells escape the anticancer activity of HER2-targeted therapy .", "label": "", "metadata": {}, "score": "38.201447"}
{"text": "The likelihood of brain metastases was 1.82-fold higher ( 95 % CI : 1.16 to 2.85 ) in patients who received trastuzumab .The authors concluded that the findings from this meta - analysis are sufficiently compelling to consider 1 year of adjuvant trastuzumab treatment for women with HER2-positive early breast cancer based on the risk : benefit ratio demonstrated in these studies .", "label": "", "metadata": {}, "score": "38.223373"}
{"text": "Results of another study , published simultaneously in The Lancet Oncology , showed that neoadjuvant therapy with trastuzumab plus chemotherapy resulted in a significantly higher rate of pathologic complete response compared with lapatinib and chemotherapy .", "label": "", "metadata": {}, "score": "38.303146"}
{"text": "As a conjugate , T - DM1 's systemic adverse events ( AEs ) are significantly minimized due to its targeted delivery by trastuzumab to HER2-positive cells .", "label": "", "metadata": {}, "score": "38.370766"}
{"text": "T - DM1 : . trastuzumab emtansine .TIL : . tumor - infiltrating lymphocytes .TKI : . tyrosine kinase inhibitor .VEGF : . vascular endothelial growth factor .", "label": "", "metadata": {}, "score": "38.37801"}
{"text": "Swain SM , Kim SB , Cortes J , et al .Pertuzumab , trastuzumab , and docetaxel for HER2-positive metastatic breast cancer ( CLEOPATRA study ) : Overall survival results from a randomised , double - blind , placebo - controlled , phase 3 study .", "label": "", "metadata": {}, "score": "38.554096"}
{"text": "These immune cells then release cytokines and cytotoxic granules enter the target cell , inducing apoptosis .Mice that lacked activating Fc receptors or in which interaction between antibody and NK cells had been disrupted showed less effective ADCC lysis of HER2-positive tumor cells upon treatment with trastuzumab [ 53 ] .", "label": "", "metadata": {}, "score": "38.638405"}
{"text": "Some studies have suggested that trastuzumab downregulates total levels of HER2 on the cell surface [ 45 , 46 ] , which may ultimately reduce downstream PI3 K and MAPK signaling .", "label": "", "metadata": {}, "score": "38.735527"}
{"text": "Conclusions .Although trastuzumab remains the standard treatment in patients with HER2 overexpressing breast cancer in neoadjuvant , adjuvant and metastatic settings , the presence of acquired and de novo resistance is a serious concern .", "label": "", "metadata": {}, "score": "38.794945"}
{"text": "Patients with clinical stages T1 through T4 were eligible , depending on nodal and hormone - receptor status .All patients received neoadjuvant chemotherapy with the combination of epirubicin , cyclophosphamide , and docetaxel .", "label": "", "metadata": {}, "score": "38.81187"}
{"text": "ASCO meeting , 100 patients with stage II / III HER2 + breast cancer were randomized to trastuzumab , lapatinib , or trastuzumab plus lapatinib [ 16 ] .", "label": "", "metadata": {}, "score": "38.844345"}
{"text": "In the present review , we will present clinical data on the main strategies that aimed at overcoming trastuzumab resistance .The targets and drug family under investigation are reported in Figure 1 .", "label": "", "metadata": {}, "score": "38.867096"}
{"text": "As a result , several clinical trials are exploring in different settings and with diverse designs the potential of anti - HER2 therapies in gastric cancer patients .", "label": "", "metadata": {}, "score": "38.927063"}
{"text": "These issues can rarely be fully addressed through the simplistic design of current therapeutic trials .At present , a physician treating an individual who has progressed on first - line trastuzumab - based therapy already faces the dilemma of whether the patient should receive further trastuzumab together with an alternative chemotherapeutic agent , continue trastuzumab in combination with lapatinib , or switch to lapatinib .", "label": "", "metadata": {}, "score": "38.951218"}
{"text": "Swain et al ( 2013 ) noted that CLEOPATRA is a phase III study to compare the safety and effectiveness of pertuzumab , trastuzumab , and docetaxel with placebo , trastuzumab , and docetaxel in patients with HER2-positive first - line metastatic breast cancer .", "label": "", "metadata": {}, "score": "39.016098"}
{"text": "In HER2-negative and HER2-positive tumors , the standard uptake value ( SUV ) decrease , studied with positron emission tomography ( PET ) , is a strong predictor of pCR after only one course of chemotherapy [ 59 ] .", "label": "", "metadata": {}, "score": "39.06032"}
{"text": "In one study , 9 of 46 patients with HER2-positive disease expressed p95HER2 ; only one of the nine showed a response to trastuzumab [ 72 ] .", "label": "", "metadata": {}, "score": "39.108883"}
{"text": "Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone , in patients with HER2-positive locally advanced breast cancer ( the NOAH trial ) : a randomised controlled superiority trial with a parallel HER .", "label": "", "metadata": {}, "score": "39.140152"}
{"text": "Since trastuzumab resistance may arise from cross - talk among other HER proteins resulting in lateral activation and incomplete inhibition of downstream signalling , one approach to overcoming trastuzumab resistance is the simultaneous inhibition of multiple HER receptors [ 56 ] .", "label": "", "metadata": {}, "score": "39.188377"}
{"text": "HER2 overexpression is associated with adverse tumor characteristics and inferior clinical outcomes in breast cancer patients .It is therefore an attractive target for therapeutic intervention , a strategy that had been clinically validated with trastuzumab and which we will explore more fully in the next section on antibody therapies .", "label": "", "metadata": {}, "score": "39.226624"}
{"text": "Different biomarkers have been studied to predict the response to anti - HER2 neoadjuvant therapies but until now , except the HER2 positivity , none has been validated .", "label": "", "metadata": {}, "score": "39.230957"}
{"text": "Trastuzumab and lapatinib have well - characterized synergistic interaction in HER2-positive breast cancer models [ 25 - 27 ] , due to partly nonoverlapping mechanisms of action .", "label": "", "metadata": {}, "score": "39.262165"}
{"text": "No authors listed .FDA okays adjuvant trastuzumab ( Herceptin ) as monotherapy .MedPage Today , January 21 , 2008 .Accessed March 26 , 2008 .", "label": "", "metadata": {}, "score": "39.29051"}
{"text": "Zagouri F , Sergentanis TN , Bartsch R , et al .Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer : A systematic review and pooled analysis .", "label": "", "metadata": {}, "score": "39.375732"}
{"text": "Pertuzumab ( Perjeta ) : .Pertuzumab is a new anti - HER2 humanized monoclonal antibody that prevents the formation of HER2 dimers .It is the first HER dimerization inhibitor that the mechanism of action is complementary to trastuzumab .", "label": "", "metadata": {}, "score": "39.410954"}
{"text": "Single - arm phase Ib / II , II and a randomized phase II first - line study of T - DM1 versus the combination of trastuzumab plus docetaxel all showed improved tolerability , and at least equivalent efficacy , compared with the current standard of care .", "label": "", "metadata": {}, "score": "39.435085"}
{"text": "Cancer Sci .Pohl M , Stricker I , Schoeneck A , et al .Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo .", "label": "", "metadata": {}, "score": "39.44742"}
{"text": "Monoclonal antibodies : pertuzumab .Resistance to trastuzumab can be explained by signaling through other HER dimerization [ 26 ] .Pertuzumab is an anti - HER2 antibody that inhibits HER2/HER3 dimerizations [ 26 , 55 ] and , thus , can prevent these potential escape pathways .", "label": "", "metadata": {}, "score": "39.448326"}
{"text": "Severe toxicities including grade 4 thrombocytopenia and transaminitis were rare at 6 % [ 52 ] .The high proportion of patients achieving objective responses in this study has allayed concerns that further antibody - based treatment may be rendered ineffective due to the proteolytic cleavage of HER2 following prior trastuzumab exposure [ 51 ] .", "label": "", "metadata": {}, "score": "39.643173"}
{"text": "PubMed View Article .Pegram M , Slamon D : Biological rationale for HER2/neu ( c - erbB2 ) as a target for monoclonal antibody therapy .", "label": "", "metadata": {}, "score": "39.645485"}
{"text": "2825 - 2831 , 1998 .View at Google Scholar \u00b7 View at Scopus .M. D. Pegram and D. J. Slamon , \" Combination therapy with trastuzumab ( Herceptin ) and cisplatin for chemoresistant metastatic breast cancer : evidence for receptor - enhanced chemosensitivity , \" Seminars in Oncology , vol .", "label": "", "metadata": {}, "score": "39.695282"}
{"text": "In this trial , patients were randomly assigned to receive chemotherapy , trastuzumab plus bevacizumab , or chemotherapy and trastuzumab alone .No difference of efficacy was observed between the two arms ( DFS , HR 1.00 ; 95 % CI 0.79 to 1.26 ) [ 53 ] .", "label": "", "metadata": {}, "score": "39.79683"}
{"text": "These data are in favor of a dual HER2 blockade .In heavily pretreated patients , the combination of trastuzumab and lapatinib significantly prolonged progression - free and overall survivals as compared with lapatinib alone [ 29 , 30 ] .", "label": "", "metadata": {}, "score": "39.90117"}
{"text": "Appendix .Trastuzumab Dosing .According to the FDA approved labeling of Herceptin for breast cancer , the usual dose of trastuzumab is a 4 mg / kg loading dose , followed by 2 mg / kg every week ( Genentech , 2006 ) .", "label": "", "metadata": {}, "score": "39.927402"}
{"text": "In a phase II clinical trial , Hurvitz et al ( 2013 ) compared the effects of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with HER 2-positive MBC .", "label": "", "metadata": {}, "score": "40.205338"}
{"text": "Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray study .Melanoma Res .Clark JW , Grothey A. Systemic chemotherapy for nonoperable metastatic colorectal cancer : Treatment recommendations .", "label": "", "metadata": {}, "score": "40.34703"}
{"text": "Tumor histology was analyzed for necrosis .Six of nine cell lines showed high expression of HER1/HER2 .Pertuzumab inhibited cell cycle progression in various cell lines .", "label": "", "metadata": {}, "score": "40.479233"}
{"text": "These findings are consistent with the results published by Berns et al .[43 ] who used a large - scale unbiased RNA interference screen and identified PTEN as the only modulator of trastuzumab sensitivity , and patients with activation of PI3 K pathway had worse clinical outcome .", "label": "", "metadata": {}, "score": "40.541"}
{"text": "Under low - serum cell culture conditions , trastuzumab induced quiescence in 38 % of BT474 cells [ 149 , 157 ] .Cotreatment with pertuzumab further increased the percentage of cells entering quiescence to 49 % .", "label": "", "metadata": {}, "score": "40.613956"}
{"text": "The combination of pertuzumab , trastuzumab and docetaxel has been found to have an OS benefit in patients with HER2 positive MBC when used in the first - line setting .", "label": "", "metadata": {}, "score": "40.65566"}
{"text": "Inhibition of HER2 signaling and proliferation and induction of apoptosis were enhanced upon treatment with the combination versus pertuzumab [ 155 ] .In addition , BT474 tumors showed complete regression when treated with trastuzumab , pertuzumab and gefitinib and remained absent for up to almost 8 months [ 155 ] .", "label": "", "metadata": {}, "score": "40.71172"}
{"text": "Trastuzumab Beyond Progression .Preclinical data showing that trastuzumab withdrawal resulted in rapid re - growth of trastuzumab - resistant cell lines [ 30 , 31 ] lent support to the strategy of continuing trastuzumab beyond disease progression in clinical practice .", "label": "", "metadata": {}, "score": "40.87097"}
{"text": "Additional knowledge is necessary to better define within the HER2 tumor subgroup which patients could benefit more from targeted therapies .Different biomarkers have been studied to predict the response after anti - HER2 neoadjuvant therapies but until now none has been validated .", "label": "", "metadata": {}, "score": "40.901283"}
{"text": "The promising role of pertuzumab in the neoadjuvant and adjuvant settings remains to be further investigated and established in the future .In a randomized , multi - center , open - label , phase II study , Gianni et al ( 2012 ) examined the combination of pertuzumab or trastuzumab , or both , with docetaxel and the combination of pertuzumab and trastuzumab without chemotherapy in the neoadjuvant setting .", "label": "", "metadata": {}, "score": "40.98453"}
{"text": "Introduction .The HER2 ( erbB2 / neu ) receptor tyrosine kinase gene is amplified and overexpressed at the protein level in 20 - 30 % of metastatic breast cancers .", "label": "", "metadata": {}, "score": "41.024635"}
{"text": "HER2-overexpressing breast cancers that have progressed on trastuzumab show particular sensitivity to PI3 K inhibition [ 25 , 105 ] , indicating that this downstream signaling pathway plays a critical role in driving progression of HER2-postive disease .", "label": "", "metadata": {}, "score": "41.040096"}
{"text": "Angiogenesis Inhibitors .The same strategy is also being evaluated in the adjuvant setting in the ongoing BETH study ( NCT00625898 ) [ 77 ] .", "label": "", "metadata": {}, "score": "41.040115"}
{"text": "F. A. Holmes , Y. M. Nagarwala , V. A. Espina , et al . , \" Correlation of molecular effects and pathologic complete response to preoperative lapatinib and trastuzumab , separately and combined prior to neoadjuvant breast cancer chemotherapy , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "41.068893"}
{"text": "Table 2 .Reported randomised phase III trials with neoadjuvant trastuzumab .Designs of the ongoing randomised neoadjuvant studies in HER2 + disease .The majority of ongoing HER2-targeted trials are investigating the efficacy of lapatinib in the neoadjuvant setting for HER2 + breast cancer ( Table 1 ) [ 16 - 24 ] .", "label": "", "metadata": {}, "score": "41.125656"}
{"text": "Furthermore , the NCCN 's clinical practice guideline on \" Central nervous system cancers \" ( Version 2.2013 ) does not mention the use of trastuzumab or trastuzumab as a therapeutic option .", "label": "", "metadata": {}, "score": "41.13943"}
{"text": "Rubinson DA , Hochster HS , Ryan DP , et al .Multi - drug inhibition of the HER pathway in metastatic colorectal cancer : Results of a phase I study of pertuzumab plus cetuximab in cetuximab - refractory patients .", "label": "", "metadata": {}, "score": "41.15368"}
{"text": "The FDA decision was predicated on 1-year data from the HERA ( HERceptin Adjuvant ) trial .It found a significant 46 % reduction in recurrence among women who took trastuzumab for 52 weeks following multi - modality anthracycline - based therapy compared with controls .", "label": "", "metadata": {}, "score": "41.1816"}
{"text": "4785 , pp .177 - 182 , 1987 .View at Google Scholar \u00b7 View at Scopus . D. J. Slamon , B. Leyland - Jones , S. Shak et al . , \" Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2 , \" New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "41.21057"}
{"text": "View at Google Scholar .L. Gianni , T. Pienkowski , Y.-H. I m , et al . , \" Neoadjuvant pertuzumab ( P ) and trastuzumab ( H ) : antitumor and safety analysis of a randomized phase II study ( ' NeoSphere ' ) , \" in Proceedings of the San Antonio Breast Cancer Symposium , 2010 , Abstract S3 - 2 . C. D. Austin , A. M. De Mazi\u00e8re , P. I. Pisacane et al . , \" Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin , \" Molecular Biology of the Cell , vol .", "label": "", "metadata": {}, "score": "41.3753"}
{"text": "Prostate cancer .Salivary gland / duct cancer .Vulvar cancer .Aetna considers pertuzumab ( Perjeta ) medically necessary when used in combination with trastuzumab for recurrent or metastatic HER2-positive breast cancer and for neoadjuvant treatment of HER2-positive breast cancer .", "label": "", "metadata": {}, "score": "41.513653"}
{"text": "The effect of pertuzumab on cell cycle distribution was analyzed by FACS .Nude mice bearing xenograft tumors were treated with pertuzumab alone , or in combination either with irinotecan or with erlotinib .", "label": "", "metadata": {}, "score": "41.550896"}
{"text": "10 , pp .2587 - 2595 , 2001 .View at Google Scholar \u00b7 View at Scopus . D. J. Slamon , B. Leyland - Jones , S. Shak et al . , \" Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2 , \" The New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "41.551258"}
{"text": "Only patients with HER2 over - expression received concurrent therapy with trastuzumab given for 34 consecutive weeks .The 30-month event - free and OS rates for patients with HER2 over - expression treated with chemotherapy and trastuzumab were 32 % and 59 % , respectively .", "label": "", "metadata": {}, "score": "41.554"}
{"text": "The ToGA study is the first randomized , prospective , multi - center , phase III trial to study the efficacy and safety of trastuzumab in HER2- positive gastric cancer .", "label": "", "metadata": {}, "score": "41.565582"}
{"text": "Pertuzumab treated DLD-1 xenograft tumors did not show enhanced necrosis , which , however , was found in HCT116 derived xenografts .The authors concluded that pertuzumab has some anti - tumor activity on human colon cancer cells in - vitro and in - vivo , in particular when combined with erlotinib .", "label": "", "metadata": {}, "score": "41.621475"}
{"text": "Patients were randomized to receive 6 cycles of chemotherapy ( carboplatin and either paclitaxel ( Taxol ) or gemcitabine ) with or without pertuzumab .The primary end point was PFS as determined by Response Evaluation Criteria in Solid Tumors and/or by CA 125 measurements .", "label": "", "metadata": {}, "score": "41.622868"}
{"text": "Trastuzumab emtansine ( T - DM1 ) is an antibody - drug conjugate incorporating the HER2-targeted anti - tumor properties of trastuzumab with the targeted delivery to HER2 over - expressing cancer cells of a highly potent anti - microtubule agent , DM1 ( N - methyl - N-[3-mercapto-1-oxopropyl]-l - alanine ester of maytansinol ) , a maytansine derivative .", "label": "", "metadata": {}, "score": "41.710716"}
{"text": "These studies provide rationale for current trials testing Met inhibition against HER2-positive breast cancer that has progressed on trastuzumab .These trials include dual blockade of Met and vascular endothelial growth factor receptor ( VEGFR ) in trastuzumab - refractory populations .", "label": "", "metadata": {}, "score": "41.72958"}
{"text": "Pertuzumab , in combination with trastuzumab and docetaxel , is indicated for patients who have not received prior treatment for metastatic breast cancer with an anti - HER2 therapy or chemotherapy .", "label": "", "metadata": {}, "score": "41.78215"}
{"text": "An ongoing phase III randomised study ( LUX - Breast 1 ) is assessing the efficacy of afatinib plus vinorelbine versus the continuation of trastuzumab plus vinorelbine in HER2-positive metastatic breast cancer following trastuzumab failure ( NCT01125566 ) .", "label": "", "metadata": {}, "score": "41.830505"}
{"text": "HER/2 neu gene amplification is uncommon in bladder cancer .Evidence from breast cancer suggests that only tumors with HER2/neu gene amplification respond to trastuzumab .", "label": "", "metadata": {}, "score": "41.939705"}
{"text": "Preclinical and clinical evidence had suggested that combining lapatinib and trastuzumab would result in more potent inhibition of HER2 compared with either drug alone .Baselga and colleagues reported final results from a trial called NeoALTTO , which compared lapatinib , trastuzumab , and the combination for women with HER2-positive breast cancer .", "label": "", "metadata": {}, "score": "42.04397"}
{"text": "C. I. Spiridon , M. A. Ghetie , J. Uhr et al . , \" Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo , \" Clinical Cancer Research , vol . 8 , no .", "label": "", "metadata": {}, "score": "42.090378"}
{"text": "Consequently , it potently inhibits HER2 as well as the dimerisation of HER2 with other HER family receptors , including HER3 [ 6 ] .The growing body of preclinical evidence supporting the central role of the HER2-HER3 interaction in driving PI3K / Akt - mediated tumorigenesis in HER2-overexpressing breast cancers strengthens the scientific rationale behind the development of this class of agents [ 26 ] .", "label": "", "metadata": {}, "score": "42.095863"}
{"text": "The authors concluded that pertuzumab and trastuzumab induce equally strong ADCC and CDC in FISH - positive USPC cell lines .Pertuzumab significantly increases trastuzumab - induced ADCC against USPC with a low HER2/neu expression and may represent a new therapeutic agent in patients harboring advanced / recurrent and/or refractory USPC .", "label": "", "metadata": {}, "score": "42.11255"}
{"text": "Patients with HER2-positive metastatic breast cancer ( MBC ) who progressed during trastuzumab treatment were randomly assigned to receive lapatinib in monotherapy or lapatinib in combination with trastuzumab .", "label": "", "metadata": {}, "score": "42.11891"}
{"text": "\" Herceptin may thus target only a small proportion of ovarian clear cell carcinomas and be of limited clinical value for treatment of this carcinoma \" ( Iwamoto et al , 2003 ) .", "label": "", "metadata": {}, "score": "42.16838"}
{"text": "Safety profiles were similar with no unexpected adverse events in the trastuzumab plus chemotherapy arm .There was no difference in symptomatic congestive heart failure between arms .", "label": "", "metadata": {}, "score": "42.18614"}
{"text": "It could prevent signaling related to truncated HER2 receptor or enhance trastuzumab - dependant ADCC , thanks to an accumulation of HER2 at the cell surface .", "label": "", "metadata": {}, "score": "42.234604"}
{"text": "In a preclinical study , co - expression of HER2 and IGF1R in breast cancer cells resulted in loss of sensitivity to trastuzumab treatment , whereas blocking ligand activation of IGF1R restored trastuzumab - related growth inhibition [ 25 ] .", "label": "", "metadata": {}, "score": "42.294613"}
{"text": "25 - 32 , 2012 .View at Google Scholar .V. Guarneri , A. Frassoldati , A. Bottini , et al . , \" Final results of a phase II randomized trial of neoadjuvant anthracycline - taxane chemotherapy plus lapatinib , trastuzumab , or both in HER2-positive breast cancer ( CHER - LOB trial ) , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "42.29725"}
{"text": "In addition to PI3 K signaling , MAPK signaling appears to contribute to progression of HER2-positive breast cancer .Stable transfection of HER2 into MCF7 estrogen receptor-", "label": "", "metadata": {}, "score": "42.32006"}
{"text": "Verma S , Miles D , Gianni L , et al ; EMILIA Study Group .Trastuzumab emtansine for HER2-positive advanced breast cancer .", "label": "", "metadata": {}, "score": "42.4406"}
{"text": "The inhibition of ErbB2 signal transduction pathways by the use of human antibodies could be a valuable alternative strategy for cancer therapy .These investigators performed a comparative analysis in - vitro and in - vivo of the anti - tumor effects of 3 different antibodies targeting different epitopes of ErbB2 : Herceptin ( trastuzumab ) , 2C4 ( pertuzumab ) and Erb - hcAb ( human anti - ErbB2-compact antibody ) , a novel fully human compact antibody .", "label": "", "metadata": {}, "score": "42.542984"}
{"text": "Gatzemeier U , Groth G , Butts C , et al .Randomized phase II trial of gemcitabine - cisplatin with or without trastuzumab in HER2-positive non - small - cell lung cancer .", "label": "", "metadata": {}, "score": "42.55841"}
{"text": "[ 42 ] .Hence , low PTEN expression could select patients with tumors resistant to trastuzumab but sensitive to lapatinib and could be used as a biomarker if the results are confirmed by several large phase 3 studies .", "label": "", "metadata": {}, "score": "42.57458"}
{"text": "Current HER2-targeted therapies have limited potential to cross the blood - brain - barrier .These researchers performed a systematic review to investigate data on HER2-targeting therapies in the treatment of brain metastases in breast cancer .", "label": "", "metadata": {}, "score": "42.588516"}
{"text": "Bang YJ , Van Cutsem E , Feyereislova A , et al ; ToGA Trial Investigators .Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro - oesophageal junction cancer ( ToGA ) : A phase 3 , open - label , randomised controlled trial .", "label": "", "metadata": {}, "score": "42.611786"}
{"text": "34 , pp .5838 - 5847 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. Gennari , S. Menard , F. Fagnoni et al . , \" Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2 , \" Clinical Cancer Research , vol .", "label": "", "metadata": {}, "score": "42.617012"}
{"text": "Translating the Role of IGF - IR in Trastuzumab Resistance Into the Clinic .We have recently reviewed the literature implicating IGF - IR overexpression and cross - talk in trastuzumab resistance [ 81 ] .", "label": "", "metadata": {}, "score": "42.63261"}
{"text": "Trastuzumab may also selectively inhibit HER2-HER3 heterodimerization [ 46 , 48 ] , reducing PI3 K signaling .Induction of cell cycle arrest by trastuzumab is mediated by p27kip1 and inhibition of cdk2 activity [ 49 , 50 ] .", "label": "", "metadata": {}, "score": "42.64939"}
{"text": "In a phase II trial , the median PFS observed with neratinib was 22.3 weeks among patients with prior trastuzumab treatment and 39.6 weeks with trastuzumab naive patients .", "label": "", "metadata": {}, "score": "42.679214"}
{"text": "These investigators examined the effectiveness and toxicity of dual targeting in HER2-positive breast cancer .A computer - based literature search was carried out using PubMed ; data reported at international meetings and clinicaltrials.gov was included .", "label": "", "metadata": {}, "score": "42.693905"}
{"text": "For example , combining trastuzumab , pertuzumab , and IGF - IR inhibition may result in greater induction of ADCC , apoptosis , and suppression of invasion .", "label": "", "metadata": {}, "score": "42.70568"}
{"text": "Clin Breast Cancer .Schneeweiss A , Chia S , Hickish T , et al .Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline - containing and anthracycline - free chemotherapy regimens in patients with HER2-positive early breast cancer : A randomized phase II cardiac safety study ( TRYPHAENA ) .", "label": "", "metadata": {}, "score": "42.711258"}
{"text": "The CLEOPATRA trial including 808 patients treated with pertuzumab , trastuzumab , and docetaxel versus trastuzumab plus docetaxel as first - line treatment against HER2-positive metastatic breast cancer showed significant improvement in median progression - free survival of 18.5 versus 12.4 months , respectively [ 152 ] .", "label": "", "metadata": {}, "score": "42.719124"}
{"text": "On the opposite side , HER2 overexpression has been associated with resistance to tamoxifen [ 6 - 9 ] .Finally , HER2 positive breast cancer is associated with an increased risk of brain metastases [ 10 ] .", "label": "", "metadata": {}, "score": "42.720886"}
{"text": "Since the initial studies that established HER2 amplification in breast cancer , structural and functional analyses have helped to identify the signaling pathways contributing to HER2-mediated cellular transformation .", "label": "", "metadata": {}, "score": "42.72818"}
{"text": "We have recently reviewed the literature supporting IGF - IR cross - talk and/or overexpression in the development of trastuzumab resistance [ 81 ] .Lu et al .", "label": "", "metadata": {}, "score": "42.831154"}
{"text": "Pohl et al ( 2009 ) examined the anti - tumor activity of pertuzumab as a single agent or in combination with erlotinib or irinotecan in human colon cancer cells in - vitro and in - vivo .", "label": "", "metadata": {}, "score": "42.85576"}
{"text": "Thus , early - response evaluation can identify a subgroup of patients with poor long - term outcome , providing the opportunity to explore a switch to an alternative therapy to improve the likelihood of pCR .", "label": "", "metadata": {}, "score": "42.85887"}
{"text": "IGF-1R Inhibitors .Two IGF-1R inhibitors are being evaluated in combination with existing HER2-directed therapies for the treatment of HER2-positive metastatic breast cancer in clinical studies .", "label": "", "metadata": {}, "score": "42.86991"}
{"text": "Stable transfection of Muc4 reduced binding of 1 \u03bc g / mL trastuzumab to HER2 by 50 % without any change in total HER2 expression , although higher concentrations of trastuzumab ( 10 or 100 \u03bc g / mL ) were still able to bind [ 67 ] .", "label": "", "metadata": {}, "score": "42.874672"}
{"text": "Baselga J , Norton L , Albanell J , et al .Recombinant humanized anti - HER2 antibody ( Herceptin ) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts .", "label": "", "metadata": {}, "score": "42.899208"}
{"text": "Only 3 studies were identified comparing trastuzumab to lapatinib .The authors concluded that no solid data exist on how to treat patients with HER2-positive disease and brain metastases .", "label": "", "metadata": {}, "score": "42.99401"}
{"text": "Significantly more women with HER2-positive breast cancer achieved complete tumor resolution when they received two targeted agents before surgery instead of one , results of a large European study showed .", "label": "", "metadata": {}, "score": "43.088715"}
{"text": "Sorscher S. Marked radiographic response of a HER-2-overexpressing biliary cancer to trastuzumab .Cancer Manag Res .National Comprehensive Cancer Network ( NCCN ) .", "label": "", "metadata": {}, "score": "43.09616"}
{"text": "Further studies are necessary to define robust , reliable , and reproducible biomarkers .References .D. Mauri , N. Pavlidis , and J. P. A. Ioannidis , \" Neoadjuvant versus adjuvant systemic treatment in breast cancer : a meta - analysis , \" Journal of the National Cancer Institute , vol .", "label": "", "metadata": {}, "score": "43.110443"}
{"text": "1159 - 1166 , 2002 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .S. Modi , A. Stopeck , H. Linden , et al . , \" HSP90 inhibition is effective in breast cancer : a phase II trial of tanespimycin ( 17-AAG ) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab , \" Clinical Cancer Research , vol .", "label": "", "metadata": {}, "score": "43.168823"}
{"text": "These promising results deserve additional research .Building on these results , the combination between trastuzumab and BKM120 , an oral pan - class 1 PI3 K inhibitor , has been developed .", "label": "", "metadata": {}, "score": "43.174538"}
{"text": "Inman et al ( 2003 ) noted that currently available systemic therapies for malignant melanoma produce low response rates in patients , and more effective treatment modalities are clearly needed .", "label": "", "metadata": {}, "score": "43.19845"}
{"text": "17 , pp .2235 - 2249 , 1998 .View at Google Scholar \u00b7 View at Scopus .K. A. Gelmon , J. Mackey , S. Verma et al . , \" Use of trastuzumab beyond disease progression : observations from a retrospective review of case histories , \" Clinical Breast Cancer , vol .", "label": "", "metadata": {}, "score": "43.207184"}
{"text": "View at Google Scholar .J. Baselga , D. Tripathy , J. Mendelsohn et al . , \" Phase II Study of Weekly Intravenous Recombinant Humanized Anti - p185HER2 Monoclonal Antibody in Patients with HER2/neu - Overexpressing Metastatic Breast Cancer , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "43.250496"}
{"text": "Pertuzumab .Pertuzumab ( Perjeta , Roche Laboratory ) is a humanized monoclonal antibody directed at the dimerization domain of HER2 .Pertuzumab and trastuzumab have complementary mechanisms of action due to their distinct binding sites .", "label": "", "metadata": {}, "score": "43.287304"}
{"text": "W. J. Kostler , B. Schwab , C. F. Singer et al . , \" Monitoring of Serum Her-2/neu Predicts Response and Progression - Free Survival to Trastuzumab - Based Treatment in Patients with Metastatic Breast Cancer , \" Clinical Cancer Research , vol .", "label": "", "metadata": {}, "score": "43.300488"}
{"text": "The combination of chemotherapy with trastuzumab and pertuzumab has also shown interesting results in the neo - adjuvant setting .The NeoSphere study ( multicenter phase II study ) evaluated the efficacy of dual inhibition using pertuzumab .", "label": "", "metadata": {}, "score": "43.354836"}
{"text": "Another approach to stimulate ADCC was recently shown by cotreating with trastuzumab plus a CD137 agonistic antibody , which bound and stimulated CD137 on NK cells to promote ADCC [ 114 ] .", "label": "", "metadata": {}, "score": "43.39135"}
{"text": "Most other combinations in development include combining a novel anti - HER2 agent with trastuzumab .Of these , the most convincing evidence for the benefit of dual inhibition over single - agent therapy is derived from the randomised phase II studies , BO17929 ( NCT00301899 ) and NeoSphere [", "label": "", "metadata": {}, "score": "43.429153"}
{"text": "The results are similar in the randomized phase 2 GEICAM 2006 - 14 study with a pCR rate in the trastuzumab group twice higher than that in the lapatinib group , with the same chemotherapy regimen as in the GeparQuinto trial [ 17 ] .", "label": "", "metadata": {}, "score": "43.43245"}
{"text": "Breast cancer HER-2 Resistance Tyrosine kinase inhibitors Monoclonal antibodies .Introduction .About 15 % of breast cancer over - expresses the human epidermal growth factor receptor 2 ( HER2 ) [ 1 , 2 ] .", "label": "", "metadata": {}, "score": "43.47328"}
{"text": "In fact , HER3 is now believed to contribute significantly to the growth of HER2-overexpressing breast cancers .The antiproliferative effect of HER3 siRNA was associated with HER3 knockdown and reduced phosphorylation of Y1289-HER3 without any off - target effect on HER2 .", "label": "", "metadata": {}, "score": "43.473743"}
{"text": "If these findings had been known before the launch of the ATAC trial , the combination arm likely would have been dropped from the study design from the outset , thereby saving considerable financial and patient resources .", "label": "", "metadata": {}, "score": "43.474823"}
{"text": "The completed trial randomized 131 women with relapsed ovarian cancer to receive gemcitabine and pertuzumab or placebo and gemcitabine ( control ) .The trial was at moderate risk of bias .", "label": "", "metadata": {}, "score": "43.517822"}
{"text": "429 - 437 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Untch , M. Rezai , S. Loibl et al . , \" Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer : results from the GeparQuattro study , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "43.5292"}
{"text": "Neoadjuvant chemotherapy in breast cancer treatment is now recognized as a standard care to increase conservative surgery [ 1 , 2 ] .Its utility is also documented in inflammatory or locally advanced tumors [ 3 ] .", "label": "", "metadata": {}, "score": "43.61265"}
{"text": "Overexpression of membranous IGF1R was associated with higher likelihood of residual disease after trastuzumab - based chemotherapy [ 58 ] .In the exploratory study presented by Holmes et al .", "label": "", "metadata": {}, "score": "43.612762"}
{"text": "Iwamoto et al ( 2003 ) found HER2/neu over - expression in only 1 of 15 clear cell ovarian carcinoma cases that were immunostained for HER-2 /neu using HercepTest .", "label": "", "metadata": {}, "score": "43.674793"}
{"text": "Feasibility and tolerability of sequential doxorubicin / paclitaxel followed by cyclophosphamide , methotrexate , and fluorouracil and its effects on tumor response as preoperative therapy .", "label": "", "metadata": {}, "score": "43.692383"}
{"text": "This is largely due to a lack of studies and difficulties in performing randomized trials .The application of targeted therapy is widespread and reported for several tumor types .", "label": "", "metadata": {}, "score": "43.717285"}
{"text": "280 - 286 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .C. C. Portera , J. M. Walshe , D. R. Rosing et al . , \" Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with trastuzumab - insensitive human epidermal growth factor receptor 2-positive metastatic breast cancer , \" Clinical Cancer Research , vol .", "label": "", "metadata": {}, "score": "43.787254"}
{"text": "D. Gajria , T. A. King , and H. Pannu , \" Combined inhibition of mTORC1 with temsirolimus and HER2 with neratinib : a phase I study in patients with metastatic HER2-amplified breast cancer , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "43.812195"}
{"text": "Pancreatic cancer .Prostate cancer .Rectal cancer .Uterine cancer .Aetna considers ado - trastuzumab emtansine ( Kadcyla ) medically necessary for the treatment of members with HER2-positive recurrent or metastatic breast cancer who were previously treated with trastuzumab .", "label": "", "metadata": {}, "score": "43.83163"}
{"text": "In recent years , an array of promising and novel anti - HER2 therapeutic agents and their combinations have entered various stages of clinical development .", "label": "", "metadata": {}, "score": "43.832726"}
{"text": "Combined administration of PI3K / mTOR inhibitor BEZ235 and MEK inhibitor AZD6244 to MMTV- neu mice achieved nearly complete tumor regression [ 29 ] .", "label": "", "metadata": {}, "score": "43.833168"}
{"text": "2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer ( HERA ) : an open - label , randomised controlled trial .", "label": "", "metadata": {}, "score": "43.97669"}
{"text": "Amongst 155 patients treated with trastuzumab , 15 % showed overexpression of EGFR [ 101 ] .EGFR expression and vascular invasion were significantly associated with overall survival of patients with metastatic disease .", "label": "", "metadata": {}, "score": "44.0027"}
{"text": "In the AVEREL study , the efficacy of bevacizumab was evaluated in first line therapy for locally recurrent or metastatic HER2 positive breast cancer .The median PFS was 16.8 months in the bevacizumab arm versus 13.9 months [ 52 ] .", "label": "", "metadata": {}, "score": "44.014626"}
{"text": "El - Sahwi K , Bellone S , Cocco E , et al .In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma .", "label": "", "metadata": {}, "score": "44.184258"}
{"text": "The result was increased levels of total HER2 within 12 - 24 h in cells treated with lapatinib or within 36 - 48 h in cells treated with lapatinib plus trastuzumab , while trastuzumab alone resulted in downregulation of HER2 expression within 24 h of treatment [ 143 ] .", "label": "", "metadata": {}, "score": "44.198345"}
{"text": "Kang YK , Rha SY , Tassone P , et al .A phase IIa dose - finding and safety study of first - line pertuzumab in combination with trastuzumab , capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer .", "label": "", "metadata": {}, "score": "44.20468"}
{"text": "Other studies employing higher doses are ongoing .These findings are promising and other studies are expected to develop these new targeted therapies .Blockade of PD-1/PD - L1 immune checkpoint .", "label": "", "metadata": {}, "score": "44.34559"}
{"text": "Any sample that tested 1 + or greater for HER2 expression on IHC and a randomly selected subset of HER2-negative samples were tested for the presence of HER2 gene amplification using the Vysis PathVysion fluorescence in situ hybridization ( FISH ) assay .", "label": "", "metadata": {}, "score": "44.436554"}
{"text": "Trastuzumab : Potential Mechanisms of Resistance .We and others have reviewed the literature examining potential mechanisms of resistance to trastuzumab [ 39 , 62 , 63 ] .", "label": "", "metadata": {}, "score": "44.44336"}
{"text": "Semiglazov VF , Bozhok AA , Semiglazova TIu , et al .HER2-positive breast cancer : Standard and double targeted therapy .Vopr Onkol .", "label": "", "metadata": {}, "score": "44.54315"}
{"text": "12 , pp .4744 - 4749 , 2001 .View at Google Scholar \u00b7 View at Scopus .I. Witzel , S. Loibl , G. Von Minckwitz et al . , \" Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial , \" Breast Cancer Research and Treatment , vol .", "label": "", "metadata": {}, "score": "44.55633"}
{"text": "Wang et al . described an increase of ER and its downstream products in 80 % of ER+/HER2 + cell lines after a treatment with trastuzumab and lapatinib .", "label": "", "metadata": {}, "score": "44.576077"}
{"text": "In HER2 positive breast cancer , HSP90 inhibitors have shown antitumor activity when combined with trastuzumab [ 70 ] .17-Demethoxygeldanamycin ( 17-AAG ) inhibits the activity of HSP90 , thereby inducing the degradation of many oncogenic proteins .", "label": "", "metadata": {}, "score": "44.589043"}
{"text": "A phase II study of oral deforolimus in combination with trastuzumab has recently been completed in HER2-overexpressing metastatic breast cancer patients with prior trastuzumab exposure ( NCT00736970 ) .", "label": "", "metadata": {}, "score": "44.600555"}
{"text": "These studies demonstrate that oncogenic HER2 exists in multiple isoforms , and that therapeutic approaches must be based upon expression of individual isoforms .Antibody - based approaches may retain efficacy in the context of overexpressed full - length HER2 , whereas kinase inhibition ( i.e. , lapatinib ) may be most effective at suppressing progression of tumors that express truncated HER2 isoforms .", "label": "", "metadata": {}, "score": "44.643036"}
{"text": "This study examined the incidences of HER2 protein over - expression and HER2 gene amplification in metastatic malignant melanoma , which remain unclear in the literature .", "label": "", "metadata": {}, "score": "44.850403"}
{"text": "633 - 640 , 2012 .View at Google Scholar .M. Untch , S. Loibl , J. Bischoff , et al . , \" Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline - taxane - based chemotherapy ( GeparQuinto , GBG 44 ) : a randomised phase 3 trial , \" The Lancet Oncology , vol .", "label": "", "metadata": {}, "score": "44.871162"}
{"text": "Certain subsets of women with particularly aggressive tumors resistant to conventional chemotherapy may benefit from EGFR inhibitor treatment .They stated that further RCTs are needed before EGFR inhibitors are introduced as first- or second - line treatment of ovarian cancer .", "label": "", "metadata": {}, "score": "44.89441"}
{"text": "Felip et al ( 2012 ) stated that pertuzumab has demonstrated pharmacodynamics activity with stable disease in non - small - cell lung cancer ( NSCLC ) .", "label": "", "metadata": {}, "score": "44.898666"}
{"text": "Although HER2 kinase mutations have been detected in some cancers including lung adenocarcinomas [ 11 ] , mutation of HER2 does not appear to be required to confer transforming potential in mammary epithelial cells , as the amplified HER2 found in overexpressing tumors is generally wild - type .", "label": "", "metadata": {}, "score": "44.96505"}
{"text": "In a single - arm phase II study , Krop et al ( 2012 ) examined if T - DM1 is effective in patients with HER2-positive MBC who have previously received all standard HER2-directed therapies .", "label": "", "metadata": {}, "score": "44.976982"}
{"text": "As such , p95HER2 has a potential role both as a prognostic and predictive biomarker .Indeed , patients with breast cancers overexpressing p95HER2 were found to have a higher incidence of lung metastases and experienced significantly shorter PFS and OS with trastuzumab treatment , compared to patients expressing only the full - length receptor [ 20 ] .", "label": "", "metadata": {}, "score": "44.982536"}
{"text": "6 , pp .1302 - 1307 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .F. J. Esteva , J. Wang , F. Lin et al . , \" CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil , epirubicin , and cyclophosphamide in HER-2-overexpressing breast cancer , \" Breast Cancer Research , vol .", "label": "", "metadata": {}, "score": "44.983837"}
{"text": "Inhibition of the HER2 oncogenic pathway with trastuzumab may result in compensatory crosstalk and activation of alternative signalling pathways , such as IGF1R and HER3 signalling pathways [ 24 ] .", "label": "", "metadata": {}, "score": "45.00348"}
{"text": "Unfortunately , these data were not reported in the different studies .Data of Survival after Neoadjuvant Anti - HER2 Therapies .Most of the studies in this review did not report data of survival .", "label": "", "metadata": {}, "score": "45.036278"}
{"text": "Patients were randomly assigned to receive Perjeta , trastuzumab and docetaxel or trastuzumab and docetaxel with a placebo .The study was designed to measure the length of time a patient lived without the cancer progressing , progression - free survival ( PFS ) .", "label": "", "metadata": {}, "score": "45.04285"}
{"text": "This strategy is being evaluated in the adjuvant setting in several randomized trials .Since several different targets are under investigation , there is a need to identify predictive biomarkers to optimize combination strategies for suitable patients .", "label": "", "metadata": {}, "score": "45.04947"}
{"text": "Several molecular mechanisms are likely to account for the benefit achieved by combined treatment with trastuzumab and lapatinib .Due to several nonoverlapping mechanisms of resistance , lapatinib may suppress signaling pathways that mediate resistance to trastuzumab .", "label": "", "metadata": {}, "score": "45.04967"}
{"text": "Chow LW , Xu B , Gupta S , Freyman A , Zhao Y , Abbas R , Van Vo ML , Bondarenko I : Combination neratinib ( HKI-272 ) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer .", "label": "", "metadata": {}, "score": "45.07421"}
{"text": "Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer .N Engl J Med .Augustovski F , Pichon Riviere A , Alcaraz A , et al .", "label": "", "metadata": {}, "score": "45.151787"}
{"text": "Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer .Gabriella Mariani Department of Medical Oncology , Istituto Nazionale Tumori , Milan , Italy Nat Clin Pract Oncol 6:93 - 104 .", "label": "", "metadata": {}, "score": "45.153336"}
{"text": "Currently , the same regimens used for adjuvant treatment are recommended for neoadjuvant therapy [ 5 ] .Unfortunately , there is no additional therapy that has been shown to improve survival for patients failing to achieve a pCR to an anthracycline - taxane regimen [ 7 ] and this group of chemoresistant patients is desperately in need of novel therapeutic options .", "label": "", "metadata": {}, "score": "45.18557"}
{"text": "Neratinib combined with trastuzumab has similarly demonstrated promising efficacy [ 60 ] .Lastly , the combination of an mTOR inhibitor and novel HER - receptor TKI is worthy of mention due to its strong preclinical rationale and promising early - phase activity [ 72 ] .", "label": "", "metadata": {}, "score": "45.220272"}
{"text": "1138 - 1144 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. Baselga , J. Cortes , S. B. Kim , S. A. I m , R. Hegg , Y. H. I m , et al . , \" Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer , \" The New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "45.253246"}
{"text": "The safety and effectiveness of Perjeta were evaluated in a single clinical trial involving 808 patients with HER2-positive metastatic breast cancer who were tested prior to treatment to determine if the HER2 protein was increased .", "label": "", "metadata": {}, "score": "45.30435"}
{"text": "The other authors declare that they have no competing interests .Penault - Llorca F , Abrial C , Mouret - Reynier M - A , Raoelfils I , Durando X , Leheurteur M , Gimbergues P , Tortochaux J , Cure H , Chollet P : Achieving higher pathological complete response rates in HER-2-positive patients with induction chemotherapy without trastuzumab in operable breast cancer .", "label": "", "metadata": {}, "score": "45.31024"}
{"text": "Hirsch FR , Langer CJ .The role of HER2/neu expression and trastuzumab in non - small cell lung cancer .Semin Oncol .", "label": "", "metadata": {}, "score": "45.324135"}
{"text": "These include dimerisation inhibitors , antibody - drug conjugates , tyrosine kinase inhibitors , HSP90 inhibitors , mTOR / PI3 K inhibitors , antiangiogenic agents , IGF-1R inhibitors , and bispecific antibodies .", "label": "", "metadata": {}, "score": "45.34326"}
{"text": "An early preclinical study demonstrated that the compound inhibited cell proliferation of HER2-overexpressing breast cancer cell lines and xenografts through downregulation of the MAP kinase and PI3K / Akt pathways and induced cell cycle arrest [ 57 ] .", "label": "", "metadata": {}, "score": "45.355213"}
{"text": "Further , inducible HER3 shRNA expression in a BT474-derived line resulted in a 3-fold reduction of 3-d culture growth , and dramatic suppression of xenograft tumor growth with reduced Ki-67 and p - S6 staining and reduced p - Akt levels [ 158 ] .", "label": "", "metadata": {}, "score": "45.355843"}
{"text": "The presence of non - overlapping mechanisms of action produces significant synergy between two HER2 monoclonal antibodies that bind to different epitopes of the HER2 extracellular region .", "label": "", "metadata": {}, "score": "45.37452"}
{"text": "The authors concluded that the combination of P with H and standard chemotherapy resulted in low rates of symptomatic LVSD .On September 30 , 2013 , the FDA granted accelerated approval to Perjeta ( pertuzumab ) as part of a complete treatment regimen for patients with early stage breast cancer before surgery ( neoadjuvant setting ) .", "label": "", "metadata": {}, "score": "45.4275"}
{"text": "Combined inhibition of HER2 and MEK using AG1478 and either U0126 or dominant negative MEK1/2 , respectively , increased tamoxifen sensitivity .Cotreatment with HER2 kinase inhibitor and tamoxifen suppressed MAPK signaling in association with reduced MCF7/HER2 xenograft tumor growth [ 28 ] .", "label": "", "metadata": {}, "score": "45.565704"}
{"text": "4097 - 4106 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. Gennari , S. Menard , F. Fagnoni et al . , \" Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2 , \" Clinical Cancer Research , vol .", "label": "", "metadata": {}, "score": "45.61153"}
{"text": "p95HER2 .Another potential mechanism of resistance to trastuzumab is the accumulation of truncated forms of the HER2 receptor that lack the extracellular trastuzumab - binding domain .", "label": "", "metadata": {}, "score": "45.61304"}
{"text": "Kawamoto T , Ishige K , Thomas M , et al .Overexpression and gene amplification of EGFR , HER2 , and HER3 in biliary tract carcinomas , and the possibility for therapy with the HER2-targeting antibody pertuzumab .", "label": "", "metadata": {}, "score": "45.6649"}
{"text": "PubMed View Article .Lancet Oncol 2012 , 13 : 25 - 32 .PubMed View Article .Dahabreh IJ , Linardou H , Siannis F , Fountzilas G , Murray S : Trastuzumab in the adjuvant treatment of early - stage breast cancer : a systematic review and meta - analysis of randomized controlled trials .", "label": "", "metadata": {}, "score": "45.70164"}
{"text": "While the substantial amount of research dedicated to the development of novel ant - HER2 agents is laudable , the vast array of treatment options in an ever - changing landscape of anti - HER2 therapy may raise more questions than answers .", "label": "", "metadata": {}, "score": "45.73076"}
{"text": "N Engl J Med .Hortobagyi GN .Trastuzumab in the treatment of breast cancer .N Engl J Med .National Horizon Scanning Centre ( NHSC ) .", "label": "", "metadata": {}, "score": "45.748882"}
{"text": "At this cut - off value , \u0394SUV had a sensitivity of 89 % while the specificity was 87 % .From these results , an SUV decrease greater than 70 % allowed for the early identification of the highly responsive tumors , which will be completely eradicated by trastuzumab - based neoadjuvant therapy , with an accuracy of 76 % [ 63 ] .", "label": "", "metadata": {}, "score": "45.799107"}
{"text": "Therefore , it is clear that a unified definition of pathologic response for neoadjuvant trials is required , much like the recent consensus statement regarding standard efficacy endpoints ( STEEP ) for adjuvant trials in early - stage disease [ 28 ] .", "label": "", "metadata": {}, "score": "45.948517"}
{"text": "The median PFS was 40.3 weeks and the overall response rate was 57 % for patients with no prior lapatinib treatment [ 50 ] .An ongoing phase III study ( NCT00915018 ) compares weekly paclitaxel with either neratinib or trastuzumab as first - line treatment for HER2-positive MBC .", "label": "", "metadata": {}, "score": "45.971146"}
{"text": "PubMed View Article .Gennari A , Sormani MP , Pronzato P , Puntoni M , Colozza M , Pfeffer U , Bruzzi P : HER2 status and efficacy of adjuvant anthracyclines in early breast cancer : a pooled analysis of randomized trials .", "label": "", "metadata": {}, "score": "46.02314"}
{"text": "HER2-positive breast cancers have poorer prognosis and are prime candidates for molecular - targeted therapy because they are driven by the unique mechanism of HER2 oncogene addiction .", "label": "", "metadata": {}, "score": "46.057762"}
{"text": "J Clin Oncol .Inman JL , Kute T , White W , et al .Absence of HER2 overexpression in metastatic malignant melanoma .J Surg Oncol .", "label": "", "metadata": {}, "score": "46.058098"}
{"text": "Human - epidermal - growth - factor - receptor-2 ( HER2- ) overexpressing breast cancers account for 20 - 25 % of invasive breast cancers and are associated with an aggressive biologic behaviour translating to poorer clinical outcomes [ 1 ] .", "label": "", "metadata": {}, "score": "46.125523"}
{"text": "The primary end point was tumor response .Of the 286 tumors centrally screened by LabCorp , 33 ( 11.5 % ) were HER2-amplified .", "label": "", "metadata": {}, "score": "46.151985"}
{"text": "52 - 58 , 2004 .View at Google Scholar \u00b7 View at Scopus . D. Tripathy , D. J. Slamon , M. Cobleigh et al . , \" Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "46.158737"}
{"text": "As a result of binding to domain II , pertuzumab sterically hinders interactions of HER2 with other receptors .Disruption of baseline as well as ligand - stimulated HER2-HER3 and HER2-EGFR dimerization has been documented upon pertuzumab treatment of HER2-positive SKBR3 breast cancer cells or MCF7 breast cancer cells , which express wild - type ( nonamplified ) levels of HER2 [ 148 ] .", "label": "", "metadata": {}, "score": "46.16902"}
{"text": "6 , pp .1068 - 1074 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. Swaby , K. Blackwell , Z. Jiang , and Y. Sun , \" Neratinib in combination with trastuzumab for the treatment of advanced breast cancer : A phase I / II study , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "46.184784"}
{"text": "Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide , methotrexate , and fluorouracil , as adjuvant or primary systemic therapy : European Cooperative Trial in Operable Breast Cancer .", "label": "", "metadata": {}, "score": "46.228584"}
{"text": "Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide , methotrexate , and fluorouracil , as adjuvant or primary systemic therapy : European Cooperative Trial in Operable Breast Cancer .", "label": "", "metadata": {}, "score": "46.228584"}
{"text": "Larsen PB , Kumler I , Nielsen DL , et al .A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer .", "label": "", "metadata": {}, "score": "46.231567"}
{"text": "PubMed .Ross JS , Fletcher JA : The HER-2/neu oncogene in breast cancer : prognostic factor , predictive factor , and target for therapy .", "label": "", "metadata": {}, "score": "46.345287"}
{"text": "PubMed View Article .Scheuer W , Friess T , Burtscher H , Bossenmaier B , Endl J , Hasmann M : Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models .", "label": "", "metadata": {}, "score": "46.35479"}
{"text": "Unfortunately , in the GeparQuinto study , only the nonresponding HER2 - cohort will undergo a second randomisation based upon early response , whereas in the HER2 + cohort early response is not used to inform further decision - making .", "label": "", "metadata": {}, "score": "46.42359"}
{"text": "4 , pp .60 - 70 , 1999 .View at Google Scholar \u00b7 View at Scopus .R. Nahta , \" Pharmacological strategies to overcome HER2 cross - talk and trastuzumab resistance , \" Current Medicinal Chemistry , vol .", "label": "", "metadata": {}, "score": "46.44412"}
{"text": "113 - 124 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Barok , J. Isola , Z. P\u00e1lyi - Krekk et al . , \" Trastuzumab causes antibody - dependent cellular cytotoxicity - mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance , \" Molecular Cancer Therapeutics , vol .", "label": "", "metadata": {}, "score": "46.44582"}
{"text": "The primary endpoint was pCR .Premature discontinuation rates were 14.0 % with trastuzumab and 33.1 % with lapatinib .\" This direct comparison of trastuzumab and lapatinib showed that pathologic complete response rate with chemotherapy and lapatinib was significantly lower than that with chemotherapy and trastuzumab , \" Gunter Von Minckwitz , MD , of German Breast Cancer Group in Neu - Isenburg , and co - authors wrote in conclusion .", "label": "", "metadata": {}, "score": "46.476734"}
{"text": "In a multi - centre phase II study , 20 % of patients with refractory brain metastases achieved a CNS objective response following treatment with lapatinib and capecitabine [ 40 ] , highlighting the promise of a small molecule TKI in this subset of patients .", "label": "", "metadata": {}, "score": "46.497845"}
{"text": "17 , pp .5650 - 5655 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . S. Varchetta , N. Gibelli , B. Oliviero et al . , \" Elements related to heterogeneity of antibody - dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2 , \" Cancer Research , vol .", "label": "", "metadata": {}, "score": "46.591873"}
{"text": "20 , pp .5813 - 5817 , 2002 .View at Google Scholar \u00b7 View at Scopus .T. Repka , E. G. Chiorean , J. Gay et al . , \" Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer : a pilot study , \" Clinical Cancer Research , vol .", "label": "", "metadata": {}, "score": "46.596127"}
{"text": "Thomas G , Chard\u00e8s T , Gaborit N , et al .HER3 as biomarker and therapeutic target in pancreatic cancer : New insights in pertuzumab therapy in preclinical models .", "label": "", "metadata": {}, "score": "46.659847"}
{"text": "Clinical Practice Guidelines in Oncology , Version.2.2005 .Jenkintown , PA : NCCN ; 2005 .Piccart - Gebhart MJ , Procter M , Leyland - Jones B , et al . ; Herceptin Adjuvant ( HERA )", "label": "", "metadata": {}, "score": "46.67207"}
{"text": "Cobleigh MA , Vogel CL , Tripathy D , et al .Multinational study of the efficacy and safety of humanized anti - HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease .", "label": "", "metadata": {}, "score": "46.69195"}
{"text": "In the NSABP B-41 study , although the pCR rate in the dual - blockade arm was 60 % , the difference was not statistically significant [ 15 ] .", "label": "", "metadata": {}, "score": "46.691982"}
{"text": "J Clin Oncol 2014 , 32 : 68 - 75 .PubMed View Article .L\u00f3pez - Tarruella S , Jerez Y , M\u00e1rquez - Rodas I , Mart\u00edn M : Neratinib ( HKI-272 ) in the treatment of breast cancer .", "label": "", "metadata": {}, "score": "46.711597"}
{"text": "6 , pp . 1063 - 1070 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .G. von Minckwitz , A. Du Bois , M. Schmidt et al . , \" Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer : a German Breast Group 26/Breast International Group 03 - 05 study , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "46.740017"}
{"text": "Figure 2 . neoALTTO ( Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation ) study design .CTCs , circulating tumour cells ; FEC , 5-fluoruracil - epirubicin - cyclophosphamide ; PET , positron emission tomography .", "label": "", "metadata": {}, "score": "46.760902"}
{"text": "Finally , ex vivo analysis of patient tumors will add significantly to the literature .Tumors can be isolated and cultured to create primary models or implanted in mice to create xenografts .", "label": "", "metadata": {}, "score": "46.77581"}
{"text": "Studies should incorporate analysis of not only total IGF - IR expression levels , but also markers of IGF - I signaling activation including phosphorylated IRS-1/2 and expression of IGFBPs , and correlate these with response to trastuzumab .", "label": "", "metadata": {}, "score": "46.78794"}
{"text": "4 , pp .395 - 402 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . Y. Nagata , K. H. Lan , X. Zhou et al . , \" PTEN activation contributes to tumor inhibition by trastuzumab , and loss of PTEN predicts trastuzumab resistance in patients , \" Cancer Cell , vol .", "label": "", "metadata": {}, "score": "46.827343"}
{"text": "Randomized controlled trials ( RCTs ) comparing anti - EGFR agents with or without conventional chemotherapy versus conventional chemotherapy alone or no treatment in women with histologically proven ovarian cancer .", "label": "", "metadata": {}, "score": "46.91031"}
{"text": "Introduction .Neoadjuvant chemotherapy is the standard of care for patients with locally advanced and inflammatory breast cancer ( IBC ) [ 1 ] , with the goal of improving operability and eradicating micrometastatic disease .", "label": "", "metadata": {}, "score": "46.915054"}
{"text": "Patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen .In combination with gemcitabine for the first - line treatment of patients with locally advanced , unresectable or metastatic pancreatic cancer .", "label": "", "metadata": {}, "score": "46.944523"}
{"text": "At the first planned interim analysis ( median follow - up of 1 year ) , 347 events ( recurrence of breast cancer , contralateral breast cancer , second non - breast malignant disease , or death ) were observed ; 127 events in the trastuzumab group and 220 in the observation group .", "label": "", "metadata": {}, "score": "47.066643"}
{"text": "956 - 960 , 2012 .View at Google Scholar .C. Mazouni , A. Hall , K. Broglio et al . , \" Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy , \" Cancer , vol .", "label": "", "metadata": {}, "score": "47.074745"}
{"text": "Molecular profiles suggested that nonresponders use autophagy and stem - cell - related pathways to evade therapy , while responders have disruption of HER2-HER3 linkages and known downstream regulators of growth and transcription [ 16 ] .", "label": "", "metadata": {}, "score": "47.079338"}
{"text": "2603 - 2614 , 2012 .View at Google Scholar .K. Tamura , C. Shimizu , T. Hojo et al . , \" Fc \u03b3 R2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer , \" Annals of Oncology , vol .", "label": "", "metadata": {}, "score": "47.149754"}
{"text": "According to NCCN , pertuzumab may be considered in combination with trastuzumab with or without cytotoxic therapy ( e.g. , vinorelbine or taxane ) for one line of therapy beyond 1st - line therapy in patients previously treated with chemotherapy and trastuzumab in the absence of pertuzumab .", "label": "", "metadata": {}, "score": "47.16642"}
{"text": "Side effects were typically mild ; In BR.21 , only 5 % of patients had to discontinue erlotinib because of toxic effects .Tyrosine kinase inhibitors targeting EGFR demonstrate activity in unselected patient populations but consideration of the molecular characteristics of tumors will certainly help us guide costly therapies for those patients most likely to benefit .", "label": "", "metadata": {}, "score": "47.187588"}
{"text": "Based on these data , the efficacy of adding pertuzumab to trastuzumab has been investigated .In the CLEOPATRA study , patients were randomized between placebo plus trastuzumab plus docetaxel or pertuzumab plus trastuzumab plus docetaxel .", "label": "", "metadata": {}, "score": "47.224216"}
{"text": "12 , pp .1999 - 2006 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .G. Cancello , E. Montagna , D. D'Agostino et al . , \" Continuing trastuzumab beyond disease progression : outcomes analysis in patients with metastatic breast cancer , \" Breast Cancer Research , vol .", "label": "", "metadata": {}, "score": "47.235172"}
{"text": "Pertuzumab : Evolving therapeutic strategies in the management of HER2-overexpressing breast cancer .Expert Opin Biol Ther .Zagouri F , Sergentanis TN , Chrysikos D , et al .", "label": "", "metadata": {}, "score": "47.270386"}
{"text": "This design can also provide valuable insight regarding drug pharmacodynamics and early evidence of drug activity and highlight potential mechanisms of resistance .As this phase of design is purely for research purposes and does not offer patients direct therapeutic benefit , there are ethical concerns that must be respected [ 40 ] .", "label": "", "metadata": {}, "score": "47.296745"}
{"text": "The results were similar in the nocomparative , randomized phase 2 CHER - LOB study with an anthracycline- and taxane - based chemotherapy [ 14 ] .", "label": "", "metadata": {}, "score": "47.302246"}
{"text": "Radiation therapy should be considered in most patients after surgical resection .Chemotherapy is reserved for palliative treatment of metastatic disease but results are disappointing .", "label": "", "metadata": {}, "score": "47.34845"}
{"text": "Interestingly , matrix metalloproteinase activation by APMA caused cleavage of membrane proteins including Muc4 in JIMT-1 , leading to increased binding of trastuzumab [ 69 ] , suggesting that Muc4 interaction with HER2 results in epitope masking such that trastuzumab can not recognize and bind to HER2 .", "label": "", "metadata": {}, "score": "47.368153"}
{"text": "As HER3 and its ligand neuregulin are implicated in pancreatic tumorigenesis , these researchers investigated whether HER3 expression could be a predictive biomarker of pertuzumab efficacy in HER2low - expressing pancreatic cancer .", "label": "", "metadata": {}, "score": "47.37552"}
{"text": "979 - 986 , 1991 .View at Google Scholar \u00b7 View at Scopus .R. J. Pietras , B. M. Fendly , V. R. Chazin , M. D. Pegram , S. B. Howell , and D. J. Slamon , \" Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells , \" Oncogene , vol .", "label": "", "metadata": {}, "score": "47.409615"}
{"text": "Thus , the combination of trastuzumab and lapatinib achieves superior PFS and OS when compared to lapatinib alone amongst patients previously treated with trastuzumab .The absolute pathologic complete response rate ( pCR ) for those treated with trastuzumab and chemotherapy was 36 % versus 29 % when treated with lapatinib and chemotherapy [ 133 ] .", "label": "", "metadata": {}, "score": "47.416824"}
{"text": "7795 - 7800 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . Y. C. Wang , G. Morrison , R. Gillihan , J. Guo , R. M. Ward , X. Fu , et al . , \" Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers - role of estrogen receptor and HER2 reactivation , \" Breast Cancer Research , vol .", "label": "", "metadata": {}, "score": "47.44343"}
{"text": "In addition , definitions of pCR in neoadjuvant trials do not consistently account for the presence of minimal residual cellularity and residual in situ carcinoma .", "label": "", "metadata": {}, "score": "47.457108"}
{"text": "J. L. Parra - Palau , K. Pedersen , V. Peg et al . , \" A major role of p95/611-CTF , a carboxy - terminal fragment of HER2 , in the down - modulation of the estrogen receptor in HER2-positive breast cancers , \" Cancer Research , vol .", "label": "", "metadata": {}, "score": "47.46433"}
{"text": "It is found in increased amounts on some types of cancer cells ( HER2-positive ) , including some breast cancers .In these HER2-positive breast cancers , the increased amount of the HER2 protein contributes to cancer cell growth and survival .", "label": "", "metadata": {}, "score": "47.471046"}
{"text": "10 , pp .4285 - 4289 , 1992 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. Baselga , L. Norton , J. Albanell , Y. M. Kim , and J. Mendelsohn , \" Recombinant humanized anti - HER2 antibody ( herceptin(TM ) ) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts , \" Cancer Research , vol .", "label": "", "metadata": {}, "score": "47.480698"}
{"text": "Inhibition of HER2 Proteolytic Cleavage .p95HER2 fragments resulting from the proteolytic cleavage of the HER2 ECD have generated much interest due to the association of the 100 - 115 kDa p95HER2 fragment with a clinically more aggressive subset of HER2-positive breast cancers [ 4 ] .", "label": "", "metadata": {}, "score": "47.50432"}
{"text": "pCR has been proven to correlate with survival endpoints ( DFS and OS ) in neoadjuvant chemotherapeutic trials [ 25 , 26 ] but its precise definition is still debated .", "label": "", "metadata": {}, "score": "47.52548"}
{"text": "Blogs .Abstract .Breast cancers over - express the human epidermal growth factor receptor 2 ( HER2 ) in about 15 % of patients .", "label": "", "metadata": {}, "score": "47.528206"}
{"text": "The authors concluded that their analysis showed a significant improvement in OS with pertuzumab , trastuzumab , and docetaxel in patients with HER2-positive metastatic breast cancer , compared with placebo , trastuzumab , and docetaxel .", "label": "", "metadata": {}, "score": "47.560734"}
{"text": "View at Publisher \u00b7 View at Google Scholar .K. Pedersen , P. D. Angelini , S. Laos et al . , \" A naturally occurring HER2 carboxy - terminal fragment promotes mammary tumor growth and metastasis , \" Molecular and Cellular Biology , vol .", "label": "", "metadata": {}, "score": "47.610935"}
{"text": "16 , pp .2698 - 2704 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .S. Vukelja , H. Rugo , C. Vogel , R. Borson , E. Tan - Chiu , and M. Birkner , \" A phase II study of trastuzumab - DM1 , a first - in - class HER2 antibody - drug conjugate , in patients with HER2 + metastatic breast cancer , \" Cancer Research , vol .", "label": "", "metadata": {}, "score": "47.667595"}
{"text": "Viani GA , Afonso SL , Stefano EJ , et al .Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer : A meta - analysis of published randomized trials .", "label": "", "metadata": {}, "score": "47.684654"}
{"text": "2710 - 2716 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. Baselga , K. A. Gelmon , S. Verma et al . , \" Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "47.72481"}
{"text": "856 - 863 , 2011 .View at Google Scholar .J. Baselga , I. Bradbury , H. Eidtmann , et al . , \" Lapatinib with trastuzumab for HER2-positive early breast cancer ( NeoALTTO ) : a randomised , open - label , multicentre , phase 3 trial , \" The Lancet , vol .", "label": "", "metadata": {}, "score": "47.755783"}
{"text": "C50.011 - C50.929 .Malignant neoplasm of breast [ HER2 positive ] .ICD-10 codes not covered for indications listed in the CPB ( not all - inclusive ) : .", "label": "", "metadata": {}, "score": "47.862026"}
{"text": "C50.011 - C50.929 .Malignant neoplasm of breast [ HER2 positive ] .ICD-10 codes not covered for indications listed in the CPB ( not all - inclusive ) : .", "label": "", "metadata": {}, "score": "47.862026"}
{"text": "485 - 490 , 2011 .View at Google Scholar . A. Valachis , A. Nearchou , P. Lind , and D. Mauri , \" Lapatinib , trastuzumab or the combination added to preoperative chemotherapy for breast cancer : a meta - analysis of randomized evidence , \" Breast Cancer Research and Treatment , vol .", "label": "", "metadata": {}, "score": "47.91797"}
{"text": "6878 , pp .279 - 280 , 2002 .View at Google Scholar \u00b7 View at Scopus .L. Arnould , M. Gelly , F. Penault - Llorca et al . , \" Trastuzumab - based treatment of HER2-positive breast cancer : an antibody - dependent cellular cytotoxicity mechanism ? \"", "label": "", "metadata": {}, "score": "47.93101"}
{"text": "All of the 49 cases of malignant melanoma were negative for HER2 over - expression by IHC .However , 2 samples ( 3 % ) were found to have a weak level of HER2 expression ( 1 + level of staining ) .", "label": "", "metadata": {}, "score": "47.97196"}
{"text": "Trastuzumab was , however , associated with a higher rate of congestive heart failure -- 2 % versus 0.3 % in the control group .Serious infusion reactions including fatal infusion reactions as well as pulmonary toxicity have been reported with trastuzumab .", "label": "", "metadata": {}, "score": "47.999573"}
{"text": "Here is the current FDA approved indication for lapatinib : .In combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline , a taxane , and trastuzumab .", "label": "", "metadata": {}, "score": "48.00201"}
{"text": "This mechanism of action is supported by findings from a preclinical study of HER2-overexpressing murine xenograft models , in which the antitumour activity of trastuzumab was markedly reduced in mice bearing defective Fc \u03b3 receptors [ 7 ] .", "label": "", "metadata": {}, "score": "48.02848"}
{"text": "HER2/neu over - expression is defined as 2 or 3 circumferential membranous staining with an anti - HER2 antibody by immunohistochemistry ( IHC ) performed on a paraffin embedded tissue .", "label": "", "metadata": {}, "score": "48.059204"}
{"text": "Cell cycle regulators including upregulation of Bcl-2 [ 126 ] and survivin , downregulation of Fox03a , and reduced expression of p27kip1 [ 64 ] may serve as molecular predictors of resistance to trastuzumab .", "label": "", "metadata": {}, "score": "48.060783"}
{"text": "Effects of a human compact anti - ErbB2 antibody on prostate cancer .Oncol Rep. 2012;28(1):297 - 302 .Kaye SB , Poole CJ , Danska - Bidzinska A , et al .", "label": "", "metadata": {}, "score": "48.145874"}
{"text": "TKIs A phase II open - label study assessed the safety and efficacy of adding pazopanib , an oral angiogenesis inhibitor targeting VEGFR , platelet - derived growth factor receptor and c - kit , to lapatinib in previously untreated HER2-positive metastatic breast cancer .", "label": "", "metadata": {}, "score": "48.20885"}
{"text": "6878 , pp .279 - 280 , 2002 .View at Google Scholar \u00b7 View at Scopus . K. S. Klos , X. Zhou , S. Lee et al . , \" Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone , \" Cancer , vol .", "label": "", "metadata": {}, "score": "48.22702"}
{"text": "In contrast , apoptosis was induced in only a small percentage of cells , with a significant increase in apoptosis seen when trastuzumab and pertuzumab were combined [ 157 ] .", "label": "", "metadata": {}, "score": "48.247185"}
{"text": "24 , pp .9330 - 9336 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. Baselga , K. A. Gelmon , S. Verma et al . , \" Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "48.262924"}
{"text": "Esteva et al . suggested that in 45 patients with HER2 + tumors who received concomitant trastuzumab and paclitaxel followed by FEC , a lower expression of genes involved with CD40 signaling was associated with a greater risk of residual disease [ 57 ] .", "label": "", "metadata": {}, "score": "48.313316"}
{"text": "Ongoing neoadjuvant studies exploring the efficacy of novel anti - HER2 agents with innovative designs , like the ' biological window ' and ' learn on the way ' , promise to deliver new knowledge of breast cancer biology and treatment .", "label": "", "metadata": {}, "score": "48.319633"}
{"text": "Pegram MD , Lipton A , Hayes DF , et al .Phase II study of receptor - enhanced chemosensitivity using recombinant humanized anti - p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu - overexpressing metastatic breast cancer refractory to chemotherapy treatment .", "label": "", "metadata": {}, "score": "48.348133"}
{"text": "[ 50 ] .Results were similar when the cutoff was set at 20 % and 30 % as well as for clinical response .In this translational study , p95 expression indicates response to neoadjuvant trastuzumab but not resistance , in contrast to what was expected [ 50 ] .", "label": "", "metadata": {}, "score": "48.358154"}
{"text": "The primary endpoint was pCR , as defined by National Surgical Adjuvant Breast and Bowel Project criteria .The pCR rate did not differ between the trastuzumab and lapatinib arms .", "label": "", "metadata": {}, "score": "48.370422"}
{"text": "The combined treatment group demonstrated a statistically significant improvement in survival with the addition of erlotinib , although the absolute improvement could be measured in weeks .", "label": "", "metadata": {}, "score": "48.433342"}
{"text": "PubMed View Article .Houston SJ , Plunkett TA , Barnes DM , Smith P , Rubens RD , Miles DW : Overexpression of c - erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer .", "label": "", "metadata": {}, "score": "48.45508"}
{"text": "2003;30(2 Suppl 3):19 - 21 .Swedish Council on Technology Assessment in Health Care ( SBU ) .Trastuzumab ( Herceptin ) for metastasized breast cancer - early assessment briefs ( Alert ) .", "label": "", "metadata": {}, "score": "48.51403"}
{"text": "Twelve months of adjuvant trastuzmab is the usual medically necessary duration for persons with HER2-positive early breast cancer ( Goldhirsch et al , 2013 ; Pivot et al , 2013 ) .", "label": "", "metadata": {}, "score": "48.51427"}
{"text": "PubMed View Article .Nahta R : Pharmacological strategies to overcome HER2 cross - talk and Trastuzumab resistance .Curr Med Chem 2012 , 19 : 1065 - 1075 .", "label": "", "metadata": {}, "score": "48.53093"}
{"text": "Neratinib single agent has been compared with the association of lapatinib plus capecitabine .Neratinib is currently developed in combination with paclitaxel , vinorelbine , capecitabine and temsirolimus [ 46 - 49 ] .", "label": "", "metadata": {}, "score": "48.57501"}
{"text": "INTACT 1 and 2 , both phase III trials , were not able to demonstrate a benefit in survival when gefitinib was combined with either carboplatin plus paclitaxel or gemcitabine plus cisplatin .", "label": "", "metadata": {}, "score": "48.67675"}
{"text": "There was no significant difference in pCR between the lapatinib and the trastuzumab group [ 42 ] .First results from the phase III ALLTO trial comparing one year of lapatinib alone , trastuzumab alone , their sequence or their combination in an adjuvant setting in 8,381 HER2 positive breast cancers have been reported [ 42 ] .", "label": "", "metadata": {}, "score": "48.765255"}
{"text": "In contrast to the combination of lapatinib and trastuzumab , addition of pertuzumab does not appear to increase ADCC ; rather both antibodies induce ADCC on their own , without any further increase when given together [ 156 ] .", "label": "", "metadata": {}, "score": "48.773743"}
{"text": "21 , pp . 8537- 8546 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus Molecular Mechanisms of Trastuzumab - Based Treatment in HER2-Overexpressing Breast Cancer .", "label": "", "metadata": {}, "score": "48.830456"}
{"text": "12 , pp .5268 - 5282 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .I. E. Krop , M. Beeram , S. Modi et al . , \" Phase I study of trastuzumab - DM1 , an HER2 antibody - drug conjugate , given every 3 weeks to patients with HER2-positive metastatic breast cancer , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "48.84059"}
{"text": "Dunnwald LK , Gralow JR , Ellis GK , Livingston RB , Linden HM , Lawton TJ , Barlow WE , Schubert EK , Mankoff DA : Residual tumor uptake of [ 99mTc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival .", "label": "", "metadata": {}, "score": "48.861385"}
{"text": "We investigated the combination of pertuzumab or trastuzumab , or both , with docetaxel and the combination of pertuzumab and trastuzumab without chemotherapy in the neoadjuvant setting ... .", "label": "", "metadata": {}, "score": "48.900215"}
{"text": "More recently , the single agent therapeutic approach with gefitinib was published in the September 2009 issue of the New England Journal of Medicine as the phase III IPASS trial , which randomized patients with adenocarcinoma of the lung to gefitinib or carboplatin plus paclitaxel .", "label": "", "metadata": {}, "score": "48.93216"}
{"text": "2343 - 2346 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. Baselga , J. Cortes , S. B. Kim , et al . , \" Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer , \" The New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "48.938515"}
{"text": "12 , no .4 , pp .395 - 402 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . Y. Nagata , K. H. Lan , X. Zhou et al . , \" PTEN activation contributes to tumor inhibition by trastuzumab , and loss of PTEN predicts trastuzumab resistance in patients , \" Cancer Cell , vol .", "label": "", "metadata": {}, "score": "48.96064"}
{"text": "IGF - IR activation may serve as a biomarker of resistance to trastuzumab .IGF - IR overexpression was associated with worse progression - free survival in patients treated with adjuvant trastuzumab [ 101 ] , and poor response to preoperative trastuzumab plus chemotherapy [ 163 ] .", "label": "", "metadata": {}, "score": "48.973595"}
{"text": "2840 - 2849 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .L. N. Harris , F. You , S. J. Schnitt et al . , \" Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer , \" Clinical Cancer Research , vol .", "label": "", "metadata": {}, "score": "48.996662"}
{"text": "J Clin Invest 2010 , 120 : 103 - 114 .PubMed Central PubMed View Article .Lu CH , Wyszomierski SL , Tseng LM , Sun MH , Lan KH , Neal CL , Mills GB , Hortobagyi GN , Esteva FJ , Yu D : Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency .", "label": "", "metadata": {}, "score": "49.032364"}
{"text": "The preoperative ( neoadjuvant ) setting is ideally suited for testing new therapies .Clinical researchers and patients have embraced the preoperative model as standard of care and as a strategy for evaluating new therapies .", "label": "", "metadata": {}, "score": "49.049057"}
{"text": "However , additional investigations that incorporate biomarker - based patient selection and more complete inhibition of IGF - IR and IGF - IR / insR signaling may be warranted and have recently been reviewed [ 161 ] .", "label": "", "metadata": {}, "score": "49.06778"}
{"text": "View at Google Scholar .R. Nahta , T. Takahashi , N. T. Ueno , M. C. Hung , and F. J. Esteva , \" P27kip1 down - regulation is associated with trastuzumab resistance in breast cancer cells , \" Cancer Research , vol .", "label": "", "metadata": {}, "score": "49.114944"}
{"text": "1573 - 1586 , 2012 .View at Google Scholar . H. Kurokawa , A. E. G. Lenferink , J. F. Simpson et al . , \" Inhibition of HER2/neu ( erbB-2 ) and mitogen - activated protein kinases enhances tamoxifen action against HER2-overexpressing , tamoxifen - resistant breast cancer cells , \" Cancer Research , vol .", "label": "", "metadata": {}, "score": "49.144882"}
{"text": "719 - 726 , 2002 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .F. J. Esteva , V. Valero , D. Booser et al . , \" Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "49.152336"}
{"text": "Pertuzumab and trastuzumab without chemotherapy eradicated tumors in a proportion of women and showed a favorable safety profile .The authors stated that these findings justified further exploration in adjuvant trials and support the neoadjuvant approach for accelerating drug assessment in early breast cancer .", "label": "", "metadata": {}, "score": "49.1898"}
{"text": "Dual HER2 Blockade Better than One as Neoadjuvant Tx .Action Points .In this study , significantly more women with HER2-positive breast cancer achieved complete tumor resolution when they received two targeted agents before surgery instead of one .", "label": "", "metadata": {}, "score": "49.198494"}
{"text": "1037 - 1044 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . Y. C. Wang , G. Morrison , R. Gillihan , et al . , \" Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers - role of estrogen receptor and HER2 reactivation , \" Breast Cancer Research , vol .", "label": "", "metadata": {}, "score": "49.23418"}
{"text": "4132 - 4141 , 2002 .View at Google Scholar \u00b7 View at Scopus . Y. Nagata , K. H. Lan , X. Zhou et al . , \" PTEN activation contributes to tumor inhibition by trastuzumab , and loss of PTEN predicts trastuzumab resistance in patients , \" Cancer Cell , vol .", "label": "", "metadata": {}, "score": "49.278866"}
{"text": "Pertuzumab is the most recent agent approved by the FDA in combination with trastuzumab and docetaxel for the treatment of patients with HER2(+ ) metastatic breast cancer who have not received prior anti - HER2 therapy or chemotherapy for metastatic disease .", "label": "", "metadata": {}, "score": "49.281548"}
{"text": "View at Google Scholar \u00b7 View at Scopus .R. Kumar , H. M. Shepard , and J. Mendelsohn , \" Regulation of phosphorylation of the c - erbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s ) in human mammary carcinoma cells , \" Molecular and Cellular Biology , vol .", "label": "", "metadata": {}, "score": "49.35541"}
{"text": "Truncated HER2 Receptor .Truncated p95HER2 fragments exhibit resistance to trastuzumab because they lack trastuzumab - binding epitopes and may arise either through proteolytic cleavage of the HER2 ECD or alternative translation - initiation sites of the HER2 protein [ 4 ] .", "label": "", "metadata": {}, "score": "49.359825"}
{"text": "Dual inhibition with pertuzumab and trastuzumab has reached an advanced phase of development in combination with chemotherapy .A randomised phase III study ( CLEOPATRA , NCT00567190 ) evaluated the benefit of adding pertuzumab to the combination of trastuzumab and docetaxel in previously untreated HER2-positive metastatic breast cancer .", "label": "", "metadata": {}, "score": "49.528423"}
{"text": "Patients received treatment until either the cancer progressed or the AEs became intolerable .The study was designed to measure PFS and OS .Results showed that patients treated with Kadcyla had a median PFS of 9.6 months compared to 6.4 months in patients treated with lapatinib plus capecitabine .", "label": "", "metadata": {}, "score": "49.550568"}
{"text": "In concordance , both PIK3CA mutations and PTEN loss were associated with inferior time - to - progression and survival in a retrospective study of 256 trastuzumab - treated HER2-positive metastatic breast cancer patients [ 23 ] .", "label": "", "metadata": {}, "score": "49.567097"}
{"text": "This was further explored in a study presented at ASCO 2007 , which demonstrated that lapatinib does not appear to increase the risk of cardiomyopathy , even when used in combination with trastuzumab .", "label": "", "metadata": {}, "score": "49.569874"}
{"text": "Similarly , HER2-positive gastric cancer cells isolated from patients with advanced disease showed reduced NK - mediated ADCC , which was improved in vitro upon stimulation with IL-2 [ 111 ] .", "label": "", "metadata": {}, "score": "49.590107"}
{"text": "Two randomized phase III trials of T - DM1 are awaiting final results ; the EMILIA trial is evaluating T - DM1 compared with lapatinib plus capecitabine .", "label": "", "metadata": {}, "score": "49.607468"}
{"text": "They reported adjusted HRs for OS and PFS and risk ratios ( RRs ) comparing adverse events in women who received gemcitabine plus pertuzumab and gemcitabine plus placebo .", "label": "", "metadata": {}, "score": "49.670193"}
{"text": "Padhani AR , Hayes C , Assersohn L , Powles T , Makris A , Suckling J , Leach MO , Husband JE : Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast - enhanced MR imaging : initial clinical results .", "label": "", "metadata": {}, "score": "49.719967"}
{"text": "473 - 482 , 2005 .View at Google Scholar \u00b7 View at Scopus . S. P. Fessler , M. T. Wotkowicz , S. K. Mahanta , and C. Bamdad , \" MUC1 is a determinant of trastuzumab ( Herceptin ) resistance in breast cancer cells , \" Breast Cancer Research and Treatment , vol .", "label": "", "metadata": {}, "score": "49.740356"}
{"text": "Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma .Cancer .", "label": "", "metadata": {}, "score": "49.81942"}
{"text": "J Clin Oncol 2010 , 28 : 105 - 113 .PubMed View Article .PLoS One 2013 , 8 : e79775 .Mahmoud S , Lee A , Ellis I , Green A : CD8(+ ) T lymphocytes infiltrating breast cancer : a promising new prognostic marker ?", "label": "", "metadata": {}, "score": "49.867363"}
{"text": "The addition of complement - containing plasma and interleukin-2 increased the cytotoxic effect induced by both mAbs .In low HER2/neu USPC expressors , trastuzumab was more potent than pertuzumab in inducing ADCC .", "label": "", "metadata": {}, "score": "49.9104"}
{"text": "Trastuzumab infusion should be interrupted for patients with dyspnea or clinically significant hypotension .Patients should be monitored until signs and symptoms completely resolve .Trastuzumab should be discontinued for infusion reactions manifesting as anaphylaxis , angioedema , interstitial pneumonitis , or acute respiratory distress syndrome .", "label": "", "metadata": {}, "score": "49.930573"}
{"text": "The truncated p95HER2 receptor retains a highly functional HER2 kinase domain where lapatinib can bind .Indeed , lapatinib monotherapy or in combination with capecitabine seems to be equally effective in patients with p95HER2-positive and p95HER2-negative breast tumors [ 48 ] .", "label": "", "metadata": {}, "score": "49.939667"}
{"text": "As reviewed below , progression on lapatinib is often associated with heightened mTOR or MEK signaling ; thus , coinhibition of PI3K / mTOR and MEK is a plausible strategy for treating lapatinib - na\u00efve or lapatinib - refractory HER2-positive breast cancer .", "label": "", "metadata": {}, "score": "50.03219"}
{"text": "They found no difference in terms of BCS between the treatment arms [ 36 ] .Once again , the number of studies and patients is relatively small and can affect the power of the meta - analysis to reveal statistically significant results ( five trials and 1442 patients for trastuzumab versus lapatinib ; 3 trials and 734 patients for trastuzumab versus combination ) [ 36 ] .", "label": "", "metadata": {}, "score": "50.31408"}
{"text": "We will also discuss data supporting therapeutic combinations of trastuzumab with agents targeted against molecules implicated in trastuzumab resistance .The roles of insulin - like growth factor - I receptor and the estrogen receptor are discussed in the context of resistance to HER2-targeted therapies .", "label": "", "metadata": {}, "score": "50.33704"}
{"text": "Well - designed neoadjuvant studies can quickly generate important preliminary data on the efficacy of novel therapies based on short - term endpoints such as pCR .", "label": "", "metadata": {}, "score": "50.358295"}
{"text": "PubMed View Article .N Engl J Med 2005 , 353 : 1673 - 1684 .PubMed View Article .Garrett JT , Arteaga CL : Resistance to HER2-directed antibodies and tyrosine kinase inhibitors .", "label": "", "metadata": {}, "score": "50.36077"}
{"text": "Mathew and Perez ( 2011 ) reviewed the clinical data of T - DM1 in terms of safety and effectiveness , and described ongoing and future trials evaluating its potential role in the management of patients with HER2-positive MBC .", "label": "", "metadata": {}, "score": "50.365852"}
{"text": "Rexer BN , Arteaga CL : Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene - amplified breast cancer : mechanisms and clinical implications .", "label": "", "metadata": {}, "score": "50.402138"}
{"text": "sHER2 can be measured by enzyme - linked immunosorbent assay ( ELISA ) .In the GeparQuattro trial , Witzel et al .found a significant positive association between pCR and elevated sHER2 levels ( above 15 ng / mL , .", "label": "", "metadata": {}, "score": "50.474716"}
{"text": "PubMed View Article .Dubsk\u00e1 L , Andera L , Sheard MA : HER2 signaling downregulation by trastuzumab and suppression of the PI3K / Akt pathway : an unexpected effect on TRAIL - induced apoptosis .", "label": "", "metadata": {}, "score": "50.503326"}
{"text": "Other CPT codes related to the CPB : .Molecular diagnostics .Molecular cytogenetics .Immunohistochemistry or immunocytochemistry , per specimen .Morphometric analysis , tumor immunohistochemistry ( e.g. , Her-2/neu , estrogen receptor / progesterone receptor ) , quantitative or semiquantitative , each antibody .", "label": "", "metadata": {}, "score": "50.509056"}
{"text": "However PET baseline characteristics and metabolic response to neoadjuvant chemotherapy are highly dependent on the histologic type of breast cancer ( i.e. , luminal versus HER2-positive versus triple - negative tumors ) [ 63 ] .", "label": "", "metadata": {}, "score": "50.549755"}
{"text": "In contrast , irreversible TKIs CL-387785 and WZ-4002 bound irreversibly to an active conformation of HER2 and suppressed HER2 signaling and growth in stable clones of wild - type or mutant T798 M , L755P , or L755S HER2 [ 130 ] .", "label": "", "metadata": {}, "score": "50.553535"}
{"text": "The coupling of smaller neoadjuvant ' proof of principle ' studies with larger adjuvant registration trials offers the promise of speeding up the time to market of new therapies .", "label": "", "metadata": {}, "score": "50.610367"}
{"text": "5 , pp .269- 280 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Cuello , S. A. Ettenberg , A. S. Clark et al . , \" Down - regulation of the erbB-2 receptor by trastuzumab ( Herceptin ) enhances tumor necrosis factor - related apoptosis - inducing ligand - mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2 , \" Cancer Research , vol .", "label": "", "metadata": {}, "score": "50.632965"}
{"text": "1138 - 1144 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. Cort\u00e9s , J. Baselga , T. Petrella , and R. Abbas , \" Pertuzumab monotherapy following trastuzumab - based treatment : activity and tolerability in patients with advanced HER2- positive breast cancer , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "50.683308"}
{"text": "FISH results on 21 other randomly selected IHC - negative samples were also negative for HER2 amplification .Flow cytometry failed to show HER2 over - expression in 2 melanoma cell lines , and treatment of these cells with trastuzumab did not affect their proliferation rate .", "label": "", "metadata": {}, "score": "50.72778"}
{"text": "Di\u00e9ras V , Bachelot T : The success story of trastuzumab emtansine , a targeted therapy in HER2-positive breast cancer .Target Oncol 2014 , 9 : 111 - 122 .", "label": "", "metadata": {}, "score": "50.72799"}
{"text": "Intra - thecal trastuzumab alone or as part of combination therapies seemed to be safe ; no serious adverse events were reported in 88.2 % of cases .", "label": "", "metadata": {}, "score": "50.756027"}
{"text": "Stebbing J , Copson E , O'Reilly S. Herceptin ( trastuzamab ) in advanced breast cancer .Cancer Treat Rev. 2000;26(4):287 - 290 .U.S. Food and Drug Administration ( FDA ) , Center for Devices and Radiologic Health .", "label": "", "metadata": {}, "score": "50.799164"}
{"text": "Lapatinib and Side Effects .As we will discuss in further detail in the following section on antibody therapies , the HER2/neu therapy with the longest track record , trastuzumab , confers a risk of cardiac toxicity , particularly when combined with anthracycline - based chemotherapy .", "label": "", "metadata": {}, "score": "50.80736"}
{"text": "K. Berns , H. M. Horlings , B. T. Hennessy et al . , \" A functional genetic approach identifies the PI3 K pathway as a major determinant of trastuzumab resistance in breast cancer , \" Cancer Cell , vol .", "label": "", "metadata": {}, "score": "50.851944"}
{"text": "The study was designed to measure the length of time a patient lived without the cancer progressing , progression - free survival ( PFS ) .", "label": "", "metadata": {}, "score": "50.872437"}
{"text": "They stated that there is an urgent need for prospective biomarker - driven trials to identify patients for whom dual targeting is cost - effective .", "label": "", "metadata": {}, "score": "50.88271"}
{"text": "1800 - 1808 , 2002 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. D. Seidman , M. N. Fornier , F. J. Esteva et al . , \" Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "50.892246"}
{"text": "Pertuzumab and erlotinib in patients with relapsed non - small cell lung cancer : A phase II study using 18F - fluorodeoxyglucose positron emission tomography / computed tomography imaging .", "label": "", "metadata": {}, "score": "50.906322"}
{"text": "However , pCR rates were not different for p95HER2-positive and p95HER2-negative tumors in any treatment group [ 14 ] .HER2 Serum Level .", "label": "", "metadata": {}, "score": "50.94191"}
{"text": "437 - 445 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .I. Witzel , S. Loibl , G. von Minckwitz , et al . , \" Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab - a translational project in the neoadjuvant GeparQuinto trial , \" British Journal of Cancer , vol .", "label": "", "metadata": {}, "score": "50.98024"}
{"text": "Thirty six percent of women treated with trastuzumab plus paclitaxel had a tumor response , compared to only 15 % of women receiving paclitaxel alone .", "label": "", "metadata": {}, "score": "50.989162"}
{"text": "119 ( 93 % ) of the 128 cardiac events ( clinical or based on assessment of LVEF ) occurred while patients were receiving trastuzumab .", "label": "", "metadata": {}, "score": "51.00482"}
{"text": "17 , pp .2235 - 2249 , 1998 .View at Google Scholar \u00b7 View at Scopus .P. Carter , L. Presta , C. M. Gorman et al . , \" Humanization of an anti - p185(HER2 ) antibody for human cancer therapy , \" Proceedings of the National Academy of Sciences of the United States of America , vol .", "label": "", "metadata": {}, "score": "51.055107"}
{"text": "With the exception of the National Cancer Institute study [ 35 ] that includes only patients with hormone receptor - positive ( HR + ) and HER2 + breast cancer , all other studies include HR + and HR - disease .", "label": "", "metadata": {}, "score": "51.126442"}
{"text": "Hyperactivated Downstream Signaling : Mechanism of Trastuzumab Resistance .Activation of downstream signaling pathways can also override growth inhibition by trastuzumab .These mechanisms have been reviewed elsewhere [ 39 ] and include increased signaling from PI3 K , focal adhesion kinase ( FAK ) , and Src .", "label": "", "metadata": {}, "score": "51.157352"}
{"text": "Latif Z , Watters AD , Dunn I , et al .HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder : A role for anti - HER2 therapy ?", "label": "", "metadata": {}, "score": "51.18875"}
{"text": "NIH/3T3 cells transfected with human HER2 formed colonies in soft agar and tumors in athymic mice [ 10 ] when cells expressed amplified levels of HER2 , demonstrating that amplified and overexpressed human HER2 acts as an oncogene .", "label": "", "metadata": {}, "score": "51.20694"}
{"text": "They identified few and mostly small clinical studies .Study designs were very heterogeneous making comparisons on end - points difficult .Overall survival for patients treated with trastuzumab varied from 8 to 25 months and 5.5 to 11 months for patients receiving lapatinib .", "label": "", "metadata": {}, "score": "51.346268"}
{"text": "Among 209 screened patients , 24 patients ( 11 % ) had tumors with 2 + or 3 + expression of HER2 .One patient achieved a partial response , and 1 patient experienced a treatment - related death due to pulmonary toxicity .", "label": "", "metadata": {}, "score": "51.365067"}
{"text": "View at Google Scholar . A. Crawford and R. Nahta , \" Targeting Bcl-2 in herceptin - resistant breast cancer cell lines , \" Current Pharmacogenomics and Personalized Medicine , vol .", "label": "", "metadata": {}, "score": "51.377678"}
{"text": "Breast Cancer Res Treat 2008 , 112 : 533 - 543 .PubMed View Article .Cameron D , Casey M , Oliva C , Newstat B , Imwalle B , Geyer CE : Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer : final survival analysis of a phase III randomized trial .", "label": "", "metadata": {}, "score": "51.394787"}
{"text": "10 , pp .1676 - 1682 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . S. S. Gayle , S. L. Arnold , R. M. O'Regan RM , and R. Nahta , \" Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance , \" Anti - Cancer Agents in Medicinal Chemistry , vol .", "label": "", "metadata": {}, "score": "51.44808"}
{"text": "It should be noted , however , that there was a great deal of crossover between the groups .Ultimately , the studies published to date reveal that the therapeutic effect of lapatinib is predominately limited to patients with HER2/neu positive breast cancer .", "label": "", "metadata": {}, "score": "51.51673"}
{"text": "Clinical relevance of different sequencing of doxorubicin and cyclophosphamide , methotrexate , and Fluorouracil in operable breast cancer .Gianni Bonadonna Department of Medical Oncology , Istituto Nazionale Tumori , Via Venezian 1 , 20133 Milan , Italy J Clin Oncol 22:1614 - 20 .", "label": "", "metadata": {}, "score": "51.64424"}
{"text": "Changes in tumor biology after PST are an early phenomenon ; so , an additional core biopsy performed after 14 days from treatment start should be considered in clinical trials ... .", "label": "", "metadata": {}, "score": "51.669456"}
{"text": "Genetic aberrations in the PI3K / Akt pathway are among the most prevalent in breast cancer and have been shown to mediate trastuzumab resistance .", "label": "", "metadata": {}, "score": "51.671585"}
{"text": "Interim analysis of OS favored the pertuzumab group but was not significant .These researchers reported results for OS after an additional year of follow - up .", "label": "", "metadata": {}, "score": "51.67605"}
{"text": "PubMed View Article .Ghebeh H , Barhoush E , Tulbah A , Elkum N , Al - Tweigeri T , Dermime S : FOXP3 + Tregs and B7-H1+/PD-1 + T lymphocytes co - infiltrate the tumor tissues of high - risk breast cancer patients : implication for immunotherapy .", "label": "", "metadata": {}, "score": "51.686325"}
{"text": "View at Google Scholar .View at Google Scholar .C. T. Fields , L. M. Crocker , M. X. Sliwkowski , and D. Anderson , \" Dual Targeting of HER2 : enhanced anti - tumour efficacy of trastuzumab - DM1 combined with pertuzumab , \" Proceedings of the American Association for Cancer Research , vol .", "label": "", "metadata": {}, "score": "51.731476"}
{"text": "The objective response rate and clinical benefit rate ( CBR ) were 3.4 % and 10.3 % in patients who received pertuzumab monotherapy after trastuzumab .", "label": "", "metadata": {}, "score": "51.769478"}
{"text": "PubMed View Article .Ravdin PM , Chamness GC : The c - erbB-2 proto - oncogene as a prognostic and predictive marker in breast cancer : a paradigm for the development of other macromolecular markers - a review .", "label": "", "metadata": {}, "score": "51.78837"}
{"text": "Several methods of CTC detection have been described , although reverse transcription - polymerase chain reaction and immunomagnetic / fluorescent approaches are the most advanced [ 57 , 58 ] .", "label": "", "metadata": {}, "score": "51.849075"}
{"text": "A similar model has been employed by the recently completed neo - tAnGo and tAnGo trials in nonselected populations [ 31 ] .Adjuvant registration trials require an enormous financial and patient investment to detect small differences in long - term outcome .", "label": "", "metadata": {}, "score": "51.86635"}
{"text": "Canadian Coordinating Office for Health Technology Assessment ( CCOHTA ) .Herceptin : Monoclonal antibody therapy for metastatic breast cancer .Issues in Emerging Health Technologies Issue 4 .", "label": "", "metadata": {}, "score": "51.877605"}
{"text": "Yang W , Klos K , Yang Y , Smith TL , Shi D , Yu D : ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A , C , and D in human breast carcinoma .", "label": "", "metadata": {}, "score": "51.934258"}
{"text": "Patients are given trastuzumab intravenously once a week .The appropriate duration of therapy is unknown , although studies have reported patients that have been treated with trastuzumab for 9 weeks .", "label": "", "metadata": {}, "score": "51.938965"}
{"text": "The remaining cleaved receptor is constitutively activated , suggesting that the presence of sHER2 also reflects a biological process leading to a more aggressive tumor behavior [ 47 ] .", "label": "", "metadata": {}, "score": "51.9747"}
{"text": "Only two agents possess regulatory approval for the treatment of HER2-positive breast cancer , with a lull of nearly a decade between the initial FDA approval of trastuzumab and that of lapatinib in 2007 .", "label": "", "metadata": {}, "score": "52.090736"}
{"text": "Pregnancy status must be verified prior to the start of Perjeta treatment .The therapy was reviewed under the agency 's priority review program , which provides for an expedited six - month review of drugs that may offer major advances in treatment .", "label": "", "metadata": {}, "score": "52.14407"}
{"text": "A wide local excision and axillary node dissection was performed .Metastatic tumor involved 9 of 28 nodes .Inter - phase fluorescence in situ hybridization ( FISH ) demonstrated chromosomal amplification of the Her-2/neu locus within the tumor and a nodal metastasis .", "label": "", "metadata": {}, "score": "52.163334"}
{"text": "Authors of a related commentary said that trials of targeted therapies could change the clinical evaluation process .Such an approach to clinical investigation could substantially reduce development costs and bring promising new drugs to patients more quickly , they wrote .", "label": "", "metadata": {}, "score": "52.349438"}
{"text": "Full guidance on trastuzumab for advanced breast cancer .Technology Appraisal Guidance No . 34 .London , UK : NICE ; March 2002 .Accessed February 4 , 2004 .", "label": "", "metadata": {}, "score": "52.358734"}
{"text": "Future studies will help to clarify the roles that KRAS and EGFR mutation status play in responses and outcomes in patients with NSCLC treated with TKIs , particularly with respect to an overall survival benefit .", "label": "", "metadata": {}, "score": "52.36353"}
{"text": "in this group of patients [ 39 ] .In addition , lapatinib has demonstrated promising activity in central nervous system ( CNS ) metastases , which affect one - third of patients with advanced HER2-positive breast cancer .", "label": "", "metadata": {}, "score": "52.399532"}
{"text": "View at Google Scholar .G. E. Konecny , M. D. Pegram , N. Venkatesan et al . , \" Activity of the dual kinase inhibitor lapatinib ( GW572016 ) against HER-2-overexpressing and trastuzumab - treated breast cancer cells , \" Cancer Research , vol .", "label": "", "metadata": {}, "score": "52.41024"}
{"text": "1124 - 1130 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .W. Scheuer , T. Friess , H. Burtscher , B. Bossenmaier , J. Endl , and M. Hasmann , \" Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models , \" Cancer Research , vol .", "label": "", "metadata": {}, "score": "52.46087"}
{"text": "In many models of acquired resistance , HER2 amplification and/or overexpression have been maintained at the parental level , as confirmed by fluorescent in situ hybridization ( FISH ) and Western blotting [ 64 ] .", "label": "", "metadata": {}, "score": "52.60157"}
{"text": "In the phase III trial of NSABP ( protocol B-41 ) , 529 patients were randomized to receive weekly paclitaxel with either trastuzumab weekly , lapatinib daily or the association trastuzumab plus lapatinib before undergoing surgery .", "label": "", "metadata": {}, "score": "52.62092"}
{"text": "c - erbB2 gene amplification was evaluated using fluorescent in - situ hybridization ( FISH ) .Sensitivity to pertuzumab and trastuzumab - induced antibody - dependent cell - mediated cytotoxicity ( ADCC ) and complement - dependent cytotoxicity ( CDC ) was evaluated in 5 h chromium release assays .", "label": "", "metadata": {}, "score": "52.62578"}
{"text": "The pertuzumab/9F7-F11 combination enhanced tumor inhibition and the median survival time in mice xenografted with HER3-expressing pancreatic cancer cells .Furthermore , HER2 and HER3 were co - expressed in 11 % and HER3 alone in 27 % of the 45 pancreatic ductal adenocarcinomas analyzed by immunohistochemistry .", "label": "", "metadata": {}, "score": "52.63434"}
{"text": "2999 - 3005 , 2011 .View at Google Scholar .N. Gaborit , C. Larbouret , J. Vallaghe et al . , \" Time - resolved fluorescence resonance energy transfer ( TR - FRET ) to analyze the disruption of EGFR / HER2 dimers : a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies , \" Journal of Biological Chemistry , vol .", "label": "", "metadata": {}, "score": "52.673138"}
{"text": "4 , pp . 1198 - 1207 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. Kumar , M. Mandal , A. Lipton , H. Harvey , and C. B. Thompson , \" Overexpression of HER2 modulates bcl-2 , Bcl - X(L ) and tamoxifen induced apoptosis in human MCP-7 breast cancer cells , \" Clinical Cancer Research , vol .", "label": "", "metadata": {}, "score": "52.68361"}
{"text": "5 , pp .1471 - 1477 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .G. Minuti , F. Cappuzzo , R. Duchnowska , J. Jassem , A. Fabi , T. O'Brien , et al . , \" Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer , \" British Journal of Cancer , vol .", "label": "", "metadata": {}, "score": "52.685234"}
{"text": "MM-111 , a bispecific HER2/HER3 antibody , reduced HER2/3-PI3 K signaling , suppressed HER2-positive xenograft tumor growth , and showed synergy with trastuzumab or lapatinib against HER2-positive breast cancers in vivo [ 159 ] .", "label": "", "metadata": {}, "score": "52.70182"}
{"text": "129 - 139 , 2012 .View at Google Scholar .M. A. Molina , R. S\u00e1ez , E. E. Ramsey et al . , \" NH2-terminal truncated HER-2 protein but not full - length receptor is associated with nodal metastasis in human breast cancer , \" Clinical Cancer Research , vol . 8 , no . 2 , pp .", "label": "", "metadata": {}, "score": "52.71604"}
{"text": "View at Google Scholar . D. L. Rowe , T. Ozbay , L. M. Bender , and R. Nahta , \" Nordihydroguaiaretic acid , a cytotoxic insulin - like growth factor - I receptor / HER2 inhibitor in trastuzumab - resistant breast cancer , \" Molecular Cancer Therapeutics , vol .", "label": "", "metadata": {}, "score": "52.744617"}
{"text": "Preliminary OS results were similar between treatment arms ; median follow - up was approximately 23 months in both arms .The authors concluded that in this randomized phase II study , first - line treatment with T - DM1 for patients with HER2-positive MBC provided a significant improvement in PFS , with a favorable safety profile , versus HT .", "label": "", "metadata": {}, "score": "52.78221"}
{"text": "4 , pp .89 - 95 , 1999 .View at Google Scholar \u00b7 View at Scopus .M. X. Sliwkowski , J. A. Lofgren , G. D. Lewis , T. E. Hotaling , B. M. Fendly , and J. A. Fox , \" Nonclinical studies addressing the mechanism of action of trastuzumab ( Herceptin ) , \" Seminars in Oncology , vol .", "label": "", "metadata": {}, "score": "52.801834"}
{"text": "HCPCS codes covered if selection criteria are met : . J9306 .Injection , pertuzumab , 1 mg [ only covered when used in combination with Trastuzumab for recurrent or metastatic HER2-positive breast cancer ] .", "label": "", "metadata": {}, "score": "52.820232"}
{"text": "Although there was a trend correlating immune cell infiltration with responsiveness , this did not reach statistical significance in this pilot study [ 52 ] .", "label": "", "metadata": {}, "score": "52.891685"}
{"text": "615 - 627 , 2012 .View at Google Scholar .O. Humbert , A. Berriolo - Riedinger , J. M. Riedinger , et al . , \" Changes in 18 F - FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer : influence of tumor subtypes , \" Annals of Oncology , vol .", "label": "", "metadata": {}, "score": "52.9467"}
{"text": "5263 - 5266 , 1999 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . S. A. Price - Schiavi , S. Jepson , P. Li et al . , \" Rat MUC4 ( sialomucin complex ) reduces binding of anti - ErbB2 antibodies to tumor cell surfaces , a potential mechanism for herceptin resistance , \" International Journal of Cancer , vol .", "label": "", "metadata": {}, "score": "53.072285"}
{"text": "69 , supplement 24 , 2009 , Abstract 5060 .View at Google Scholar . A. D. Basso , D. B. Solit , P. N. Munster , and N. Rosen , \" Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2 , \" Oncogene , vol .", "label": "", "metadata": {}, "score": "53.073166"}
{"text": "1377 - 1385 , 2003 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .K. Pedersen , P. D. Angelini , S. Laos et al . , \" A naturally occurring HER2 carboxy - terminal fragment promotes mammary tumor growth and metastasis , \" Molecular and Cellular Biology , vol .", "label": "", "metadata": {}, "score": "53.078827"}
{"text": "The role of immunohistochemistry and fluorescence in situ hybridization for HER2/neu in assessing the prognosis of breast cancer .Semin Oncol . 1999;4 ( Suppl 12):108 - 116 .", "label": "", "metadata": {}, "score": "53.083687"}
{"text": "Perjeta 's accelerated approval for neoadjuvant treatment is based on a study designed to measure pCR .In the study , 417 subjects were randomly assigned to receive 1 of 4 neoadjuvant treatment regimens : ( i ) trastuzumab plus docetaxel , ( ii )", "label": "", "metadata": {}, "score": "53.134975"}
{"text": "Pertuzumab in association with trastuzumab and docetaxel as compared with trastuzumab plus docetaxel significantly prolonged progression - free survival when used as first line in the metastatic setting ( 18.5 versus 12.4 months , . )", "label": "", "metadata": {}, "score": "53.15023"}
{"text": "12 , pp .3319 - 3331 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. Nahta , \" Deciphering the role of insulin - like growth factor - I receptor in trastuzumab resistance , \" Chemotherapy Research and Practice , vol .", "label": "", "metadata": {}, "score": "53.155308"}
{"text": "PubMed Central PubMed View Article .Stagg J , Divisekera U , McLaughlin N , Sharkey J , Pommey S , Denoyer D , Dwyer KM , Smyth MJ : Anti - CD73 antibody therapy inhibits breast tumor growth and metastasis .", "label": "", "metadata": {}, "score": "53.210335"}
{"text": "The clinical benefit rate for the combination was initially reported as 24.7 % versus 12.4 % for lapatinib alone [ 120 ] .Although a trend for improved overall survival was observed in the combination arm , this had not yet reached statistical significance at the time that the first study was reported [ 120 ] .", "label": "", "metadata": {}, "score": "53.227516"}
{"text": "1065 - 1075 , 2012 .View at Google Scholar .R. Nahta , S. Shabaya , T. Ozbay , and D. L. Rowe , \" Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status : what we have learned from clinical specimens , \" Current Pharmacogenomics and Personalized Medicine , vol .", "label": "", "metadata": {}, "score": "53.30571"}
{"text": "11 , pp .3958 - 3965 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . H. J. Burstein , Y. Sun , L. Y. Dirix et al . , \" Neratinib , an irreversible ErbB receptor tyrosine kinase inhibitor , in patients with advanced ErbB2-positive breast cancer , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "53.3088"}
{"text": "Truncated HER2 : Mechanism of Trastuzumab Resistance .Trastuzumab has been shown to block cleavage of HER2 ECD and prevent formation of constitutively active p95HER2 [ 47 ] .", "label": "", "metadata": {}, "score": "53.356216"}
{"text": "Future efforts should be directed towards biomarker - driven , HER2-directed therapies for optimal selection of therapy for the individual patient .Acknowledgment .", "label": "", "metadata": {}, "score": "53.37156"}
{"text": "One patient who had a pathologic complete response showed the most intense ADCC , whereas four others who had partial responses showed intermediate ADCC .Lack of response to trastuzumab was associated with inability to mount an ADCC response [ 109 ] .", "label": "", "metadata": {}, "score": "53.394146"}
{"text": "Pancreatic Cancer .Erlotinib is also approved for the treatment of pancreatic cancers when used in combination with a chemotherapy drug gemcitabine for the first - line treatment of patients with locally advanced , unresectable or metastatic pancreatic cancer .", "label": "", "metadata": {}, "score": "53.402573"}
{"text": "The HER-2/neu oncogene in breast cancer : Prognostic factor , predictive factor , and target for therapy .Stem Cells .Perez EA .", "label": "", "metadata": {}, "score": "53.44156"}
{"text": "The comparison of 2 years versus 1 year of trastuzumab treatment involved a landmark analysis of 3,105 patients who were disease - free 12 months after randomization to one of the trastuzumab groups , and was planned after observing at least 725 DFS events .", "label": "", "metadata": {}, "score": "53.494938"}
{"text": "Among the chemotherapy alone group , the 1-year DFS rate was 94.7 % ( 95 % CI : 85.2 - 100 % ) and the 3-year DFS rate was 85.3 % ( 95 % CI : 67.6 - 100 ) .", "label": "", "metadata": {}, "score": "53.500053"}
{"text": "117 - 127 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Barbareschi , L. V. Cuorvo , S. Girlando , et al . , \" PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti - Her2 therapy , \" Virchows Archiv , vol .", "label": "", "metadata": {}, "score": "53.511322"}
{"text": "Pivot X , Romieu G , Debled M , et al ; PHARE trial investigators .6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer ( PHARE ) : A randomised phase 3 trial .", "label": "", "metadata": {}, "score": "53.549004"}
{"text": "In 1982 , a seminal paper was published showing that DNA from NIH/3T3 cells transformed with genetic material from chemically - induced rat neuroblastomas could ultimately result in development of fibrosarcomas when injected into mice [ 1 ] .", "label": "", "metadata": {}, "score": "53.590397"}
{"text": "12 , pp .1915 - 1924 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .C. Rousseau , A. Devillers , C. Sagan et al . , \" Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [ 18 F]fluorodeoxyglucose positron emission tomography , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "53.653328"}
{"text": "View at Google Scholar .T. W. Miller , B. N. Rexer , J. T. Garrett , and C. L. Arteaga , \" Mutations in the phosphatidylinositol 3-kinase pathway : role in tumor progression and therapeutic implications in breast cancer , \" Breast Cancer Research , vol .", "label": "", "metadata": {}, "score": "53.719162"}
{"text": "These researchers aimed to establish the recommended dosing of the erlotinib and pertuzumab combination ; assessed safety , preliminary efficacy , and pharmacokinetics ; and analyzed biomarkers .", "label": "", "metadata": {}, "score": "53.74649"}
{"text": "31 , pp .3460 - 3469 , 2000 .View at Google Scholar \u00b7 View at Scopus . Y. Izumi , L. Xu , E. Di Tomaso , D. Fukumura , and R. K. Jain , \" Herceptin acts as an anti - angiogenic cocktail , \" Nature , vol .", "label": "", "metadata": {}, "score": "53.747093"}
{"text": "Estrogen - receptor-( ER- ) negative tumors are usually associated with a higher pCR rate compared to ER - positive tumors [ 37 - 39 ] including HER2-positive tumors [ 40 ] .", "label": "", "metadata": {}, "score": "53.8003"}
{"text": "The CONKO-001 trial was a phase III trial published at the ASCO 2008 annual meeting and demonstrated that the addition of gemcitabine following resection of pancreatic cancer significantly increased disease - free and overall survival compared to observation alone .", "label": "", "metadata": {}, "score": "53.830128"}
{"text": "The choice of chemotherapy to accompany the blockade is not obvious and these investigators do not know if dual is better than single blockade .They stated that further clinical trials are urgently needed .", "label": "", "metadata": {}, "score": "53.854015"}
{"text": "Trastuzumab at a dose of 4 mg / kg was given intravenously on week 1 ; then , weekly doses of 2 mg / kg were given .", "label": "", "metadata": {}, "score": "53.882523"}
{"text": "Several objective responses were observed in a phase I study [ 68 ] , and this combination is currently being investigated in a randomized trial in the neoadjuvant setting ( neoPHOEBE trial ) .", "label": "", "metadata": {}, "score": "53.90608"}
{"text": "View at Publisher \u00b7 View at Google Scholar .G. E. Konecny , Y. G. Meng , M. Untch et al . , \" Association between HER-2/neu and Vascular Endothelial Growth Factor Expression Predicts Clinical Outcome in Primary Breast Cancer Patients , \" Clinical Cancer Research , vol .", "label": "", "metadata": {}, "score": "53.914803"}
{"text": "View at Google Scholar \u00b7 View at Scopus . E. Yao , W. Zhou , S. T. Lee - Hoeflich et al . , \" Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3 K inhibitor , trastuzumab , and pertuzumab , \" Clinical Cancer Research , vol .", "label": "", "metadata": {}, "score": "53.956287"}
{"text": "The pCR rates reported here correspond to the absence of invasive carcinoma both in breast and axilla .Table 2 : Randomized trials with neoadjuvant lapatinib versus trastuzumab or lapatinib versus trastuzumab versus lapatinib plus trastuzumab .", "label": "", "metadata": {}, "score": "53.965683"}
{"text": "4 , pp .395 - 402 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . E. Razis , M. Bobos , V. Kotoula et al . , \" Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer , \" Breast Cancer Research and Treatment , vol .", "label": "", "metadata": {}, "score": "53.9831"}
{"text": "793 - 799 , 2012 .View at Google Scholar .J. P. Joshi , N. E. Brown , S. E. Griner , and R. Nahta , \" Growth differentiation factor 15 ( GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells , \" Biochemical Pharmacology , vol .", "label": "", "metadata": {}, "score": "53.991356"}
{"text": "655 - 662 , 2012 .View at Google Scholar . H. M. Kuerer , L. A. Newman , T. L. Smith et al . , \" Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin - based neoadjuvant chemotherapy , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "53.997925"}
{"text": "Additional studies have confirmed lapatinib efficacy in the setting of p95HER2-positive disease in contrast to trastuzumab [ 73 - 75 ] .Truncated isoforms of HER2 may result from MMP - based cleavage or alternative translation start sites [ 76 , 77 ] and are reviewed elsewhere [ 78 ] .", "label": "", "metadata": {}, "score": "54.01876"}
{"text": "16 - 32 , 2012 .View at Google Scholar .T. A. Bailey , H. Luan , R. J. Clubb , M. Naramura , V. Band , S. M. Raja , et al . , \" Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance , \" Journal of Carcinogenesis , vol .", "label": "", "metadata": {}, "score": "54.03116"}
{"text": "Stimulation of HER2-overexpressing cells with GDF15 also induced phosphorylation of TGF beta receptor substrate Smad2 and nonreceptor tyrosine kinase Src , both of which were blocked after treatment with the TGF beta receptor type II kinase inhibitor SB431542 .", "label": "", "metadata": {}, "score": "54.04956"}
{"text": "2688 - 2695 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Scaltriti , F. Rojo , A. Oca\u00f1a et al . , \" Expression of p95HER2 , a truncated form of the HER2 receptor , and response to Anti - HER2 therapies in breast cancer , \" Journal of the National Cancer Institute , vol .", "label": "", "metadata": {}, "score": "54.07218"}
{"text": "2688 - 2695 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Scaltriti , F. Rojo , A. Oca\u00f1a et al . , \" Expression of p95HER2 , a truncated form of the HER2 receptor , and response to anti - HER2 therapies in breast cancer , \" Journal of the National Cancer Institute , vol .", "label": "", "metadata": {}, "score": "54.07218"}
{"text": "HER2 over - expression is increasingly recognized as a frequent molecular abnormality , driven as in breast cancer by gene amplification .There is mounting evidence of the role of HER2 over - expression in patients with gastric cancer , and it has been solidly correlated to poor outcomes and a more aggressive disease .", "label": "", "metadata": {}, "score": "54.09642"}
{"text": "Further , the lack of biomarker - based selection of patients in these trials may have obscured the subset of patients that derived benefit , if any .", "label": "", "metadata": {}, "score": "54.130806"}
{"text": "View at Google Scholar . Y. Lu , X. Zi , Y. Zhao , D. Mascarenhas , and M. Pollak , \" Insulin - like growth factor - I receptor signaling and resistance to transtuzumab ( Herceptin ) , \" Journal of the National Cancer Institute , vol .", "label": "", "metadata": {}, "score": "54.1456"}
{"text": "Patients were randomly assigned via central randomization procedure with web - based software to continue trastuzumab for another 6 months ( 12 months total duration ; control group ) or to discontinue trastuzumab at 6 months ( 6 months total duration ; experimental group ) .", "label": "", "metadata": {}, "score": "54.20664"}
{"text": "Multiple signaling pathways may cooperate simultaneously with IGF - IR to drive trastuzumab resistance , such as increased FAK , GDF15 , or VEGF signaling , or reduced immune stimulation of ADCC .", "label": "", "metadata": {}, "score": "54.249817"}
{"text": "12 , pp .1940 - 1949 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .V. Guarneri , K. Broglio , S. W. Kau et al . , \" Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "54.78517"}
{"text": "Lapatinib plus capecitabine is approved for HER2-overexpressing breast cancers that have progressed on trastuzumab ( second - line ) , and as first - line therapy combined with letrozole for ER - positive , HER2-positive metastatic breast cancer .", "label": "", "metadata": {}, "score": "54.815254"}
{"text": "Gefitinib ( Iressa , ZD1839 ) and erlotinib ( Tarceva , OSI-774 ) are small molecules that target the EGFR TK and are the two most extensively studied TKIs in lung cancer .", "label": "", "metadata": {}, "score": "54.876495"}
{"text": "The authors report no financial conflict of interests .References . D. J. Slamon , G. M. Clark , S. G. Wong , W. J. Levin , A. Ullrich , and W. L. McGuire , \" Human breast cancer : correlation of relapse and survival with amplification of the HER-2/neu oncogene , \" Science , vol .", "label": "", "metadata": {}, "score": "54.877586"}
{"text": "In order to translate 4D5 clinically , a derivative that includes the antigen binding loops of 4D5 and the human variable region and immunoglobulin G1 constant domains was constructed [ 35 ] .", "label": "", "metadata": {}, "score": "54.885284"}
{"text": "Modifier 0I .Her-2/neu .Other HCPCS codes related to the CPB : . G0461 .Immunohistochemistry or immunocytochemistry , per specimen ; first single or multiplex antibody stain . G0462 .", "label": "", "metadata": {}, "score": "54.9244"}
{"text": "PubMed View Article .Hamilton A , Piccart M : The contribution of molecular markers to the prediction of response in the treatment of breast cancer : a review of the literature on HER-2 , p53 and BCL-2 .", "label": "", "metadata": {}, "score": "54.928"}
{"text": "Immunohistochemical ( IHC ) analysis revealed reactivity for HMW cytokeratins , CK5 and CK7 , p53 , p63 , CEA ( focal ) , androgen receptor , EGFR , estrogen receptor ( ER ) , MUC5AC , and strong / diffuse membranous staining for Her-2/neu .", "label": "", "metadata": {}, "score": "54.98197"}
{"text": "Multiple proapoptotic proteins are regulated by PI3 K signaling including survivin and BIM [ 107 ] .Incomplete inhibition of PI3 K signaling may prevent induction of these proteins , preventing apoptosis in response to HER2-targeted treatments such as lapatinib [ 107 ] .", "label": "", "metadata": {}, "score": "54.989487"}
{"text": "The 3-year overall survival rates were 87 % with trastuzumab versus 79 % without trastuzumab ( . ) after a median followup of 36.1 months [ 5 ] .", "label": "", "metadata": {}, "score": "54.990696"}
{"text": "As such , it will be the focus of this section .Breast Cancer .Phase I trials have shown that lapatinib is well tolerated , with mild diarrhea and skin rash as common adverse effects .", "label": "", "metadata": {}, "score": "55.042538"}
{"text": "The response rates and toxicities for patients treated with docetaxel and trastuzumab or paclitaxel and trastuzumab were not significantly different , though survival in both arms was better than expected .", "label": "", "metadata": {}, "score": "55.054924"}
{"text": ", have published data suggesting there is increased metabolic clearance of the drug in patients who are actively smoking , which may decrease the efficacy of the therapy .", "label": "", "metadata": {}, "score": "55.060337"}
{"text": "628 - 638 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .S. Loibl , J. Bruey , G. Von Minckwitz , et al . , \" Validation of p95 as a predictive marker for trastuzumab - based therapy in primary HER2-positive breast cancer : a translational investigation from the neoadjuvant GeparQuattro study , \" in ASCO Annual Meeting , 2011 .", "label": "", "metadata": {}, "score": "55.075836"}
{"text": "The cumulative dose of IT trastuzumab given was 1,040 mg ( SD 697.9 , median of 1,215 , range of 55 to 1,675 ) .The protective effect of prior radiosurgery or neurosurgery upon CNS - PFS was sizeable but did not reach formal statistical significance ( HR 0.28 , 95 % CI : 0.06 to 1.37 ) .", "label": "", "metadata": {}, "score": "55.0995"}
{"text": "Ann Oncol .Felip E , Ranson M , Cedres S , et al .A phase Ib , dose - finding study of erlotinib in combination with a fixed dose of pertuzumab in patients with advanced non - small - cell lung cancer .", "label": "", "metadata": {}, "score": "55.133965"}
{"text": "McNeil C. Herceptin raises its sights beyond advanced breast cancer .J Natl Cancer Inst .Bast RC , Ravdin P , Hayes DF , et al .", "label": "", "metadata": {}, "score": "55.167053"}
{"text": "HER2 over - expression has been reported in 6 % to 35 % of stomach and gastroesophageal tumors .Gravalos and Jimeno ( 2008 ) noted that gastric cancer is the second leading cause of cancer mortality in the world and its management , especially in advanced stages , has evolved relatively little .", "label": "", "metadata": {}, "score": "55.243538"}
{"text": "34 , pp .5366 - 5372 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. Schwarz - Dose , M. Untch , R. Tiling et al . , \" Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [ 18 F]fluorodeoxyglucose , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "55.27189"}
{"text": "HER2 gene copy number was found to be increased by 2- to over 20-fold in a subset of breast tumors [ 8 ] .", "label": "", "metadata": {}, "score": "55.3125"}
{"text": "19 , pp .5290 - 5303 , 2012 .View at Google Scholar .S. Mabuchi , C. Kawase , D. A. Altomare et al . , \" mTOR is a promising therapeutic target both in cisplatin - sensitive and cisplatin - resistant clear cell carcinoma of the ovary , \" Clinical Cancer Research , vol .", "label": "", "metadata": {}, "score": "55.340675"}
{"text": "1215 - 1219 , 1996 .View at Google Scholar \u00b7 View at Scopus .J. Shou , S. Massarweh , C. K. Osborne et al . , \" Mechanisms of tamoxifen resistance : increased estrogen receptor - HER2/neu cross - talk in ER / HER2-positive breast cancer , \" Journal of the National Cancer Institute , vol .", "label": "", "metadata": {}, "score": "55.38943"}
{"text": "Immunohistochemistry for HER2 protein expression was attempted for 182 pathologic samples from 169 patients .Twenty - eight of the 179 evaluable samples ( 16 % ) revealed 2 + or 3 + staining .", "label": "", "metadata": {}, "score": "55.500244"}
{"text": "2000 update of recommendations for the use of tumor markers in breast and colorectal cancer : Clinical practice guidelines of the American Society of Clinical Oncology .", "label": "", "metadata": {}, "score": "55.58168"}
{"text": "39 - 48 , 2012 .View at Google Scholar Genomes and Genes .Species .Luca Gianni .Summary .Publications .Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer ( NOAH ) : follow - up of a randomised controlled superiority trial with a parallel HER2-negative cohort .", "label": "", "metadata": {}, "score": "55.614334"}
{"text": "19 , pp .8022 - 8030 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .K. Berns , H. M. Horlings , B. T. Hennessy et al . , \" A Functional Genetic Approach Identifies the PI3 K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer , \" Cancer Cell , vol .", "label": "", "metadata": {}, "score": "55.643456"}
{"text": "PubMed Central PubMed View Article .Liu B , Fan Z , Edgerton SM , Yang X , Lind SE , Thor AD : Potent anti - proliferative effects of metformin on trastuzumab - resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions .", "label": "", "metadata": {}, "score": "55.659317"}
{"text": "Optimal treatment duration , selection and use of biomarkers , and the expense of combining two costly drugs must be rigorously examined , wrote Gnant and Steger .", "label": "", "metadata": {}, "score": "55.659775"}
{"text": "Pertuzumab .The HER2 mAb pertuzumab ( 2C4 , Omnitarg ; Genetech ) binds to domain II of HER2 [ 146 ] , whereas trastuzumab binds to domain IV [ 147 ] .", "label": "", "metadata": {}, "score": "55.66121"}
{"text": "Evidence Summary Report No . 1 - 15 .Toronto , ON : Cancer Care Ontario ; updated January 2002 .Sledge GW Jr. Gemcitabine combined with paclitaxel or paclitaxel / trastuzumab in metastatic breast cancer .", "label": "", "metadata": {}, "score": "55.73587"}
{"text": "12 , pp .926 - 935 , 2004 .View at Google Scholar \u00b7 View at Scopus .R. Nahta and R. M. O'Regan , \" Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers , \" Breast Cancer Research and Treatment , vol .", "label": "", "metadata": {}, "score": "55.806744"}
{"text": "2688 - 2695 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. Sperinde , X. Jin , J. Banerjee et al . , \" Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab - treated breast cancer patients , \" Clinical Cancer Research , vol .", "label": "", "metadata": {}, "score": "55.807877"}
{"text": "The accumulation of HER2 in cell lines treated with lapatinib corresponded with increased heterodimerization between HER2 and EGFR or HER3 [ 143 ] .However , these dimers were inactive , as phosphorylation of HER2 was suppressed in the presence of lapatinib alone or when combined with trastuzumab [ 143 ] .", "label": "", "metadata": {}, "score": "55.809837"}
{"text": "S21-S22 , 2001 .View at Google Scholar \u00b7 View at Scopus .L. Yen , X. L. You , A. E. Al Moustafa et al . , \" Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis , \" Oncogene , vol .", "label": "", "metadata": {}, "score": "55.82106"}
{"text": "G. E. Konecny , M. D. Pegram , N. Venkatesan et al . , \" Activity of the dual kinase inhibitor lapatinib ( GW572016 ) against HER-2-overexpressing and trastuzumab - treated breast cancer cells , \" Cancer Research , vol .", "label": "", "metadata": {}, "score": "55.84138"}
{"text": "Tumors from 3,807 patients patients were centrally tested for HER2 status : 22.1 % were HER2-positive ; 594 patients were randomized 1:1 at sites in Europe , Latin America , and Asia .", "label": "", "metadata": {}, "score": "55.884933"}
{"text": "As a result , more than 600 articles addressing this issue now appear on PubMed .Multiple signaling molecules have been proposed as mediators of resistance and potential new molecular targets for therapeutic intervention in this subtype of breast cancer .", "label": "", "metadata": {}, "score": "55.897377"}
{"text": "3016 - 3025 , 2001 .View at Google Scholar .K. Kono , A. Takahashi , F. Ichihara , H. Sugai , H. Fujii , and Y. Matsumoto , \" Impaired antibody - dependent cellular cytotoxicity mediated by Herceptin in patients with gastric cancer , \" Cancer Research , vol .", "label": "", "metadata": {}, "score": "55.903107"}
{"text": "These potentially practice - changing findings have led Genentech / Hoffman - La Roche to seek regulatory approval for the drug combination [ 45 ] .", "label": "", "metadata": {}, "score": "55.937405"}
{"text": "Although gene expression profiling ( GEP ) has identified the same five subtypes of IBC as originally described for noninflammatory breast cancer , differences in several key pathways and proteins do exist [ 39 ] .", "label": "", "metadata": {}, "score": "56.000652"}
{"text": "Given the rapidly expanding array of new imaging modalities , well - planned neoadjuvant studies with prospective integration of imaging endpoints are required to define and compare the role of molecular and functional imaging as early - response predictors .", "label": "", "metadata": {}, "score": "56.054047"}
{"text": "Some data suggested that the fragment C \u03b3 receptor ( Fc \u03b3 R ) polymorphism has an effect on ADCC , which is one of the mechanisms of action of the trastuzumab .", "label": "", "metadata": {}, "score": "56.06436"}
{"text": "473 - 482 , 2005 .View at Google Scholar \u00b7 View at Scopus . A. C. Chen , I. Migliaccio , M. Rimawi , S. Lopez - Tarruella , C. J. Creighton , S. Massarweh , et al . , \" Upregulation of mucin4 in ER - positive / HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies , \" Breast Cancer Research and Treatment , vol .", "label": "", "metadata": {}, "score": "56.19745"}
{"text": "20 , pp .5887 - 5894 , 2000 .View at Google Scholar \u00b7 View at Scopus .P. J. Roberts , J. E. Usary , D. B. Darr , P. M. Dillon , A. D. Pfefferle , M. C. Whittle , et al . , \" Combined PI3K / mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models , \" Clinical Cancer Research , vol .", "label": "", "metadata": {}, "score": "56.214302"}
{"text": "26 , supplement 20 , 2008 , Abstract 1016 .View at Google Scholar .B. D. Cohen , D. A. Baker , C. Soderstrom et al . , \" Combination therapy enhances the inhibition of tumor growth with the fully human anti - type 1 insulin - like growth factor receptor monoclonal antibody CP-751,871 , \" Clinical Cancer Research , vol .", "label": "", "metadata": {}, "score": "56.21516"}
{"text": "PubMed .Sj\u00f6gren S , Ingan\u00e4s M , Lindgren A , Holmberg L , Bergh J : Prognostic and predictive value of c - erbB-2 overexpression in primary breast cancer , alone and in combination with other prognostic markers .", "label": "", "metadata": {}, "score": "56.276245"}
{"text": "26 , pp .23441 - 23450 , 2003 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . Y. Izumi , L. Xu , E. Di Tomaso , D. Fukumura , and R. K. Jain , \" Herceptin acts as an anti - angiogenic cocktail , \" Nature , vol .", "label": "", "metadata": {}, "score": "56.31126"}
{"text": "Membrane mucins such as Muc4 have been shown to reduce matrix - cell interactions and adhesion [ 65 ] and to stimulate HER2 signaling via an EGF - like domain [ 66 ] .", "label": "", "metadata": {}, "score": "56.37048"}
{"text": "1829 - 1838 , 1994 .View at Google Scholar \u00b7 View at Scopus .R. J. Pietras , M. D. Pegram , R. S. Finn , D. A. Maneval , and D. J. Slamon , \" Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA - reactive drugs , \" Oncogene , vol .", "label": "", "metadata": {}, "score": "56.412674"}
{"text": "HER2-positive lines whose proliferation was inhibited by nanoMolar concentrations of lapatinib showed inhibition of Akt / mTORc1 signaling in contrast to nonresponsive cell lines [ 122 , 123 ] .", "label": "", "metadata": {}, "score": "56.421608"}
{"text": "Wagner AD , Unverzagt S , Grothe W , et al .Chemotherapy for advanced gastric cancer .Cochrane Database Syst Rev. 2010;(3):CD004064 .Andersson M , Lidbrink E , Bjerre K , et al .", "label": "", "metadata": {}, "score": "56.529343"}
{"text": "View at Google Scholar \u00b7 View at Scopus .T. T. Junttila , R. W. Akita , K. Parsons et al . , \" Ligand - independent HER2/HER3/PI3 K complex is disrupted by trastuzumab and is effectively inhibited by the PI3 K inhibitor GDC-0941 , \" Cancer Cell , vol .", "label": "", "metadata": {}, "score": "56.623337"}
{"text": "12 , pp .3319 - 3331 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. Sperinde , X. Jin , J. Banerjee et al . , \" Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab - treated breast cancer patients , \" Clinical Cancer Research , vol .", "label": "", "metadata": {}, "score": "56.653965"}
{"text": "4 , pp .263 - 274 , 2009 .View at Google Scholar \u00b7 View at Scopus .R. Nahta , D. Yu , M. C. Hung , G. N. Hortobagyi , and F. J. Esteva , \" Mechanisms of disease : understanding resistance to HER2-targeted therapy in human breast cancer , \" Nature Clinical Practice Oncology , vol .", "label": "", "metadata": {}, "score": "56.739094"}
{"text": "Coimmunoprecipitation experiments showed that Muc4 and HER2 interact [ 67 ] .A subsequent report [ 69 ] showed increased expression of Muc4 in JIMT-1 HER2-overexpressing breast cancer cells which display primary resistance to trastuzumab versus sensitive cell lines .", "label": "", "metadata": {}, "score": "56.85612"}
{"text": "Combination therapy did not affect erlotinib 's pharmacokinetics ; however , pertuzumab mean exposures ( maximum concentration , 231 mg / L ; area under the concentration - time curve from 0 to 21 days , 1,780 mg d / L ) were slightly higher than in previous studies .", "label": "", "metadata": {}, "score": "56.910736"}
{"text": "2917 - 2923 , 1993 .View at Google Scholar \u00b7 View at Scopus .T. M. Ward , E. Iorns , X. Liu , N. Hoe , P. Kim , S. Singh , et al . , \" Truncated p110 ERBB2 induces mammary epithelial cell migration , invasion and orthotopic xenograft formation , and is associated with loss of phosphorylated STAT5 , \" Oncogene .", "label": "", "metadata": {}, "score": "56.914608"}
{"text": "1989 - 1995 , 2012 .View at Google Scholar . A. Robidoux , G. Tang , P. Rastogi , et al . , \" Evaluation of lapatinib as a component of neoadjuvant therapy for HER2 + operable breast cancer : NSABP protocol B-41 , \" Journal of Clinical Oncology , 2012 .", "label": "", "metadata": {}, "score": "57.052303"}
{"text": "As an example of oncogene addiction , HER2 amplification is generally responsive to HER2 kinase inhibition which suppresses downstream PI3 K and MEK signaling [ 104 ] .", "label": "", "metadata": {}, "score": "57.052956"}
{"text": "460 - 469 , 1999 .View at Google Scholar \u00b7 View at Scopus . A. E. Ring , I. E. Smith , S. Ashley , L. G. Fulford , and S. R. Lakhani , \" Oestrogen receptor status , pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer , \" British Journal of Cancer , vol .", "label": "", "metadata": {}, "score": "57.067345"}
{"text": "Three USPC cell lines stained heavily for HER2/neu by IHC and showed amplification of the c - erbB2 gene by FISH .The remaining FISH - negative USPCs expressed HER2/neu at 0/1 + levels .", "label": "", "metadata": {}, "score": "57.132072"}
{"text": "4 , pp .535 - 541 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .X. Cheng , Y. Li , B. Liu , et al . , \" 18 F - FDG PET / CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer : a meta - analysis , \" Acta Radiologica , vol .", "label": "", "metadata": {}, "score": "57.140182"}
{"text": "The incidences of thrombocytopenia and increased serum aminotransferase levels were higher with T - DM1 , whereas the incidences of diarrhea , nausea , vomiting , and palmar - plantar erythrodysesthesia were higher with lapatinib plus capecitabine .", "label": "", "metadata": {}, "score": "57.223087"}
{"text": "Preclinical studies have suggested that mTOR targeting could reverse resistance to trastuzumab [ 65 ] .In a phase I / II study , patients with HER2-positive metastatic breast cancer received trastuzumab combined with everolimus , after resistance to trastuzumab .", "label": "", "metadata": {}, "score": "57.257904"}
{"text": "582 - 593 , 2012 .View at Google Scholar .P. K. Foreman , M. Gore , P. A. Kobel , L. Xu , H. Yee , C. Hannum , et al . , \" ErbB3 inhibitory surrobodies inhibit tumor cell proliferation in vitro and in vivo , \" Molecular Cancer Therapeutics , vol .", "label": "", "metadata": {}, "score": "57.276405"}
{"text": "24 , pp .11991 - 11999 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .W. E. Carson , R. Parihar , M. J. Lindemann , N. Personeni , J. Dierksheide , N. J. Meropol , et al . , \" Interleukin-2 enhances the natural killer cell response to Herceptin - coated Her2/neu - positive breast cancer cells , \" European Journal of Immunology , vol .", "label": "", "metadata": {}, "score": "57.322243"}
{"text": "Stathopoulos EN , Sanidas E , Kafousi M , Mavroudis D , Askoxylakis J , Bozionelou V , Perraki M , Tsiftsis D , Georgoulias V : Detection of CK-19 mRNA - positive cells in the peripheral blood of breast cancer patients with histologically and immunohistochemically negative axillary lymph nodes .", "label": "", "metadata": {}, "score": "57.362427"}
{"text": "Data regarding clinical benefit were corroborated by two additional phase III trials reported on at ASCO 2009 and in the Journal of Clinical Oncology in February of 2010 .", "label": "", "metadata": {}, "score": "57.371918"}
{"text": "6 , pp .803 - 814 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .T. Maruyama , K. Mimura , S. Izawa , A. Inoue , S. Shiba , M. Watanabe , et al . , \" Lapatinib enhances herceptin - mediated antibody - dependent cellular cytotoxicity by up - regulation of cell surface HER2 expression , \" Anticancer Research , vol .", "label": "", "metadata": {}, "score": "57.376656"}
{"text": "As such , HER2 + breast cancer represents the ideal paradigm for a discussion of targeted neoadjuvant breast cancer therapy .Search strategy .Ongoing clinical trials were identified using the ClinicalTrials.gov database on 22 May 2008 [ 8 ] .", "label": "", "metadata": {}, "score": "57.387955"}
{"text": "Mechanisms of Action of Trastuzumab .Ironically , the mode of action of trastuzumab remains incompletely defined despite its routinary clinical application .Extensive preclinical research has been conducted to elucidate these mechanisms , and the following possibilities have been proposed .", "label": "", "metadata": {}, "score": "57.458733"}
{"text": "646 - 653 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Scaltriti , F. Rojo , A. Oca\u00f1a et al . , \" Expression of p95HER2 , a truncated form of the HER2 receptor , and response to Anti - HER2 therapies in breast cancer , \" Journal of the National Cancer Institute , vol .", "label": "", "metadata": {}, "score": "57.5026"}
{"text": "In contrast to the classical design , in which an experimental therapy is compared with a standard therapy , examples of novel designs are available amongst the ongoing anti - HER2 neoadjuvant studies : the so - called ' biological window ' design and ' learn on the way ' design .", "label": "", "metadata": {}, "score": "57.55221"}
{"text": "Haldar K , Gaitskell K , Bryant A , et al .Epidermal growth factor receptor blockers for the treatment of ovarian cancer .Cochrane Database Syst Rev. 2011;(10):CD007927 .", "label": "", "metadata": {}, "score": "57.587456"}
{"text": "2999 - 3005 , 2011 .View at Google Scholar .K. L. Blackwell , H. J. Burstein , A. M. Storniolo et al . , \" Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive , trastuzumab - refractory metastatic breast cancer , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "57.688477"}
{"text": "HER3 knockdown or pharmacologic blockade improved response to lapatinib [ 142 ] .Lapatinib and trastuzumab appear to differ in their effects on expression and dimerization of erbB / HER family members .", "label": "", "metadata": {}, "score": "57.701035"}
{"text": "104 , pp .975 - 981 , 2012 .View at Google Scholar .X. Zeng , D. Sachdev , H. Zhang , M. Gaillard - Kelly , and D. Yee , \" Sequencing of type i insulin - like Growth factor receptor inhibition affects chemotherapy response in vitro and in vivo , \" Clinical Cancer Research , vol .", "label": "", "metadata": {}, "score": "57.730927"}
{"text": "It is overexpressed on tumor - infiltrating lymphocytes ( TIL ) .The PD-1 ligand , PD - L1 , is expressed by multiple carcinoma , including breast cancers .", "label": "", "metadata": {}, "score": "57.747467"}
{"text": "Gabriella Mariani Department of Medical Oncology , Istituto Nazionale Tumori , Milan , Italy Nat Clin Pract Oncol 6:93 - 104 .Current data do not support the use of trastuzumab for more than 1 year .", "label": "", "metadata": {}, "score": "57.809376"}
{"text": "5 , pp .649 - 657 , 1986 .View at Google Scholar \u00b7 View at Scopus .R. Brandt , A. M. L. Wong , and N. E. Hynes , \" Mammary glands reconstituted with Neu / ErbB2 transformed HC11 cells provide a novel orthotopic tumor model for testing anti - cancer agents , \" Oncogene , vol .", "label": "", "metadata": {}, "score": "57.809464"}
{"text": "Bethesda , MD : NCI ; April 25 , 2005 .Accessed April 27 , 2005 .Genentech Inc. Interim analysis of phase III studies shows Herceptin plus chemotherapy omproves disease - free survival in the adjuvant setting for early - stage HER2-positive breast cancer patients .", "label": "", "metadata": {}, "score": "57.83446"}
{"text": "Huybrechts M , Hulstaert F , Neyt M , et al .Trastuzumab in early stage breast cancer .KCE Reports No . 34B.Brussels , Belgium : Belgian Health Care Knowledge Centre ( KCE ) ; 2006 .", "label": "", "metadata": {}, "score": "57.84714"}
{"text": "PubMed View Article .Tural D , Serdengecti S , Demirelli F , Ozt\u00fcrk T , Ilvan S , Turna H , Ozg\u00fcroglu M , B\u00fcy\u00fck\u00fcnal E : Clinical significance of p95HER2 overexpression , PTEN loss and PI3 K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab - based therapies .", "label": "", "metadata": {}, "score": "57.864475"}
{"text": "Ann Oncol .2001;12 Suppl 1:S81-S87 .National Cancer Institute ( NCI ) .Herceptin combined with chemotherapy improves disease - free survival for patients with early - stage breast cancer .", "label": "", "metadata": {}, "score": "57.876312"}
{"text": "Paclitaxel was added after six weeks , and neoadjuvant therapy continued for a total of 18 weeks .Surgery followed completion of neoadjuvant therapy , and patients received adjuvant treatment with paclitaxel and the same anti - HER2 regimen as in the neoadjuvant .", "label": "", "metadata": {}, "score": "57.911983"}
{"text": "These studies will provide us with valuable knowledge regarding interindividual differences in drug metabolism and the efficacy of novel agents [ 59 , 60 ] .", "label": "", "metadata": {}, "score": "58.1426"}
{"text": "J Clin Oncol 2010 , 28 : 3167 - 3175 .PubMed View Article .Stagg J , Loi S , Divisekera U , Ngiow SF , Duret H , Yagita H , Teng MW , Smyth MJ : Anti - ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti - PD-1 or anti - CD137 mAb therapy .", "label": "", "metadata": {}, "score": "58.45047"}
{"text": "However , this would first require the development of validated assays for the accurate measurement of resistance factors in archival tissue specimens , and to date , advancements in this arena have been slow [ 24 ] .", "label": "", "metadata": {}, "score": "58.53493"}
{"text": "Invaluable data for the appropriate selection of patients and the evaluation of endpoints for a subsequent adjuvant registration trial can be generated by a well - designed neoadjuvant pilot trial : this concept is currently being developed and explored by the Breast International Group ( Brussels , Belgium ) .", "label": "", "metadata": {}, "score": "58.552303"}
{"text": "[ 91 ] .Met amplification ( FISH - positivity ) was significantly associated with resistance to trastuzumab ( 44.4 % versus 16 % in nonamplified ) and shorter time to progression ( 5.7 versus 9.9 months ) .", "label": "", "metadata": {}, "score": "58.657295"}
{"text": "The exact mechanisms by which IGF - IR promotes trastuzumab resistance , the mechanisms mediating interactions between these receptors , and the mechanisms underlying growth suppressive effects of IGF - IR - targeted therapies [ 86 , 87 ] are unclear and warrant further study .", "label": "", "metadata": {}, "score": "58.877247"}
{"text": "1630 - 1639 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Scaltriti , C. Verma , M. Guzman et al . , \" Lapatinib , a HER2 tyrosine kinase inhibitor , induces stabilization and accumulation of HER2 and potentiates trastuzumab - dependent cell cytotoxicity , \" Oncogene , vol .", "label": "", "metadata": {}, "score": "58.88166"}
{"text": "American Society of Clinical Oncology Annual Meeting ; 1 - 5 June 2008 ; Chicago , IL .Dowsett M , Smith IE , Ebbs SR , Dixon JM , Skene A , A'Hern R , Salter J , Detre S , Hills M , Walsh G : Prognostic value of Ki67 expression after short - term presurgical endocrine therapy for primary breast cancer .", "label": "", "metadata": {}, "score": "58.882984"}
{"text": "To evaluate the addition of paclitaxel to an anthracycline - based adjuvant regimen and to compare this combination with the same regimen given as primary systemic ( neoadjuvant ) therapy ... .", "label": "", "metadata": {}, "score": "58.930046"}
{"text": "16 , pp .4226 - 4235 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .V. Serra , B. Markman , M. Scaltriti et al . , \" NVP - BEZ235 , a dual PI3K / mTOR inhibitor , prevents PI3 K signaling and inhibits the growth of cancer cells with activating PI3 K mutations , \" Cancer Research , vol .", "label": "", "metadata": {}, "score": "58.97609"}
{"text": "TRYPHAENA is another comparative trial performed in the neoadjuvant setting .The primary endpoint was to assess the cardiac safety .The pCR rates were quite similar in the three arms ( 61.6 % , 57 % , and 66.2 % , respectively ) [ 60 ] .", "label": "", "metadata": {}, "score": "59.05976"}
{"text": "Pazo Cid and Anton ( 2013 ) stated that the prognostic value of HER2 in gastric cancer is controversial .Consensus guidelines have standardized the testing of HER2 status in gastric cancer .", "label": "", "metadata": {}, "score": "59.06572"}
{"text": "Eur J Clin Pharmacol 2014 , 70 : 531 - 538 .PubMed View Article .Cho HS , Mason K , Ramyar KX , Stanley AM , Gabelli SB , Denney DW Jr , Leahy DJ : Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab .", "label": "", "metadata": {}, "score": "59.169403"}
{"text": "A more recent report [ 144 ] further confirmed the findings that lapatinib increases expression of cell surface HER2 in the HER2-positive SKBR3 and BT474 lines and enhances trastuzumab - mediated ADCC by almost twofold .", "label": "", "metadata": {}, "score": "59.181503"}
{"text": "Detail Information .Publications 26 .Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer ( NOAH ) : follow - up of a randomised controlled superiority trial with a parallel HER2-negative cohort .", "label": "", "metadata": {}, "score": "59.186005"}
{"text": "Trastuzumab was given until disease progression .The primary end point was OS ; secondary end points included overall response rate ( ORR ) , progression - free survival , time to progression , duration of response , and safety .", "label": "", "metadata": {}, "score": "59.204826"}
{"text": "4 , 2008 , Abstract R60 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .W. Xia , R. J. Mullin , B. R. Keith et al . , \" Anti - tumor activity of GW572016 : a dual tyrosine kinase inhibitor blocks EGF activation of EGFR / erbB2 and downstream Erk1/2 and AKT pathways , \" Oncogene , vol .", "label": "", "metadata": {}, "score": "59.315933"}
{"text": "Adults with locally advanced or metastatic NSCLC who have failed platinum - based and docetaxel chemotherapies .Dosing recommendation for gefitinib : dosing is 250 mg per day .", "label": "", "metadata": {}, "score": "59.427452"}
{"text": "More recently , longer term evaluation of 291 patients showed that median PFS and overall survival both reached statistical significance for the combination arm [ 132 ] .", "label": "", "metadata": {}, "score": "59.477062"}
{"text": "2006;12(14 Pt 2):4377s-4383s .Serrano - Olvera A , Duenas - Gonzalez A , Gallardo - Rincon D , et al .Prognostic , predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer .", "label": "", "metadata": {}, "score": "59.52706"}
{"text": "11 , pp .783 - 792 , 2001 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .C. L. Arteaga , M. X. Sliwkowski , C. K. Osborne , E. A. Perez , F. Puglisi , and L. Gianni , \" Treatment of HER2-positive breast cancer : current status and future perspectives , \" Nature Reviews Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "59.570744"}
{"text": "Kumler I , Tuxen MK , Nielsen DL .A systematic review of dual targeting in HER2-positive breast cancer .Cancer Treat Rev. 2014;40(2):259 - 270 .", "label": "", "metadata": {}, "score": "59.573326"}
{"text": "One study also included persons with high - risk node - negative breast cancer : tumor greater than 2 cm , estrogen / progestin receptor negative , nuclear grade 2 to 3 or age less than 35 years .", "label": "", "metadata": {}, "score": "59.65592"}
{"text": "Xia et al .[124 ] first demonstrated that acquired resistance to lapatinib was associated with increased ER signaling in preclinical models .Cell line models of HER2-positive breast cancer that had acquired resistance to lapatinib or to lapatinib plus trastuzumab showed increased expression of ER or a downstream target of ER ( progesterone receptor , IGF - IR , Cav-1 ) [ 125 ] .", "label": "", "metadata": {}, "score": "59.7276"}
{"text": "20 , pp .7159 - 7163 , 1987 .View at Google Scholar \u00b7 View at Scopus .M. E. Arcila , J. E. Chaft , K. Nafa , S. Roy - Chowdhuri , C. Lau , M. Zaidinski , et al . , \" Prevalence , clinicopathologic associations , and molecular spectrum of ERBB2 ( HER2 ) tyrosine kinasemutations in lung adenocarcinomas , \" Clinical Cancer Research , vol .", "label": "", "metadata": {}, "score": "59.737396"}
{"text": "A total of 13 articles ( 17 patients ) were eligible .The mean age of patients at IT trastuzumab administration was 48.2 years ( SD 8.4 , range of 38 to 66 ) .", "label": "", "metadata": {}, "score": "59.752502"}
{"text": "In addition , mutation of residues 996 - 998 impaired autophosphorylation of HER2 even when cells were stimulated with heregulin [ 15 ] .However , upon stimulation with heregulin , mutant 996 - 998 HER2 was still able to heterodimerize with HER3 , although to a lesser degree than wild - type HER2 , and retained the ability to phosphorylate HER3 , as HER2 kinase function was still intact [ 15 ] .", "label": "", "metadata": {}, "score": "59.86377"}
{"text": "1301 - 1307 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . H. J. Burstein , A. M. Storniolo , S. Franco et al . , \" A phase II study of lapatinib monotherapy in chemotherapy - refractory HER2-positive and HER2-negative advanced or metastatic breast cancer , \" Annals of Oncology , vol .", "label": "", "metadata": {}, "score": "59.929302"}
{"text": "Patients treated with lapatinib had higher rates of grade 3 diarrhea ( 23.4 % , 21.1 % , respectively ) and grade 3 liver - enzyme alterations ( 17.5 % , 9.9 % ) compared with trastuzumab ( 2 % , 7.4 % ) .", "label": "", "metadata": {}, "score": "59.96382"}
{"text": "Subjects in the HERA study were assigned to 3 groups : ( i ) 2 years of treatment with trastuzumab , ( ii ) 1 year of trastuzumab , and ( iii ) observation .", "label": "", "metadata": {}, "score": "60.08187"}
{"text": "Allard WJ , Matera J , Miller MC , Repollet M , Connelly MC , Rao C , Tibbe AG , Uhr JW , Terstappen LW : Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases .", "label": "", "metadata": {}, "score": "60.116142"}
{"text": "We [ 92 ] showed by gene microarray , real - time PCR , and ELISA assays that the transcript and endogenous and secreted GDF15 protein are overexpressed in cells with acquired or intrinsic trastuzumab resistance .", "label": "", "metadata": {}, "score": "60.153847"}
{"text": "CTCs can be identified in the blood of 10 % to 30 % of patients with early breast cancer and their detection is associated with poor long - term DFS [ 54 - 56 ] .", "label": "", "metadata": {}, "score": "60.175053"}
{"text": "5 , pp .851 - 852 , 2010 .View at Google Scholar \u00b7 View at Scopus .V. Serra , B. Markman , M. Scaltriti et al . , \" NVP - BEZ235 , a dual PI3K / mTOR inhibitor , prevents PI3 K signaling and inhibits the growth of cancer cells with activating PI3 K mutations , \" Cancer Research , vol .", "label": "", "metadata": {}, "score": "60.24232"}
{"text": "View at Google Scholar \u00b7 View at Scopus .26 , no .15S , p. 8s , 2008 .View at Google Scholar . A. Berriolo - Riedinger , C. Touzery , J. M. Riedinger et al . , \" [ 18 F]FDG - PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy , \" European Journal of Nuclear Medicine and Molecular Imaging , vol .", "label": "", "metadata": {}, "score": "60.292187"}
{"text": "View at Google Scholar .28 , supplement 15s , 2010 , Abstract 1012 .View at Google Scholar .S. K. Rabindran , C. M. Discafani , E. C. Rosfjord et al . , \" Antitumor activity of HKI-272 , an orally active , irreversible inhibitor of the HER-2 tyrosine kinase , \" Cancer Research , vol .", "label": "", "metadata": {}, "score": "60.347164"}
{"text": "PubMed Central PubMed View Article .Borg A , Baldetorp B , Fern\u00f6 M , Killander D , Olsson H , Ryd\u00e9n S , Sigurdsson H : ERBB2 amplification is associated with tamoxifen resistance in steroid - receptor positive breast cancer .", "label": "", "metadata": {}, "score": "60.348892"}
{"text": "One of the more common side effects resulting from agents targeting the EGFR pathway ( whether small molecule TKIs or antibodies against EGFR ) is an acne - like rash , which is approximately 60 % more common than with patients taking placebo .", "label": "", "metadata": {}, "score": "60.350906"}
{"text": "Birmingham , UK : NHSC ; 2005 .Clamon G , Herndon J , Kern J , et al .Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb - B2 : 39810 : A phase II trial of Cancer and Leukemia Group B. Cancer .", "label": "", "metadata": {}, "score": "60.41313"}
{"text": "Harris L , Fritsche H , Mennel R , Norton L , Ravdin P , Taube S , Somerfield MR , Hayes DF , Bast RC Jr : American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer .", "label": "", "metadata": {}, "score": "60.441513"}
{"text": "A phase II study ( EGF103009 ) of lapatinib monotherapy presented at the 2006 ASCO meeting looked at patients with relapsed or refractory inflammatory breast cancer .", "label": "", "metadata": {}, "score": "60.48844"}
{"text": "A total of 34 women were enrolled ; 1 was excluded ( refused treatment ) ; and 18 had tumors with known HER2 amplification .No major tumor responses were observed .", "label": "", "metadata": {}, "score": "60.582363"}
{"text": "4 , pp .1452 - 1459 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Scaltriti , C. Verma , M. Guzman et al . , \" Lapatinib , a HER2 tyrosine kinase inhibitor , induces stabilization and accumulation of HER2 and potentiates trastuzumab - dependent cell cytotoxicity , \" Oncogene , vol .", "label": "", "metadata": {}, "score": "60.60567"}
{"text": "Cancer Res 2005 , 65 : 2554 - 2559 .PubMed View Article .Shattuck DL , Miller JK , Carraway KL 3rd , Sweeney C : Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells .", "label": "", "metadata": {}, "score": "60.811195"}
{"text": "6 , pp .803 - 814 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . K. L. Blackwell , H. J. Burstein , A. M. Storniolo et al . , \" Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive , trastuzumab - refractory metastatic breast cancer , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "60.826824"}
{"text": "This pilot study evaluates the efficacy and cardiac tolerability of AT followed by paclitaxel with trastuzumab started with AT or paclitaxel alone and investigates pharmacokinetic interactions ... .", "label": "", "metadata": {}, "score": "60.980167"}
{"text": "6 , pp .3550 - 3558 , 1994 .View at Google Scholar \u00b7 View at Scopus .J. T. Garrett , M. G. Olivares , C. Rinehart et al . , \" Transcriptional and posttranslational up - regulation of HER3 ( ErbB3 ) compensates for inhibition of the HER2 tyrosine kinase , \" Proceedings of the National Academy of Sciences of the United States of America , vol .", "label": "", "metadata": {}, "score": "61.009438"}
{"text": "Lapatinib treatment suppressed GDF15-mediated HER2 phosphorylation [ 92 ] , suggesting that lapatinib may remain effective in cancers that are resistant to trastuzumab due to upregulation of GDF15 .", "label": "", "metadata": {}, "score": "61.028877"}
{"text": "No difference with regard to response rates or survival was noted between HER2-positive ( 2 + or 3 + ) and HER2-negative ( 0 - 1 + ) patients .", "label": "", "metadata": {}, "score": "61.05353"}
{"text": "In addition to transforming NIH/3T3 cells , neuT was able to transform mammary epithelial cells [ 6 ] .The transforming potential of the mutated neu protein was shown to be due to increased receptor dimerization and kinase activity [ 7 ] .", "label": "", "metadata": {}, "score": "61.133583"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .S. M. Pupa , S. Menard , D. Morelli , B. Pozzi , G. De Palo , and M. I. Colnaghi , \" The extracellular domain of the c - erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage , \" Oncogene , vol . 8 , no .", "label": "", "metadata": {}, "score": "61.142715"}
{"text": "The inferiority of the lapatinib compared to trastuzumab has already been highlighted in the interim analysis of the MA.31/EGF108919 trial ( metastatic first line ) with a shorter progression - free survival in the lapatinib arm ( 8.8 versus 11.4 months ) [ 31 ] .", "label": "", "metadata": {}, "score": "61.169113"}
{"text": "Survival , recurrence , brain metastases , cardiotoxicity and directions for future research were discussed .Relevant reports were reviewed by two reviewers independently and the references from these reports were searched for additional trials , using guidelines set by QUOROM statement criteria .", "label": "", "metadata": {}, "score": "61.204926"}
{"text": "26 , pp .23441 - 23450 , 2003 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . H. A. Lane , A. B. Motoyama , I. Beuvink , and N. E. Hynes , \" Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling , \" Annals of Oncology , vol .", "label": "", "metadata": {}, "score": "61.20912"}
{"text": "151 - 162 , 2012 .View at Google Scholar .P. S. Hegde , D. Rusnak , M. Bertiaux et al . , \" Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles , \" Molecular Cancer Therapeutics , vol .", "label": "", "metadata": {}, "score": "61.25563"}
{"text": "PubMed View Article .Pandolfi PP : Breast cancer - loss of PTEN predicts resistance to treatment .N Engl J Med 2004 , 351 : 2337 - 2338 .", "label": "", "metadata": {}, "score": "61.26267"}
{"text": "2440 - 2446 , 2003 .View at Google Scholar \u00b7 View at Scopus .R. Parihar , P. Nadella , A. Lewis et al . , \" A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies : analysis of sustained interferon \u03b3 production in a subset of patients , \" Clinical Cancer Research , vol .", "label": "", "metadata": {}, "score": "61.274986"}
{"text": "583 - 593 , 2012 .View at Google Scholar .W. Xia , L. H. Liu , P. Ho , and N. L. Spector , \" Truncated ErbB2 receptor ( p95ErbB2 ) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR / ErbB2 kinase inhibitor GW572016 , \" Oncogene , vol .", "label": "", "metadata": {}, "score": "61.30482"}
{"text": "4717 , pp .976 - 978 , 1985 .View at Google Scholar \u00b7 View at Scopus .R. M. Hudziak , J. Schlessinger , and A. Ullrich , \" Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells , \" Proceedings of the National Academy of Sciences of the United States of America , vol .", "label": "", "metadata": {}, "score": "61.390095"}
{"text": "264 , no .18 , pp .10667 - 10671 , 1989 .View at Google Scholar \u00b7 View at Scopus .R. Hazan , B. Margolis , M. Dombalagian , A. Ullrich , A. Zilberstein , and J. Schlessinger , \" Identification of autophosphorylation sites of HER2/neu , \" Cell Growth & Differentiation , vol .", "label": "", "metadata": {}, "score": "61.403137"}
{"text": "Universit\u00e9 Paris Sud , Facult\u00e9 de M\u00e9decine .References .Slamon DJ , Clark GM : Amplification of c - erbB-2 and aggressive human breast tumors ?", "label": "", "metadata": {}, "score": "61.647346"}
{"text": "11 , pp .783 - 792 , 2001 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .N. L. Spector and K. L. Blackwell , \" Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "61.67529"}
{"text": "Figure 1 .Trial design of ongoing randomised neoadjuvant studies targeting HER2 with new agents .Table 1 .Ongoing randomised neoadjuvant studies targeting HER2 with new agents .", "label": "", "metadata": {}, "score": "61.695095"}
{"text": "However , in the spring of 2009 , the FDA issued a warning on erlotinib reporting serious gastrointestinal tract , skin , and ocular disorders in some patients taking the drug .", "label": "", "metadata": {}, "score": "61.73584"}
{"text": "46 , pp .19503 - 19508 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. Tanizaki , I. Okamoto , S. Fumita , W. Okamoto , K. Nishio , and K. Nakagawa , \" Roles of BIM induction and survivin downregulation in lapatinib - induced apoptosis in breast cancer cells with HER2 amplification , \" Oncogene , vol .", "label": "", "metadata": {}, "score": "61.756252"}
{"text": "About 39 % of subjects who received Perjeta plus trastuzumab and docetaxel achieved pCR , compared to about 21 % who received trastuzumab plus docetaxel .", "label": "", "metadata": {}, "score": "61.75792"}
{"text": "184 - 190 , 2011 .View at Google Scholar . E. E. W. Cohen , M. W. Lingen , L. E. Martin et al . , \" Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR , \" Clinical Cancer Research , vol .", "label": "", "metadata": {}, "score": "61.78414"}
{"text": "19 , pp .8022 - 8030 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. C. Faber , D. Li , Y. Song et al . , \" Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3 K inhibition , \" Proceedings of the National Academy of Sciences of the United States of America , vol .", "label": "", "metadata": {}, "score": "61.79326"}
{"text": "12 , pp .5021 - 5026 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Scaltriti , C. Verma , M. Guzman et al . , \" Lapatinib , a HER2 tyrosine kinase inhibitor , induces stabilization and accumulation of HER2 and potentiates trastuzumab - dependent cell cytotoxicity , \" Oncogene , vol .", "label": "", "metadata": {}, "score": "61.864548"}
{"text": "24 , pp .1852 - 1857 , 2001 .View at Google Scholar \u00b7 View at Scopus .L. Jerome , N. Alami , S. Belanger et al . , \" Recombinant human insulin - like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo , \" Cancer Research , vol .", "label": "", "metadata": {}, "score": "61.864937"}
{"text": "5 , pp .429 - 440 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . H. A. Lane , A. B. Motoyama , I. Beuvink , and N. E. Hynes , \" Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling , \" Annals of Oncology , vol .", "label": "", "metadata": {}, "score": "62.024876"}
{"text": "The BOLERO-3 study compared the combination of everolimus , trastuzumab plus vinorelbine to trastuzumab and vinorelbine .In this study , several biomarkers ( PTEN , PIK3CA and pS6 ) were analyzed to find some subpopulation for whom the benefit of everolimus was higher .", "label": "", "metadata": {}, "score": "62.102905"}
{"text": "12 , pp .2012 - 2017 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Kaufmann , G. N. Hortobagyi , A. Goldhirsch et al . , \" Recommendations from an international expert panel on the use of neoadjuvant ( primary ) systemic treatment of operable breast cancer : an update , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "62.205402"}
{"text": "2012;13(6):432 - 441 t .Pazo Cid RA , Anton A. Advanced HER2-positive gastric cancer : Current and future targeted therapies .Crit Rev Oncol Hematol .", "label": "", "metadata": {}, "score": "62.364803"}
{"text": "Lapatinib .Despite improvement of pCR rates , all patients do not equally benefit from trastuzumab therapy .Indeed multiple pathways can contribute to acquired or intrinsic resistance to trastuzumab [ 21 , 22 ] .", "label": "", "metadata": {}, "score": "62.460068"}
{"text": "496 - 501 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . E. J. Jung , L. Santarpia , J. Kim , et al . , \" Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients , \" Cancer , vol .", "label": "", "metadata": {}, "score": "62.49765"}
{"text": "Yakes FM , Chinratanalab W , Ritter CA , King W , Seelig S , Arteaga CL : Herceptin - induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody - mediated effects on p27 , cyclin D1 , and antitumor action .", "label": "", "metadata": {}, "score": "62.51304"}
{"text": "[ 9 ] .In this study , trastuzumab was introduced later after anthracyclines and concomitantly with docetaxel while in the other studies , trastuzumab was given upfront for a longer period of time [ 4 , 7 , 8 ] .", "label": "", "metadata": {}, "score": "62.514267"}
{"text": "Impaired stimulation of an ADCC response has been associated with trastuzumab resistance .Immune cells including natural killer ( NK ) cells , monocytes , and macrophages express Fc gamma receptors such as CD16 [ 53 ] .", "label": "", "metadata": {}, "score": "62.667618"}
{"text": "1448 - 1455 , 2010 .View at Google Scholar \u00b7 View at Scopus .J. Koopmann , C. N. W. Rosenzweig , Z. Zhang et al . , \" Serum markers in patients with resectable pancreatic adenocarcinoma : macrophage inhibitory cytokine 1 versus CA19 - 9 , \" Clinical Cancer Research , vol .", "label": "", "metadata": {}, "score": "62.79188"}
{"text": "Kruger S , Weitsch G , Buttner H , et al .Overexpression of c - erbB-2 oncoprotein in muscle - invasive bladder carcinoma : Relationship with gene amplification , clinicopathological parameters and prognostic outcome .", "label": "", "metadata": {}, "score": "62.795677"}
{"text": "W. Xia , R. J. Mullin , B. R. Keith et al . , \" Anti - tumor activity of GW572016 : a dual tyrosine kinase inhibitor blocks EGF activation of EGFR / erbB2 and downstream Erk1/2 and AKT pathways , \" Oncogene , vol .", "label": "", "metadata": {}, "score": "62.8682"}
{"text": "532 - 537 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. C. Staff , A. J. Bock , C. Becker , T. Kempf , K. C. Wollert , and B. Davidson , \" Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer , \" Gynecologic Oncology , vol .", "label": "", "metadata": {}, "score": "62.89506"}
{"text": "This phosphoprotein was found to be related to the epidermal growth factor receptor ( EGFR ) and was called neu [ 2 ] .The transforming version of neu ( neuT ) and the wild - type gene were subsequently cloned , and neuT was confirmed to possess oncogenic activity including its ability to transform NIH/3T3 cells in contrast to wild - type neu [ 3 , 4 ] .", "label": "", "metadata": {}, "score": "62.976067"}
{"text": "2065 - 2072 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. J. Pietras , M. D. Pegram , R. S. Finn , D. A. Maneval , and D. J. Slamon , \" Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA - reactive drugs , \" Oncogene , vol .", "label": "", "metadata": {}, "score": "63.010597"}
{"text": "4 , pp .704 - 712 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . Y. J. Park , H. Lee , and J. H. Lee , \" Macrophage inhibitory cytokine-1 transactivates ErbB family receptors via the activation of Src in SK - BR-3 human breast cancer cells , \" BMB Reports , vol .", "label": "", "metadata": {}, "score": "63.067383"}
{"text": "Waltham , MA : UpToDate ; reviewed January 2012 .Wolff AC , Hammond MEH , Schwartz JN , et al .American Society of Clinical Oncology / College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer .", "label": "", "metadata": {}, "score": "63.10152"}
{"text": "Lapatinib ditosylate monohydrate ( Tykerb , GW572016 ) is an oral dual erbB1/2TK inhibitor that reversibly inhibits both EGFR and HER2/neu .It became FDA approved in March 2007 for use in combination with an oral chemotherapy agent known as capecitabine ( Xeloda ) , for the treatment of patients with advanced or metastatic HER2 + breast cancer who have already received previous therapy with anthracyclines , taxanes and trastuzumab .", "label": "", "metadata": {}, "score": "63.12313"}
{"text": "Two placebo - controlled randomised phase III studies are in progress to evaluate the benefit of adding everolimus to trastuzumab and paclitaxel in the first - line metastatic setting ( BOLERO-1 ) and to trastuzumab and vinorelbine in patients with prior trastuzumab and taxane exposure ( BOLERO-3 ) ( NCT00876395 , NCT01007942 ) .", "label": "", "metadata": {}, "score": "63.138203"}
{"text": "4730 , pp .1132 - 1139 , 1985 .View at Google Scholar \u00b7 View at Scopus .C. I. Bargmann , M. C. Hung , and R. A. Weinberg , \" Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185 , \" Cell , vol .", "label": "", "metadata": {}, "score": "63.160057"}
{"text": "Adverse events were generally grade 1/2 and manageable .The objective response rate was 20 % ( 3/15 patients ; 2 responders had mutant HER1 , 1 responder had wild - type HER1 ) , median overall PFS was 9.3 weeks .", "label": "", "metadata": {}, "score": "63.18449"}
{"text": "1204 - 1214 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. Nahta , L. X. Yuan , B. Zhang , R. Kobayashi , and F. J. Esteva , \" Insulin - like growth factor - I receptor / human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells , \" Cancer Research , vol .", "label": "", "metadata": {}, "score": "63.271774"}
{"text": "Tissue blocks were retrieved and reviewed to confirm the diagnosis .From the 101 cases identified , 49 ( 31 stage III and 18 stage IV ) had sufficient residual tumor sample to enable an assay to be performed .", "label": "", "metadata": {}, "score": "63.43719"}
{"text": "6 , no . 7 , p. 115 , 2008 .View at Publisher \u00b7 View at Google Scholar .N. L. Spector and K. L. Blackwell , \" Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "63.47274"}
{"text": "28 , no .4 , pp .865 - 871 , 1982 .View at Google Scholar \u00b7 View at Scopus . A. L. Schechter , D. F. Stern , and L. Vaidyanathan , \" The neu oncogene : an erb - B - related gene encoding a 185,000-M(r ) tumour antigen , \" Nature , vol .", "label": "", "metadata": {}, "score": "63.604"}
{"text": "6 , pp .3410 - 3415 , 2003 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .K. K. Kim , J. J. Lee , Y. Yang , K. H. You , and J. H. Lee , \" Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells , \" Carcinogenesis , vol .", "label": "", "metadata": {}, "score": "63.656284"}
{"text": "Iwamoto H , Fukasawa H , Honda T , et al .HER-2/neu expression in ovarian clear cell carcinomas .Int J Gynecol Cancer .", "label": "", "metadata": {}, "score": "63.668484"}
{"text": "Burris HA 3rd , Rugo HS , Vukelja SJ , et al .Phase II study of the antibody drug conjugate trastuzumab - DM1 for the treatment of human epidermal growth factor receptor 2 ( HER2)-positive breast cancer after prior HER2-directed therapy .", "label": "", "metadata": {}, "score": "63.70746"}
{"text": "12 , pp .2024 - 2031 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .V. Semiglazov , W. Eiermann , M. Zambetti , et al . , \" Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin ( NOAH ) study , \" European Journal of Surgical Oncology , vol .", "label": "", "metadata": {}, "score": "63.75765"}
{"text": "Report IRR No . 62 .Buenos Aires , Argentina : Institute for Clinical Effectiveness and Health Policy ( IECS ) ; 2005 .Swanton C , Futreal A , Eisen T. Her2-targeted therapies in non - small cell lung cancer .", "label": "", "metadata": {}, "score": "63.76534"}
{"text": "The patients received erlotinib ( days -8 to -1 ) , then combination therapy ( 21-day cycles for 6 cycles ) .Pertuzumab was given intravenous at 840 mg , then 420 mg once every 3 weeks , with erlotinib given daily ( 100 or 150 mg ) .", "label": "", "metadata": {}, "score": "63.867386"}
{"text": "Another more recently described mechanism of trastuzumab resistance is elevated expression of GDF15 [ 92 ] .GDF15 is found at chromosomal location 19p13.11 and encodes a disulfide - linked homodimer - secreted cytokine of approximately 34 kiloDaltons , structurally similar to the TGF beta cytokine [ 93 ] .", "label": "", "metadata": {}, "score": "64.03769"}
{"text": "However , when the investigators looked at EGFR status in these patients , the benefit was restricted to patients with mutations in EGFR .In contrast , those without an EGFR mutation had a significantly shorter progression - free survival with gefitinib ( median 1.5 versus 6.5 months ) , although there was crossover between the two treatment groups .", "label": "", "metadata": {}, "score": "64.12029"}
{"text": "1900 - 1908 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . D. L. Shattuck , J. K. Miller , K. L. Carraway III , and C. Sweeney , \" Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells , \" Cancer Research , vol .", "label": "", "metadata": {}, "score": "64.14398"}
{"text": "S21-S22 , 2001 .View at Google Scholar \u00b7 View at Scopus .X. F. Le , F. X. Claret , A. Lammayot et al . , \" The role of cyclin - dependent kinase inhibitor p27Kip1 in anti - HER2 antibody - induced G1 cell cycle arrest and tumor growth inhibition , \" Journal of Biological Chemistry , vol .", "label": "", "metadata": {}, "score": "64.16504"}
{"text": "Mutations localize to the ATP binding site , the gatekeeper residue , or the activation loop [ 130 ] .Mutant HER2 protein retains autophosphorylation , downstream signaling , and heterodimerization abilities [ 130 ] .", "label": "", "metadata": {}, "score": "64.245316"}
{"text": "Lapatinib was still effective as a single agent in tumors that had received prior trastuzumab exposure , achieving clinical benefit rates ranging from 12.4 % to 25 % [ 120 , 121 ] .", "label": "", "metadata": {}, "score": "64.29206"}
{"text": "Neither patients nor investigators were masked to treatment .The number of serious adverse events was similar in groups A , B , and D ( 15 to 20 serious adverse events per group in 10 to 17 % of patients ) but lower in group C ( 4 serious adverse events in 4 % of patients ) .", "label": "", "metadata": {}, "score": "64.30564"}
{"text": "Expression was evaluated semi - quantitatively and correlated with tumor stage and other clinicopathological data .Of the 600 specimens in the cohort , 31 patients ( 5.2 % ) had positive Her2/neu expression .", "label": "", "metadata": {}, "score": "64.32695"}
{"text": "Mutation T798 M at the gatekeeper residue and an ATP binding site mutation ( L755S and L755P ) showed reduced response to lapatinib , with IC50s of up to 50 times higher relative to wild - type HER2 [ 130 ] .", "label": "", "metadata": {}, "score": "64.3822"}
{"text": "The biological window design provides an especially valuable opportunity for the rapid evaluation of pharmacodynamic endpoints with biologic therapy .Imaging modalities have not reliably been shown to predict the response to neoadjuvant therapy .", "label": "", "metadata": {}, "score": "64.50963"}
{"text": "5 , pp .1538 - 1545 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .X. Huang , L. Gao , S. Wang et al . , \" Heterotrimerization of the growth factor receptors erbB2 , erbB3 , and insulin - like growth factor - I receptor in breast cancer cells resistant to herceptin , \" Cancer Research , vol .", "label": "", "metadata": {}, "score": "64.62018"}
{"text": "6 , pp .803 - 814 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .T. Maruyama , K. Mimura , S. Izawa , et al . , \" Lapatinib enhances herceptin - mediated antibody - dependent cellular cytotoxicity by up - regulation of cell surface HER2 expression , \" Anticancer Research , vol .", "label": "", "metadata": {}, "score": "64.67219"}
{"text": "Homs MY , Voest EE , Siersema PD .Emerging drugs for esophageal cancer .Expert Opin Emerg Drugs .Fleming GF , Sill MW , Darcy KM , et al .", "label": "", "metadata": {}, "score": "64.87826"}
{"text": "A phase II study evaluated the efficacy of everolimus combined with trastuzumab and paclitaxel in patients who were resistant to trastuzumab and taxane therapy .The median PFS was 5.5 months and the median OS was 18.1 months [ 67 ] .", "label": "", "metadata": {}, "score": "64.996185"}
{"text": "14 , pp .7245 - 7252 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. K. Chakraborty , K. Liang , and M. P. DiGiovanna , \" Co - targeting insulin - like growth factor I receptor and HER2 : dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer , \" Cancer Research , vol .", "label": "", "metadata": {}, "score": "65.01906"}
{"text": "PubMed Central PubMed View Article .Ann Oncol 2014 , 25 : 1544 - 1550 .PubMed View Article .Muenst S , Soysal SD , Gao F , Obermann EC , Oertli D , Gillanders WE : The presence of programmed death 1 ( PD-1)-positive tumor - infiltrating lymphocytes is associated with poor prognosis in human breast cancer .", "label": "", "metadata": {}, "score": "65.04741"}
{"text": "442 - 446 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . K. S. Selander , D. A. Brown , G. B. Sequeiros et al . , \" Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases , \" Cancer Epidemiology Biomarkers and Prevention , vol .", "label": "", "metadata": {}, "score": "65.13357"}
{"text": "The most commonly histopathological types are muco - epidermoid cancer , adenoid cystic cancer and adenocarcinomas .Malignant salivary gland tumors generally present as painless , slow - growing tumors that are indistinguishable from benign tumors .", "label": "", "metadata": {}, "score": "65.13838"}
{"text": "6221 , pp .230 - 231 , 1989 .View at Google Scholar \u00b7 View at Scopus . D. J. Slamon , G. M. Clark , S. G. Wong , W. J. Levin , A. Ullrich , and W. L. McGuire , \" Human breast cancer : correlation of relapse and survival with amplification of the HER-2/neu oncogene , \" Science , vol .", "label": "", "metadata": {}, "score": "65.14902"}
{"text": "188 - 194 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Kaufmann , G. Von minckwitz , H. D. Bear et al . , \" Recommendations from an international expert panel on the use of neoadjuvant ( primary ) systemic treatment of operable breast cancer : new perspectives 2006 , \" Annals of Oncology , vol .", "label": "", "metadata": {}, "score": "65.23888"}
{"text": "This could partially be explained by the fact that data from only 280 patients was available for analysis .Moreover inclusion criteria varied among studies and one study included T4 tumors [ 7 ] .", "label": "", "metadata": {}, "score": "65.34816"}
{"text": "In a review on systemic therapies for recurrent and/or metastatic salivary gland cancers , Vattemi and colleagues ( 2008 ) noted that salivary gland carcinomas are rare cancers , comprising 1 to 5 % of head and neck cancers .", "label": "", "metadata": {}, "score": "65.35474"}
{"text": "Combining HER2-Targeted Therapies .Lapatinib .Lapatinib ( Tykerb ; GlaxoSmithKline ) is a dual EGFR / HER2 kinase inhibitor that reduces EGFR and HER2 signaling and induces apoptosis in multiple models of HER2-overexpressing breast cancer [ 116 , 117 ] .", "label": "", "metadata": {}, "score": "65.55525"}
{"text": "117 - 127 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .X. F. Le , F. X. Claret , A. Lammayot et al . , \" The role of cyclin - dependent kinase inhibitor p27Kip1 in anti - HER2 antibody - induced G1 cell cycle arrest and tumor growth inhibition , \" Journal of Biological Chemistry , vol .", "label": "", "metadata": {}, "score": "65.60114"}
{"text": "mTOR inhibitors / PI3 K inhibitors .The mammalian target of rapamycin ( mTOR ) is a serine - threonine protein kinase that mediates mRNA translation and protein synthesis .", "label": "", "metadata": {}, "score": "65.74267"}
{"text": "1124 - 1130 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Toi , H. Iwata , Y. Fujiwara et al . , \" Lapatinib monotherapy in patients with relapsed , advanced , or metastatic breast cancer : efficacy , safety , and biomarker results from Japanese patients phase II studies , \" British Journal of Cancer , vol .", "label": "", "metadata": {}, "score": "65.75198"}
{"text": "40 , pp .24747 - 24755 , 1994 .View at Google Scholar \u00b7 View at Scopus .S. P. Soltoff , K. L. Carraway III , S. A. Prigent , W. G. Gullick , and L. C. Cantley , \" ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor , \" Molecular and Cellular Biology , vol .", "label": "", "metadata": {}, "score": "65.982346"}
{"text": "12 , pp .4147 - 4156 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .T. Utermark , T. Rao , H. Cheng , Q. Wang , S. H. Lee , Z. C. Wang , et al . , \" The p110alpha and p110beta isoforms of PI3 K play divergent roles in mammary gland development and tumorigenesis , \" Genes & Development , vol .", "label": "", "metadata": {}, "score": "66.00006"}
{"text": "4811 , pp .178 - 182 , 1987 .View at Google Scholar \u00b7 View at Scopus . E. Di Marco , J. H. Pierce , C. L. Knicley , and P. P. Di Fiore , \" Transformation of NIH 3T3 cells by overexpression of the normal coding sequence of the rat neu gene , \" Molecular and Cellular Biology , vol .", "label": "", "metadata": {}, "score": "66.00188"}
{"text": "Epidermal Growth Factor Receptor Family Signalling Pathway .HER2 belongs to a family of transmembrane receptor tyrosine kinases , which also includes HER1 ( also known as epidermal growth factor receptor ( EGFR ) ) , HER3 , and HER4 .", "label": "", "metadata": {}, "score": "66.015854"}
{"text": "Note : Dosing information is provided as an appendix to the background section .Background .The HER2 gene normally produces a small amount of protein called HER2 growth factor cell - surface receptor , which is responsible for growth and division of cells .", "label": "", "metadata": {}, "score": "66.04581"}
{"text": "Forty percent of patients showed no invasive residual tumor in the breast and had no histologic nodal involvement at surgery ( ypT0/is , ypN0 ) .", "label": "", "metadata": {}, "score": "66.05469"}
{"text": "447 - 456 , 2011 .View at Publisher \u00b7 View at Google Scholar .M. Pegram , Challenges in HER2-Positive Breast Cancer , ASCO Educational Book , Alexandria , Va , USA , 2011 .", "label": "", "metadata": {}, "score": "66.062"}
{"text": "Small Molecule Tyrosine Kinase Inhibitors with the EGF or HER2 Receptors as a Target .Neha Vapiwala , MD and Geoffrey Geiger , MD The Abramson Cancer Center of the University of Pennsylvania Last Modified : September 13 , 2010 .", "label": "", "metadata": {}, "score": "66.100044"}
{"text": "Pathologic complete response was assessed at surgery and adjuvant therapy given to complete 1 year of H. A total of 225 patients were randomized .Diarrhea was the most common adverse event .", "label": "", "metadata": {}, "score": "66.104004"}
{"text": "Vascular endothelial growth factor inhibitors .The vascular endothelial growth factor ( VEGF ) plays a key role in progression of this cancer by promoting tumor angiogenesis [ 51 ] .", "label": "", "metadata": {}, "score": "66.12453"}
{"text": "1846 - 1850 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . K. L. Blackwell , H. J. Burstein , A. M. Storniolo et al . , \" Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive , trastuzumab - refractory metastatic breast cancer , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "66.253494"}
{"text": "Figure 4 .GeparQuinto study design for HER2-negative cohort .Reprinted with permission from GBG ( German Breast Group ) .Figure 5 .", "label": "", "metadata": {}, "score": "66.31877"}
{"text": "One study was conducted in the neoadjuvant setting ( 417 patients ) , whereas all the others dealt with patients with recurrent , metastatic , or refractory disease ( 1,023 patients ) .", "label": "", "metadata": {}, "score": "66.45031"}
{"text": "T - DM1 was well - tolerated with no dose - limiting cardiotoxicity .Most adverse events ( AEs ) were grade 1 or 2 ; the most frequent grade greater than or equal to 3 AEs were hypokalemia ( 8.9 % ) , thrombocytopenia ( 8.0 % ) , and fatigue ( 4.5 % ) .", "label": "", "metadata": {}, "score": "66.51001"}
{"text": "In addition to changes in signaling which may reduce sensitivity to lapatinib , recent evidence indicates that HER2 kinase domain mutations are associated with reduced lapatinib efficacy .", "label": "", "metadata": {}, "score": "66.57992"}
{"text": "628 - 638 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .N. U. Lin , V. Di\u00e9ras , D. Paul et al . , \" Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer , \" Clinical Cancer Research , vol .", "label": "", "metadata": {}, "score": "66.62147"}
{"text": "Ventana Medical Systems , Inc. HER-2/neu Gene Amplification Analysis in Breast Cancer with the INFORM \u00ae HER-2/neu Gene Detection System .Tucson , AZ : Ventana Medical Systems , Inc. ; 1998 - 1999 .", "label": "", "metadata": {}, "score": "66.94824"}
{"text": "Luca Gianni Fondazione IRCCS Istituto Nazionale Tumori , Milan , Italy Lancet 375:377 - 84 .We aimed to assess event - free survival in patients with HER2-positive locally advanced or inflammatory breast cancer receiving neoadjuvant chemotherapy with or without 1 year of trastuzumab ... .", "label": "", "metadata": {}, "score": "66.96392"}
{"text": "More than 4,800 participants are enrolled in this trial , which will provide further data on safety , effectiveness , and long - term outcomes .", "label": "", "metadata": {}, "score": "67.0601"}
{"text": "6 , pp .783 - 791 , 2002 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .K. Wu , P. J. I. Salas , L. Yee , N. Fregien , and K. L. Carraway , \" Tissue and tumor expression of a cell surface glycoprotein complex containing an integral membrane glycoprotein activator of p185(neu ) , \" Oncogene , vol .", "label": "", "metadata": {}, "score": "67.15497"}
{"text": "Capecitabine / Cyclophosphamide / Methotrexate for patients with metastatic breast cancer : a dose - finding , feasibility , and efficacy study .Gabriella Mariani Istituto Nazionale per lo Studio e la Cura dei Tumori , Milan , Italy Clin Breast Cancer 7:321 - 5 .", "label": "", "metadata": {}, "score": "67.35861"}
{"text": "The receptor for GDF15 has not been identified ; however , a potential cross - talk is activated by GDF15 , which induced phosphorylation of HER2 and downstream Akt and Erk1/2 in HER2-overexpressing SKBR3 [ 99 , 100 ] and BT474 [ 92 ] breast cancer cells .", "label": "", "metadata": {}, "score": "67.42819"}
{"text": "11337 - 11345 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. C. Franklin , K. D. Carey , F. F. Vajdos , D. J. Leahy , A. M. De Vos , and M. X. Sliwkowski , \" Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex , \" Cancer Cell , vol .", "label": "", "metadata": {}, "score": "67.45364"}
{"text": "Activation of PI3 K Pathway .HER2 overexpression leads to an activation of multiple signaling pathways including the PI3K / Akt pathway that result in the modification of cell growth , differentiation , and survival .", "label": "", "metadata": {}, "score": "67.542206"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. J. Bock , H. T. Stavnes , T. Kempf et al . , \" Expression and clinical role of growth differentiation factor-15 in ovarian carcinoma effusions , \" International Journal of Gynecological Cancer , vol .", "label": "", "metadata": {}, "score": "67.54427"}
{"text": "However , lapatinib appears to retain cytotoxic activity in these cells [ 137 ] .Another report [ 138 ] suggested that increased phosphorylation of IGF - IR , HER3 , or EGFR correlates with response to lapatinib , but not to trastuzumab .", "label": "", "metadata": {}, "score": "67.57608"}
{"text": "Gabriella Mariani Istituto Nazionale per lo Studio e la Cura dei Tumori , Milan , Italy Clin Breast Cancer 7:321 - 5 .Role of anthracyclines in the treatment of early breast cancer .", "label": "", "metadata": {}, "score": "67.59609"}
{"text": "This receptor is involved in proliferation and survival of epithelial cells .Activation of HER2 generates activation of downstream signaling pathways including mitogen - activated protein kinase ( MAPK ) and phosphoinositide 3-kinase ( PI3K / Akt ) [ 3 ] .", "label": "", "metadata": {}, "score": "67.615234"}
{"text": "The EMILIA study , a multicentre , open - label , randomised , phase III study comparing the efficacy of T - DM1 versus the combination of capecitabine and lapatinib in patients who have received prior taxane- and trastuzumab - based regimens , is nearing completion ( NCT00829166 ) .", "label": "", "metadata": {}, "score": "67.617004"}
{"text": "22 , pp .8105 - 8108 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .P. Stephens , C. Hunter , G. Bignell , S. Edkins , H. Davies , J. Teague , et al . , \" Lung cancer : intragenic ERBB2 kinase mutations in tumours , \" Nature , vol .", "label": "", "metadata": {}, "score": "67.629135"}
{"text": "Accessed September 20 , 1999 .Ravdin PM .Should HER2 status be routinely measured for all breast cancer patients ?Semin Oncol . 1999;4 ( Suppl 12):117 - 123 .", "label": "", "metadata": {}, "score": "67.67575"}
{"text": "Pazo Cid RA , Anton A. Advanced HER2-positive gastric cancer : Current and future targeted therapies .Crit Rev Oncol Hematol .Hurvitz SA , Dirix L , Kocsis J , et al .", "label": "", "metadata": {}, "score": "67.7693"}
{"text": "PubMed Central PubMed .Mukohara T : Mechanisms of resistance to anti - human epidermal growth factor receptor 2 agents in breast cancer .Cancer Sci 2011 , 102 : 1 - 8 .", "label": "", "metadata": {}, "score": "67.772125"}
{"text": "628 - 638 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Scaltriti , S. Chandarlapaty , L. Prudkin et al . , \" Clinical benefit of lapatinib - based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor , \" Clinical Cancer Research , vol .", "label": "", "metadata": {}, "score": "67.78795"}
{"text": "PubMed View Article .Hicklin DJ , Ellis LM : Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis .J Clin Oncol 2005 , 23 : 1011 - 1027 .", "label": "", "metadata": {}, "score": "67.96657"}
{"text": "117 - 127 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. C. Faber , K. K. Wong , and J. A. Engelman , \" Differences underlying EGFR and HER2 oncogene addiction , \" Cell Cycle , vol .", "label": "", "metadata": {}, "score": "67.99011"}
{"text": "93 , no .24 , pp .1852 - 1857 , 2001 .View at Google Scholar \u00b7 View at Scopus .P. Nagy , E. Friedl\u00e4nder , M. Tanner et al . , \" Decreased accessibility and lack of activation of ErbB2 in JIMT-1 , a herceptin - resistant , MUC4-expressing cancer cell line , \" Cancer Research , vol .", "label": "", "metadata": {}, "score": "68.02716"}
{"text": "32 , pp .28468 - 28473 , 2002 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .X. Qian , W. C. Dougall , M. E. Hellman , and M. I. Greene , \" Kinase - deficient neu proteins suppress epidermal growth factor receptor function and abolish cell transformation , \" Oncogene , vol .", "label": "", "metadata": {}, "score": "68.08398"}
{"text": "52 , pp .33245 - 33254 , 1997 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . K. L. Carraway III , E. A. Rossi , M. Komatsu et al . , \" An intramembrane modulator of the ErbB2 receptor tyrosine kinase that potentiates neuregulin signaling , \" Journal of Biological Chemistry , vol .", "label": "", "metadata": {}, "score": "68.162994"}
{"text": "View at Google Scholar \u00b7 View at Scopus .M. Scaltriti , S. Chandarlapaty , L. Prudkin et al . , \" Clinical benefit of lapatinib - based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor , \" Clinical Cancer Research , vol .", "label": "", "metadata": {}, "score": "68.21744"}
{"text": "A thorough discussion of the detailed function of all the members of the EGFR family is beyond the scope of this review and as such , we will be focusing on EGFR itself ( [ HER1 ] or ErbB1 ) and HER2 .", "label": "", "metadata": {}, "score": "68.57864"}
{"text": "Small EJ , Halabi S , Dalbagni G , et al .Overview of bladder cancer trials in the Cancer and Leukemia Group B. Cancer .", "label": "", "metadata": {}, "score": "68.71713"}
{"text": "41 , pp .6255 - 6263 , 2002 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Scaltriti , S. Chandarlapaty , L. Prudkin et al . , \" Clinical benefit of lapatinib - based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor , \" Clinical Cancer Research , vol .", "label": "", "metadata": {}, "score": "68.75541"}
{"text": "Structural modeling of the HER2 dimers bound to lapatinib showed that HER2 homodimers and heterodimers are more stable when lapatinib is bound [ 143 ] .", "label": "", "metadata": {}, "score": "68.83531"}
{"text": "Lapatinib and Trastuzumab .A preclinical study in HER2-overexpressing breast cancer cell lines suggested that dual anti - HER2 blockade was synergistic because lapatinib induced HER2 accumulation at the cell surface , resulting in enhanced trastuzumab - binding and increased trastuzumab - mediated ADCC [ 41 ] .", "label": "", "metadata": {}, "score": "68.95572"}
{"text": "11 , pp .3981 - 3986 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Komatsu , C. A. C. Carraway , N. L. Fregien , and K. L. Carraway , \" Reversible disruption of cell - matrix and cell - cell interactions by overexpression of sialomucin complex , \" Journal of Biological Chemistry , vol .", "label": "", "metadata": {}, "score": "68.991905"}
{"text": "The Met ligand HGF can promote invasiveness of HER2-expressing breast cancer cells through a MEK - dependent mechanism that results in reduced E - cadherin and internalization of ZO-1 , indicative of basement membrane breakdown and EMT [ 89 ] .", "label": "", "metadata": {}, "score": "69.00854"}
{"text": "The primary end - point was DFS , with a pre - specified non - inferiority margin of 1.15 .Analyses were carried out in the intention - to - treat population .", "label": "", "metadata": {}, "score": "69.1061"}
{"text": "Luca Gianni Department of Medical Oncology , San Raffaele Institute , Milan , Italy Lancet Oncol 12:236 - 44 .We aimed to assess disease - free survival and overall survival after a median follow - up of 4 years for patients enrolled on the Herceptin Adjuvant ( HERA ) trial ... .", "label": "", "metadata": {}, "score": "69.209724"}
{"text": "11 , pp .3139 - 3147 , 1994 .View at Google Scholar \u00b7 View at Scopus .P. Nagy , E. Friedl\u00e4nder , M. Tanner et al . , \" Decreased accessibility and lack of activation of ErbB2 in JIMT-1 , a herceptin - resistant , MUC4-expressing cancer cell line , \" Cancer Research , vol .", "label": "", "metadata": {}, "score": "69.297424"}
{"text": "Key secondary end points included OS , ORR , duration of objective response , clinical benefit rate , and quality of life .Median PFS was 9.2 months with HT and 14.2 months with T - DM1 ( hazard ratio , 0.59 ; 95 % CI : 0.36 to 0.97 ) ; median follow - up was approximately 14 months in both arms .", "label": "", "metadata": {}, "score": "69.3391"}
{"text": "Phosphorylation and dimerization of p95HER2 has been shown to be stimulated by the HER3 ligand heregulin , causing interaction with HER3 but not EGFR [ 71 ] .", "label": "", "metadata": {}, "score": "69.354645"}
{"text": "5994 , pp .513 - 516 , 1984 .View at Google Scholar \u00b7 View at Scopus .C. I. Bargmann , M. C. Hung , and R. A. Weinberg , \" The neu oncogene encodes an epidermal growth factor receptor - related protein , \" Nature , vol .", "label": "", "metadata": {}, "score": "69.36743"}
{"text": "The overall safety profile was acceptable , but did include a less than 10 % incidence of grade 3 diarrhoea , fatigue , and stomatitis [ 70 ] .", "label": "", "metadata": {}, "score": "69.462845"}
{"text": "DownersGrove , IL : VysisInc.;May11,1999 .Accessed September 20 , 1999 .Vysis Inc. FDA approves Vysis PathVysion \u2122 breast cancer test to detect and quantify HER-2 gene .", "label": "", "metadata": {}, "score": "69.56706"}
{"text": "82 ] first demonstrated that increased IGF - IR signaling due to stable overexpression of IGF - IR in SKBR3 cells can abrogate trastuzumab - mediated G1 arrest .", "label": "", "metadata": {}, "score": "69.65875"}
{"text": "525 - 526 , 2004 .View at Google Scholar .R. K. Kancha , N. von Bubnoff , N. Bartosch , C. Peschel , R. A. Engh , and J. Duyster , \" Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib , \" PLoS One , vol .", "label": "", "metadata": {}, "score": "69.88792"}
{"text": "Ultimately , which signaling pathway is activated may be a result of whether HER2 is found primarily in homodimers or heterodimers .One study suggested that HER2 homodimers selectively activated Ras - MAPK , while heterodimers activated both MAPK and PI3 K signaling pathways [ 24 ] .", "label": "", "metadata": {}, "score": "69.924065"}
{"text": "12 , pp .1927 - 1934 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .S. Dawood , S. D. Merajver , P. Viens et al . , \" International expert panel on inflammatory breast cancer : consensus statement for standardized diagnosis and treatment , \" Annals of Oncology , vol .", "label": "", "metadata": {}, "score": "69.94777"}
{"text": "Patients were included in this study based on perceived therapeutic response to gefitinib , as all patients had the adenocarcinoma subtype of NSCLC and all were either former or light smokers .", "label": "", "metadata": {}, "score": "70.061935"}
{"text": "5 , pp .2063 - 2073 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .C. Garcia - Echeverria , M. A. Pearson , A. Marti et al . , \" In vivo antitumor activity of NVP - AEW541-a novel , potent , and selective inhibitor of the IGF - IR kinase , \" Cancer Cell , vol .", "label": "", "metadata": {}, "score": "70.125725"}
{"text": "Reprinted with permission from GBG ( German Breast Group ) .Translational research .Traditionally , translational research in breast cancer has been characterised by efforts to validate single predictive biomarkers using available tumour blocks from completed clinical trials , with largely disappointing results .", "label": "", "metadata": {}, "score": "70.151276"}
{"text": "HER2 interacts with erbB family members EGFR and HER3 .Increased levels of EGFR and HER3 ligands have been associated with reduced response to trastuzumab and have previously been reviewed in this context [ 39 ] .", "label": "", "metadata": {}, "score": "70.21445"}
{"text": "The data for this paper were obtained by searching the PubMed database using Entrez .The citation lists of all retrieved articles were examined to identify potentially relevant articles , and proceedings from conferences of the American Society of Clinical Oncology and San Antonio Breast Cancer Symposium were searched for relevant abstracts .", "label": "", "metadata": {}, "score": "70.24302"}
{"text": "Genentech , the manufacturer of Perjeta , has committed to take steps designed to resolve these production issues in a timely manner . \" Genentech is currently developing a plan to mitigate the effect on patients of any potential shortage of Perjeta . \" Breast cancer is the second leading cause of cancer - related death among women .", "label": "", "metadata": {}, "score": "70.323135"}
{"text": "39 , pp .5459 - 5465 , 2001 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . D. B. Weiner , J. Liu , J. A. Cohen , W. V. Williams , and M. I. Greene , \" A point mutation in the neu oncogene mimics ligand induction of receptor aggregation , \" Nature , vol .", "label": "", "metadata": {}, "score": "70.346794"}
{"text": "HER2 kinase function is not required for homodimerization , as mutation of Lys732 in the ATP - binding site of HER2 results in ablation of the kinase function , and this kinase - dead HER2 can still interact with HER2 , as assessed by transfection and coimmunoprecipitation experiments [ 15 ] .", "label": "", "metadata": {}, "score": "70.68335"}
{"text": "Decision tree from GeparQuinto study .B , bevacizumab ; EC , epirubicin - cyclophosphamide ; H , trastuzumab ; Her-2 , human epidermal growth factor receptor 2 ; L , lapatinib ; Pw , paclitaxel weekly ; T , docetaxel .", "label": "", "metadata": {}, "score": "70.76123"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .P. P. Di Fiore , J. H. Pierce , M. H. Kraus , et al . , \" erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells , \" Science , vol .", "label": "", "metadata": {}, "score": "70.902"}
{"text": "NSCLC : 150 mg / day .Pancreatic cancer : 100 mg / day in combination with gemcitabine .Note : Active cigarette smoking affects the absorption of erlotinib .", "label": "", "metadata": {}, "score": "70.9384"}
{"text": "The most common side effects observed in patients receiving Perjeta in combination with trastuzumab and docetaxel were diarrhea , hair loss , a decrease in infection - fighting white blood cells , nausea , fatigue , rash , and nerve damage ( peripheral sensory neuropathy ) .", "label": "", "metadata": {}, "score": "70.95775"}
{"text": "Gnant disclosed relationships with AstraZeneca , Novartis , Roche , Schering , Pfizer , Novartis , AstraZeneca , sanofi - aventis , GlaxoSmithKline , and Amgen .", "label": "", "metadata": {}, "score": "70.982544"}
{"text": "The results confirm those from a previous report at the San Antonio Breast Cancer Symposium .Three important lessons can be learned from the results of GeparQuinto , Stephen K. Chia , MD , of the British Columbia Cancer Agency in Vancouver , B.C. , wrote in an accompanying commentary .", "label": "", "metadata": {}, "score": "71.03688"}
{"text": "These investigators searched the Cochrane Gynaecological Cancer Group Trials Register , The Cochrane Central Register of Controlled Trials ( CENTRAL )Issue 4 , 2010 , MEDLINE and EMBASE up to October 2010 .", "label": "", "metadata": {}, "score": "71.1658"}
{"text": "Using a chimeric receptor where the EGFR C - terminus was replaced with the C - terminus of HER2 demonstrated that the HER2 C - terminus can replace the autophosphorylation tyrosine residues in EGFR [ 12 ] .", "label": "", "metadata": {}, "score": "71.17495"}
{"text": "View at Google Scholar \u00b7 View at Scopus .X. Qian , D. M. O'Rourke , H. Zhao , and M. I. Greene , \" Inhibition of p185(neu ) kinase activity and cellular transformation by co - expression of a truncated neu protein , \" Oncogene , vol .", "label": "", "metadata": {}, "score": "71.19146"}
{"text": "Health consequences of long - term use of Herceptin .Pre - assessment No . 26 .Ottawa , ON : CCOHTA ; November 2003 .", "label": "", "metadata": {}, "score": "71.22987"}
{"text": "41 , pp .6255 - 6263 , 2002 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . D. Zhang , A. Pal , W. G. Bornmann et al . , \" Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells , \" Molecular Cancer Therapeutics , vol .", "label": "", "metadata": {}, "score": "71.334045"}
{"text": "18 , pp .4910 - 4918 , 2012 .View at Google Scholar .B. L. Margolis , I. Lax , R. Kris et al . , \" All autophosphorylation sites of epidermal growth factor ( EGF ) receptor and HER2/neu are located in their carboxyl - terminal tails .", "label": "", "metadata": {}, "score": "71.68039"}
{"text": "The most common side effects observed in patients receiving Perjeta in combination with trastuzumab and docetaxel were diarrhea , fatigue , hair loss , leukopenia , nausea , rash , and peripheral sensory neuropathy .", "label": "", "metadata": {}, "score": "71.806244"}
{"text": "Non - Small Cell Lung Cancer .More than half of non - small cell lung cancers ( NSCLC ) express too much EGFR : approximately 50 % of adenocarcinomas and nearly 80 % of squamous cell carcinomas .", "label": "", "metadata": {}, "score": "72.1282"}
{"text": "Waltham , MA : UpToDate ; reviewed January 2015 .Ryan DP , Mamon H , Fernandez - del Castillo C. Ampullary carcinoma : Treatment and prognosis .", "label": "", "metadata": {}, "score": "72.14011"}
{"text": "Homs and colleagues ( 2009 ) evaluated current treatment strategies and new developments including targeted therapy for esophageal cancer .Published clinical trials as well as abstracts were selected regarding chemo - radiation or targeted therapy for esophageal cancer .", "label": "", "metadata": {}, "score": "72.15818"}
{"text": "These include : adenocarcinoma histology , female sex , non - smoking history and Asian ethnicity .Many of these findings are believed to be due to differences in the frequency of EGFR and K - ras mutations , the former of which are more common in non - smokers and Asian populations .", "label": "", "metadata": {}, "score": "72.23074"}
{"text": "2572 - 2577 , 2012 .View at Google Scholar .Abstract .Through the use of surrogate markers of efficacy , neoadjuvant studies may facilitate the implementation of new treatments into clinical practice .", "label": "", "metadata": {}, "score": "72.281525"}
{"text": "Randomization was in a 1:1 ratio , stratified by geographical region and previous treatment status .The primary end - point was PFS ( assessed independently ) , which has been reported previously ; no follow - up data were gathered for the primary end - point .", "label": "", "metadata": {}, "score": "72.46501"}
{"text": "1647 - 1655 , 1997 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . E. Penuel , R. W. Akita , and M. X. Sliwkowski , \" Identification of a region within the ErbB2/HER2 intracellular domain that is necessary for ligand - independent association , \" Journal of Biological Chemistry , vol .", "label": "", "metadata": {}, "score": "72.60078"}
{"text": "Dimerisation in turn induces tyrosine kinase phosphorylation and downstream signalling onto the PI3 K and mitogen - activated protein ( MAP ) kinase cascades , leading to cell survival and proliferation , respectively .", "label": "", "metadata": {}, "score": "72.60686"}
{"text": "6050 , pp .226 - 230 , 1986 .View at Google Scholar \u00b7 View at Scopus .L. Coussens , T. L. Yang - Feng , and Y. C. Liao , \" Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene , \" Science , vol .", "label": "", "metadata": {}, "score": "72.60986"}
{"text": "15 , pp .8933 - 8938 , 2003 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . H. H. Kim , S. L. Sierke , and J. G. Koland , \" Epidermal growth factor - dependent association of phosphatidylinositol 3- kinase with the erbB3 gene product , \" Journal of Biological Chemistry , vol .", "label": "", "metadata": {}, "score": "72.61588"}
{"text": "Lapatinib blocks ligand - induced heterodimer signaling and prevents signaling via a frequently expressed truncated version of the HER2 receptor ( p95 ) that could render cells resistant to trastuzumab .", "label": "", "metadata": {}, "score": "72.650955"}
{"text": "Secondary end points included PFS ( investigator - assessed ) , the ORR , and the time to symptom progression .Two interim analyses of OS were conducted .", "label": "", "metadata": {}, "score": "72.70021"}
{"text": "We and others [ 81 , 84 - 86 ] have shown that IGF - IR and HER2 can interact , facilitating cross - talk such that IGF - I induces phosphorylation of HER2 , and IGF - IR inhibition reduces HER2 phosphorylation .", "label": "", "metadata": {}, "score": "72.75582"}
{"text": "Check W. More than one way to look for HER2 .College of American Pathologists CAP Today , March 1999:1 .VysisInc .PathVysion \u2122 HER-2DNAProbeKit .", "label": "", "metadata": {}, "score": "72.88001"}
{"text": "In vitro kinase phosphorylation of HER2 followed by tryptic digestion and HPLC separation of the phosphopeptides identified the specific phosphorylation sites as Y1248 , Y1023 , Y1112 , Y1127 , Y1139 , Y1196 , Y1221 , and Y1222 , all within the C - terminus [ 13 ] .", "label": "", "metadata": {}, "score": "72.95943"}
{"text": "Nash and colleagues ( 2007 ) reported the case of a 44-year old man was referred for a right chest nodule of 3-month duration .", "label": "", "metadata": {}, "score": "73.04684"}
{"text": "Aetna does not provide health care services and , therefore , can not guarantee any results or outcomes .Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates .", "label": "", "metadata": {}, "score": "73.06048"}
{"text": "Past failures have been marred by duplicative trial designs , poorly planned translational research , and overestimation of the benefit of experimental therapy in unselected populations .", "label": "", "metadata": {}, "score": "73.27179"}
{"text": "IDEAL-2 was a seminal study that led to the FDA 's accelerated approval of gefitinib .The full study was published in October 2003 in the Journal of the American Medical Association and was a double blind , randomized , phase II study conducted at 30 U.S. medical centers .", "label": "", "metadata": {}, "score": "73.33771"}
{"text": "PubMed .Lu Y , Zi X , Zhao Y , Pollak M : Overexpression of ErbB2 receptor inhibits IGF - I - induced Shc - MAPK signaling pathway in breast cancer cells .", "label": "", "metadata": {}, "score": "73.34519"}
{"text": "Use of formalin - fixed paraffin - embedded samples for gene expression studies in breast cancer patients .Valeria Musella Department of Experimental Oncology and Molecular Medicine , Fondazione IRCCS Istituto Nazionale dei Tumori , Milan , Italy PLoS ONE 10:e0123194 .", "label": "", "metadata": {}, "score": "73.79871"}
{"text": "Lapatinib is a reversible small - molecule TKI of EGFR and HER2 which was first found to possess antitumour activity in HER2-dependent cells lines [ 36 ] .", "label": "", "metadata": {}, "score": "74.143394"}
{"text": "PTEN loss leads to the constitutive activation of Akt , which in turn activates mTOR in the PI3K / Akt signalling pathway .Everolimus Everolimus is the most advanced mTOR inhibitor undergoing clinical investigation and is being developed in combination with existing HER2-directed therapies with or without chemotherapy .", "label": "", "metadata": {}, "score": "74.32624"}
{"text": "In the intention - to - treat population , 267 patients died by data cut - off ( May 14 , 2012 ) , 154 ( 38 % ) of 406 in the placebo group and 113 ( 28 % ) of 402 in the pertuzumab group .", "label": "", "metadata": {}, "score": "74.50394"}
{"text": "Kinase signaling can then stimulate autophosphorylation and downstream signaling , primarily through the PI3K - Akt - mTOR and Ras - Raf - MEK - Erk1/2 pathways .", "label": "", "metadata": {}, "score": "74.80931"}
{"text": "Inhibition of Akt resulted in an increased expression and phosphorylation of Fox03a transcription factor in responsive cell lines [ 123 ] .Interestingly , Fox03a upregulates ER signaling , which has been documented as a potential mechanism of lapatinib resistance [ 123 , 124 ] , perhaps due to inhibition of apoptosis mediated by Bcl-2 family proteins [ 125 ] .", "label": "", "metadata": {}, "score": "75.049065"}
{"text": "This Clinical Policy Bulletin may be updated and therefore is subject to change .You are now leaving the Aetna website .Links to various non - Aetna sites are provided for your convenience only .", "label": "", "metadata": {}, "score": "75.27351"}
{"text": "Luca Gianni Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale Tumori , Milan , Italy J Clin Oncol 27:4798 - 808 .To review data relating to anthracyclines in the adjuvant treatment of early breast cancer ... .", "label": "", "metadata": {}, "score": "75.389496"}
{"text": "Lancet .Harris L , Fritsche H , Mennel R , et al .American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer .", "label": "", "metadata": {}, "score": "75.61714"}
{"text": "2007 ASCO Annual Meeting Proceedings .43rdAmerican Society of Clinical Oncology Annual Meeting ; 1 - 5 June 2007 ; Chicago , IL .First analysis of efficacy and safety of the GBG / AGO multicenter intergroup - study ' GeparQuattro ' .", "label": "", "metadata": {}, "score": "75.99583"}
{"text": "[34 ] .Data from other prospective studies examining the same issue but using different chemotherapeutic regimens are awaited ( Pandora , NCT00444587 ; THOR , NCT00448279 ) [ 35 ] .", "label": "", "metadata": {}, "score": "76.12979"}
{"text": "3 - 7 , 1990 .View at Google Scholar \u00b7 View at Scopus . D. Graus - Porta , R. R. Beerli , J. M. Daly , and N. E. Hynes , \" ErbB-2 , the preferred heterodimerization partner of all ErbB receptors , is a mediator of lateral signaling , \" EMBO Journal , vol .", "label": "", "metadata": {}, "score": "76.30098"}
{"text": "Median follow - up was 30 months in both groups .Effectiveness end - points were analyzed in the intention - to - treat population and safety was analyzed by treatment received .", "label": "", "metadata": {}, "score": "76.62516"}
{"text": "237 - 243 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. B. Welsh , L. M. Sapinoso , S. G. Kern et al . , \" Large - scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum , \" Proceedings of the National Academy of Sciences of the United States of America , vol .", "label": "", "metadata": {}, "score": "76.777176"}
{"text": "U.S. Food and Drug Administration ( FDA ) .Diagnostic Aids for Cancer : June 1996 through September 1999 .Rockville , MD : FDA ; 1999 .", "label": "", "metadata": {}, "score": "76.84444"}
{"text": "The investigators reported an overall response rate of 7.3 % after a median treatment duration of 8 weeks , and the median progression - free interval was 2 months .", "label": "", "metadata": {}, "score": "76.992874"}
{"text": "ErbB2 , a tyrosine kinase receptor over - expressed in many human cancer types , contributes to prostate cancer progression by activating the androgen receptor in a steroid poor environment , thus promoting androgen - independent cell growth .", "label": "", "metadata": {}, "score": "77.15509"}
{"text": "There was no significant difference either in median PFS or in the secondary end points between the 2 arms .No differences were seen in an exploratory biomarker analysis of HER3 mRNA expression between the 2 arms .", "label": "", "metadata": {}, "score": "77.170425"}
{"text": "PubMed Central PubMed View Article .Mukhopadhyay P , Chakraborty S , Ponnusamy MP , Lakshmanan I , Jain M , Batra SK : Mucins in the pathogenesis of breast cancer : implications in diagnosis , prognosis and therapy .", "label": "", "metadata": {}, "score": "77.39162"}
{"text": "Reviewed by Robert Jasmer , MD Associate Clinical Professor of Medicine , University of California , San Francisco and Dorothy Caputo , MA , RN , BC - ADM , CDE , Nurse Planner .", "label": "", "metadata": {}, "score": "77.4406"}
{"text": "Waltham , MA : UpToDate ; reviewed January 2015 .Pertuzumab ( Perjeta ) : .Sakai K , Yokote H , Murakami - Murofushi K , et al .", "label": "", "metadata": {}, "score": "77.81196"}
{"text": "Colon cancer .Gastric cancer .Hepatobiliary cancers ( cholangiocarcinoma and gallbladder cancer ) .Lung cancer ( including non - small - cell lung cancer ) .", "label": "", "metadata": {}, "score": "77.96878"}
{"text": "Intravenous infusion , for therapy , prophylaxis , or diagnosis ( specify substance or drug ) ; initial , up to 1 hour .each additional hour ( List separately in addition to code for primary procedure ) .", "label": "", "metadata": {}, "score": "78.17107"}
{"text": "4 , pp .317 - 328 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . S. Diermeier - Daucher , M. Hasmann , and G. Brockhoff , \" Flow cytometric FRET analysis of erbB receptor interaction on a cell - by - cell basis , \" Annals of the New York Academy of Sciences , vol .", "label": "", "metadata": {}, "score": "78.181366"}
{"text": "Malignant neoplasm of esophagus [ HER2 positive ] .C16.0 - C16.9 .Malignant neoplasm of stomach [ HER2 positive ] .C40.00- C34.92 .", "label": "", "metadata": {}, "score": "78.20687"}
{"text": "Predictive Factors of Response in HER2-Positive Breast Cancer Treated by Neoadjuvant Therapy .1 Medical Oncology , Centre Georges Fran\u00e7ois Leclerc , 21000 Dijon , France 2 Medical Oncology , Centre Jean Perrin , 63000 Clermont - Ferrand , France 3 Oncology Department , CHU Treichville , BP V3 Abidjan , Cote D'Ivoire .", "label": "", "metadata": {}, "score": "78.209076"}
{"text": "Luca Gianni Department of Medical Oncology , San Raffaele Hospital , Via Olgettina 60 , Milan , Italy J Clin Oncol 31:1719 - 25 .The potential predictive value of plasma VEGF - A is consistent with findings in HER2-negative LR / MBC , warranting prospective evaluation ... .", "label": "", "metadata": {}, "score": "78.30868"}
{"text": "Coinhibition using Met siRNA or Met kinase inhibitor SU11274 plus trastuzumab resulted in greater inhibition of proliferation versus either approach alone and was associated with greater inhibition of Akt phosphorylation [ 90 ] .", "label": "", "metadata": {}, "score": "78.31341"}
{"text": "Co- authors disclosed relationships with GlaxoSmithKline , Roche , Novartis , Amgen , Abbott , AstraZeneca , Pizer , and Bristol - Myers Squibb .", "label": "", "metadata": {}, "score": "78.323"}
{"text": "Results from the GEICAM 2006 - 14 phase II randomized trial , \" Cancer Research , vol .71 , supplement 24 , 2011 .View at Google Scholar .", "label": "", "metadata": {}, "score": "78.35695"}
{"text": "Hepatobiliary cancers ( cholangiocarcinoma and gallbladder cancer ) .Intra - hepatic bile duct cancer .Melanoma .Neuroendocrine cervical cancer .Osteosarcoma .Ovarian cancer .", "label": "", "metadata": {}, "score": "78.405014"}
{"text": "With gefitinib , other common adverse effects ( ? 1 % of patients ) include : diarrhea , nausea , vomiting , anorexia , inflammation of the linings of the mouth , dehydration , skin reactions , elevations of liver enzymes , and conjunctivitis or eyelid swelling .", "label": "", "metadata": {}, "score": "78.788925"}
{"text": "On examination , palpable nodes were noted in the right axilla .Radiographical studies were significant only for right axillary lymphadenopathy .Histologically , a nodular dermal proliferation composed of poorly differentiated epithelioid cells in nests and focally forming ducts with pseudopapillary architecture comprised the primary tumor .", "label": "", "metadata": {}, "score": "78.85238"}
{"text": "4785 , pp .177 - 182 , 1987 .View at Google Scholar \u00b7 View at Scopus . A. L. Schechter , M. C. Hung , and L. Vaidyanathan , \" The neu gene : an erbB - homologous gene distinct from and unlinked to the gene encoding the EGF receptor , \" Science , vol .", "label": "", "metadata": {}, "score": "79.12244"}
{"text": "NCCN Clinical Practice Guidelines in Oncology , Version 1.2015 .Fort Washington , PA : NCCN ; 2015 .Leitao MM , Zivanovic O. Small cell neuroendocrine carcinoma of the cervix .", "label": "", "metadata": {}, "score": "79.33416"}
{"text": "With lapatinib , the opposite effect was observed , with 92.3 % ( 12/13 ) of patients with low PTEN achieving pCR compared with 41.2 % ( 7/17 ) of patients with normal PTEN [ 42 ] .", "label": "", "metadata": {}, "score": "79.472916"}
{"text": "Physicians and other healthcare professionals may also receive Continuing Medical Education ( CME ) and Continuing Education ( CE ) credits at no cost for participating in MedPage Today - mptabsoluteurled educational activities .", "label": "", "metadata": {}, "score": "79.58412"}
{"text": "C61 .Malignant neoplasm of prostate .C67.0 - C67.9 .Malignant neoplasm of bladder .C80.1 .Malignant ( primary ) neoplasm , unspecified .", "label": "", "metadata": {}, "score": "79.598785"}
{"text": "PubMed View Article .J Clin Oncol 2011 , 29 : 3126 - 3132 .PubMed Central PubMed View Article .Breast Cancer Res Treat 2013 , 141 : 437 - 446 .", "label": "", "metadata": {}, "score": "79.725815"}
{"text": "HSP90 belongs to a family of chaperone proteins which facilitate the conformational maturation and folding of various signalling proteins , including HER2 .In a preclinical study , interference with its function led to ubiquitylation and proteasomal degradation of HER2 and the resultant abrogation of the PI3K / Akt pathway , in turn causing growth inhibition of HER2-overexpressing tumours in murine xenograft models [ 65 ] .", "label": "", "metadata": {}, "score": "79.82362"}
{"text": "Three hundred ninety two patients ( of 417 eligible ) underwent surgery .Thirty two percent of patients had locally advanced breast cancer and 7 % an inflammatory tumor .", "label": "", "metadata": {}, "score": "80.36643"}
{"text": "There is also a p95HER2 that is present in the cytoplasm , and additional forms expressed in cell nuclei have been described [ 79 ] .", "label": "", "metadata": {}, "score": "80.48498"}
{"text": "Clin Cancer Res 2011 , 17 : 5132 - 5139 .PubMed View Article .Breast Cancer Res Treat 2013 , 139 : 107 - 113 .", "label": "", "metadata": {}, "score": "80.54172"}
{"text": "PubMed View Article .Cancer 2011 , 117 : 1837 - 1846 .PubMed View Article .N Engl J Med 2001 , 344 : 783 - 792 .", "label": "", "metadata": {}, "score": "80.69097"}
{"text": "The lipid phosphatase PTEN dephosphorylates PIP3 to create PIP2 , counteracting the kinase function of PI3K. Three human p110 isoforms exist ( alpha , beta , and delta ) and are encoded by distinct genes .", "label": "", "metadata": {}, "score": "81.25563"}
{"text": "PubMed Central PubMed View Article Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer . 1 Department of Haematology - Oncology , National University Cancer Institute , National University Health System , Singapore 119228 2 Cancer Science Institute , National University of Singapore , Singapore 117599 .", "label": "", "metadata": {}, "score": "81.72041"}
{"text": "Giampaolo Bianchini Department of Medical Oncology , Ospedale San Raffaele , 20132 Milan , Italy Lancet Oncol 15:e58 - 68 .Research - based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study .", "label": "", "metadata": {}, "score": "81.914795"}
{"text": "J Clin Oncol 2013 , 31 : 1719 - 1725 .PubMed View Article .Baker H : 2013 San Antonio Breast Cancer Symposium .Lancet Oncol 2014 , 15 : 138 .", "label": "", "metadata": {}, "score": "82.04166"}
{"text": "Nicola Nicolai Urology , Fondazione IRCCS Istituto Nazionale dei Tumori , Milan , Italy BJU Int 104:340 - 6 .Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer .", "label": "", "metadata": {}, "score": "82.42249"}
{"text": "1411 - 1420 , 2012 .View at Google Scholar . D. Yee , \" Insulin - like growth factor receptor inhibitors : baby or the bathwater ? \"", "label": "", "metadata": {}, "score": "82.77797"}
{"text": "Abbreviations .Competing interests .FC has received unrestricted research grants from Hoffmann - La Roche ( Grenzach - Wyhlen , Germany ) and GlaxoSmithKline ( Uxbridge , Middlesex , UK ) and has participated in advisory boards for GlaxoSmithKline .", "label": "", "metadata": {}, "score": "83.40866"}
{"text": "In addition , lapatinib has been shown to upregulate HER3 .HER3 possesses multiple PI3 K binding sites in its cytoplasmic tail ; as a result , HER2/HER3 represents the most potent erbB dimer pair due to activation of PI3 K signaling [ 139 - 141 ] .", "label": "", "metadata": {}, "score": "83.70025"}
{"text": "Heat shock protein 90 ( HSP90 ) is a chaperone which stabilizes oncogenic proteins .Inhibition of HSP90 leads to the degradation of these proteins involved in cancer biology [ 69 ] .", "label": "", "metadata": {}, "score": "83.863014"}
{"text": "PubMed View Article .Br J Cancer 2012 , 106 : 1367 - 1373 .PubMed Central PubMed View Article .N Engl J Med 2006 , 355 : 2733 - 2743 .", "label": "", "metadata": {}, "score": "83.86349"}
{"text": "The GeparQuinto study described in Figures 3 , 4 , 5 is an example of one such ' learn on the way ' approach [ 7 ] .", "label": "", "metadata": {}, "score": "83.89801"}
{"text": "Anthracyclines .Luca Gianni Division of Medical Oncology A , Istituto Nazionale Tumori , Milan , Italy Cancer Chemother Biol Response Modif 21:29 - 40 .", "label": "", "metadata": {}, "score": "84.387085"}
{"text": "Domains I , II , and IV of the extracellular region were involved in HER2-EGFR heterodimerization [ 19 ] .The intracellular portion still plays a critical role in mediating optimal receptor - receptor interactions ; the relative contributions of various regions of the HER2 protein in facilitating dimerization are comprehensively reviewed elsewhere [ 20 ] .", "label": "", "metadata": {}, "score": "84.7834"}
{"text": "They note that , although rare , extra - pulmonary large or small cell neuroendocrine tumors occur in a wide variety of organs .The NCCN guidelines state that the cervix is the most common extra - pulmonary location of these tumors , followed by the esophagus , larynx and pharynx , colon and rectum , and prostate .", "label": "", "metadata": {}, "score": "85.00274"}
{"text": "Maurizio Callari Department of Experimental Oncology and Molecular Medicine , Fondazione IRCCS Istituto Nazionale dei Tumori , Milan , Italy PLoS ONE 9:e86511 .", "label": "", "metadata": {}, "score": "85.23789"}
{"text": "The primary objectives were ORR by independent review and safety .Most AEs were grades 1 to 2 ; the most frequent grade greater than or equal to 3 events were thrombocytopenia ( 9.1 % ) , fatigue ( 4.5 % ) , and cellulitis ( 3.6 % ) .", "label": "", "metadata": {}, "score": "85.26251"}
{"text": "Median PFS gain was 12 weeks for the high pS6 level subgroup ( HR 0.48 ; 95 % CI 0.24 to 0.96 ) and 18 weeks for the low PTEN subgroup ( HR 0.41 ; 95 % CI 0.20 to 0.82 ) .", "label": "", "metadata": {}, "score": "85.42579"}
{"text": "PubMed View Article .N Engl J Med 2005 , 353 : 1659 - 1672 .PubMed View Article .J Clin Oncol 2005 , 23 : 3676 - 3685 .", "label": "", "metadata": {}, "score": "85.79068"}
{"text": "Like many small molecule tyrosine kinase inhibitors , lapatinib is generally well tolerated .The most common side effects reported are diarrhea , fatigue , nausea and rash .", "label": "", "metadata": {}, "score": "85.8271"}
{"text": "Aron Goldhirsch Department of Medicine , European Institute of Oncology , Milan , Italy Lancet 382:1021 - 8 .International expert consensus on primary systemic therapy in the management of early breast cancer : highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer , Cremona , Italy ( 2010 ) .", "label": "", "metadata": {}, "score": "86.132965"}
{"text": "Org \u00a9 2015 All Rights Researved Princeton , New Jersey 08540 , USA FDA Approves Perjeta for Type of Late - Stage Breast Cancer .New Anti - HER2 Therapy to Treat Patients with HER2-positive Metastatic Breast Cancer .", "label": "", "metadata": {}, "score": "86.15908"}
{"text": "The other category is small cell lung cancer ( SCLC ) , which represents the remaining 20 % .This distinction of NSCLC versus SCLC is made based on the appearance of the lung cancer cells under the microscope , as well as their clinical behavior and influences treatment recommendations .", "label": "", "metadata": {}, "score": "86.50551"}
{"text": "Giampaolo Bianchini Department of Medical Oncology , hSR San Raffaele , Via Olgettina 60 , Milano 20132 , Italy J Natl Cancer Inst Monogr 2011:91 - 4 .", "label": "", "metadata": {}, "score": "86.77037"}
{"text": "Investigator - assessed median PFS was 12.4 months ( 95 % CI : 10.4 to 13.5 ) in the placebo group and 18.7 months ( 16.6 to 21.6 ) in the pertuzumab group ( HR 0.69 , 95 % CI : 0.58 to 0.81 ) .", "label": "", "metadata": {}, "score": "87.10092"}
{"text": "N Engl J Med 2012 , 367 : 1783 - 1791 .PubMed View Article .Lancet Oncol 2014 , 15 : 689 - 699 .", "label": "", "metadata": {}, "score": "87.17035"}
{"text": "Small tyrosine kinase inhibitors : Lapatinib and neratinib .Lapatinib .Lapatinib is a small molecule , dual tyrosine kinase inhibitor ( TKI ) of EGFR and HER2 .", "label": "", "metadata": {}, "score": "87.50111"}
{"text": "About 170,000 new cases of lung cancer are diagnosed each year in the U.S. , and lung cancer is the leading cause of cancer death worldwide in both men and women .", "label": "", "metadata": {}, "score": "87.59749"}
{"text": "Clin Cancer Res 2014 , 20 : 1935 - 1945 .PubMed View Article .J Clin Oncol 2007 , 25 : 5410 - 5417 .", "label": "", "metadata": {}, "score": "87.93318"}
{"text": "N Engl J Med 2012 , 366 : 109 - 119 .PubMed View Article .Ann Oncol 2013 , 24 : 2278 - 2284 .", "label": "", "metadata": {}, "score": "88.08714"}
{"text": "Acknowledgments .The author wishes to acknowledge the funding support no . R01CA157754 and the Winship Cancer Institute Breast Cancer Program Pilot Award .References .", "label": "", "metadata": {}, "score": "88.43632"}
{"text": "Technology Appraisal Guidance 107 .London , UK : NICE ; August 2006 .Accessed April 4 , 2007 .Smith I , Procter M , Gelber RD , et al ; HERA study team .", "label": "", "metadata": {}, "score": "88.57545"}
{"text": "Competing interests .Pernelle Lavaud declares that she has no competing interests .Fabrice Andr\u00e9 has a Research contract and is on the Advisory Board for Novartis and Astra Zeneca .", "label": "", "metadata": {}, "score": "88.80496"}
{"text": "The most common AEs reported in patients treated with Kadcyla were constipation , fatigue , headache , elevated levels of liver enzymes , nausea , pain in the muscles or joints , and thrombocytopenia .", "label": "", "metadata": {}, "score": "89.011765"}
{"text": "Reprinted with permission from GlaxoSmithKline and SOLTI ( Spanish Breast Cancer Cooperative Group ) .The ' learn on the way ' design uses information gained from an initial treatment period to guide decisions regarding further therapy .", "label": "", "metadata": {}, "score": "90.37335"}
{"text": "J Clin Oncol .Additional Information .Copyright Aetna Inc.All rights reserved .Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice .", "label": "", "metadata": {}, "score": "90.98718"}
{"text": "J9264 .Injection , paclitaxel protein - bound particles , 1 mg .J9265 .Paclitaxel , 30 mg .ICD-10 codes covered if selection criteria are met : .", "label": "", "metadata": {}, "score": "91.007965"}
{"text": "The overall response rate ( ORR ) was 22 % , the CBR was 59 % , the median PFS was six months and the median OS was seventeen months [ 71 ] .", "label": "", "metadata": {}, "score": "91.140305"}
{"text": "J Clin Oncol 2010 , 28 : 2024 - 2031 .PubMed View Article .J Clin Oncol 2008 , 26 : 1789 - 1796 .", "label": "", "metadata": {}, "score": "91.19516"}
{"text": "PubMed Central PubMed .J Clin Oncol 2010 , 28 : 1301 - 1307 .PubMed View Article .Eur J Cancer 2013 , 49 : 3763 - 3772 .", "label": "", "metadata": {}, "score": "91.559074"}
{"text": "Carmelo Carlo - Stella Cristina Gandini Medical Oncology Unit , Istituto Nazionale Tumori , Milan , Italy Clin Cancer Res 13:2313 - 7 .The clinical translation of cell and gene therapy approaches represent a challenging strategy that might achieve systemic tumor targeting and increased intratumor delivery of the therapeutic agent ... .", "label": "", "metadata": {}, "score": "92.080536"}
{"text": "Press Release .South San Francisco , CA : Genentech ; April 25 , 2005 .Accessed April 27 , 2005 .National Comprehensive Cancer Network ( NCCN ) .", "label": "", "metadata": {}, "score": "92.27614"}
{"text": "PubMed Central PubMed View Article .Cancer Chemother Pharmacol 2013 , 72 : 1205 - 1212 .PubMed View Article .Ann Oncol 2013 , 24 : 109 - 116 .", "label": "", "metadata": {}, "score": "92.62158"}
{"text": "Downers Grove , IL : Vysis Inc. ; December 14 , 1998 .Accessed September 20 , 1999 .DAKO Inc.DAKO HercepTest \u2122 Information Center .", "label": "", "metadata": {}, "score": "92.67095"}
{"text": "Class Ia PI3Ks are heterodimers of a p85 regulatory subunit and p110 catalytic subunit [ 27 ] .Upon growth factor stimulation , p85 binds to membrane bound receptors or adaptor proteins , thus recruiting PI3 K to the cell membrane .", "label": "", "metadata": {}, "score": "93.28122"}
{"text": "Luca Gianni Istituto Nazionale Tumori , Milan , Italy , and Hospital Vall d Hebron , Barcelona , Spain Clin Cancer Res 11:8715 - 21 .", "label": "", "metadata": {}, "score": "93.625015"}
{"text": "Cerebrospinal fluid ( CSF ) response was noted in 66.7 % of cases .The median OS was 13.5 months , whereas the median central nervous system - progression - free survival ( CNS - PFS ) was 7.5 months .", "label": "", "metadata": {}, "score": "94.0773"}
{"text": "Gynecol Oncol .National Comprehensive Cancer Network ( NCCN ) .Esophageal cancer .NCCN Clinical Practice Guidelines in Oncology .Version.1.2010 .Fort Washington , PA : NCCN ; 2010 .", "label": "", "metadata": {}, "score": "94.97447"}
{"text": "Luca Gianni Division of Medical Oncology , Fondazione Istituto di Ricovero e Cura a Carattere Scientifico , Instituto Nazionale Tumori , Milan , Italy J Clin Oncol 26:3777 - 84 .", "label": "", "metadata": {}, "score": "95.19325"}
{"text": "Horizon Scanning Technology Briefing .Birmingham , UK : National Horizon Scanning Centre ; 2006 .National Institute for Health and Clinical Excellence ( NICE ) .", "label": "", "metadata": {}, "score": "96.057594"}
{"text": "Other HCPCS codes related to the CPB : . J9171 .Injection , docetaxel , 1 mg .J9265 .Injection , paclitaxel , 30 mg .", "label": "", "metadata": {}, "score": "96.31151"}
{"text": "N Engl J Med 2012 , 366 : 2443 - 2454 .PubMed Central PubMed View Article .N Engl J Med 2012 , 366 : 2455 - 2465 .", "label": "", "metadata": {}, "score": "96.81981"}
{"text": "Tucson , AZ : Ventana ; 2002 .Accessed June 20 , 2002 .Crump M , O'Malley F ; Breast Cancer Disease Site Group .", "label": "", "metadata": {}, "score": "96.872604"}
{"text": "Report No . 23 .Montreal , QC : Technology Assessment Unit of the McGill University Health Centre ( MUHC ) ; 2006 .National Horizon Scanning Centre .", "label": "", "metadata": {}, "score": "97.59335"}
{"text": "Median duration of response was not reached as a result of insufficient events ( lower limit of 95 % CI : 6.2 months ) , and median PFS time was 4.6 months ( 95 % CI : 3.9 to 8.6 months ) .", "label": "", "metadata": {}, "score": "97.93974"}
{"text": "PMA No . P980024/S001 .Issued December 31 , 2001 .Rockville , MD : FDA ; April 25 , 2002 .Accessed June 20 , 2002 .", "label": "", "metadata": {}, "score": "99.42707"}
{"text": "12 , pp .4892 - 4900 , 2001 .View at Google Scholar \u00b7 View at Scopus .61 , no .12 , pp .", "label": "", "metadata": {}, "score": "105.00484"}
{"text": "NCCN Clinical Practice Guidelines in Oncology , Version 1.2014 .Fort Washington , PA : NCCN ; 2014 .National Comprehensive Cancer Network ( NCCN ) .", "label": "", "metadata": {}, "score": "105.28479"}
{"text": "6 , pp .3247 - 3252 , 1990 .View at Google Scholar \u00b7 View at Scopus .91 , no .5 , pp .", "label": "", "metadata": {}, "score": "105.49098"}
{"text": "17 , pp .5404 - 5413 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . 9 , no . 3 , pp .", "label": "", "metadata": {}, "score": "105.58498"}
{"text": "34 , pp .5838 - 5847 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .112 , no . 3 , pp .", "label": "", "metadata": {}, "score": "105.66414"}
{"text": "29 , no .23 , pp .3126 - 3132 , 2011 .View at Publisher \u00b7 View at Google Scholar .28 , supplement 15s , 2010 , Abstract 1013 .", "label": "", "metadata": {}, "score": "105.69017"}
{"text": "15 , pp .5027 - 5037 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .122 , pp . 1066 - 1075 , 2012 .", "label": "", "metadata": {}, "score": "106.345375"}
{"text": "PubMed View Article .J Clin Oncol 2012 , 30 : 1594 - 1600 .PubMed View Article .Lancet Oncol 2013 , 14 : 461 - 471 .", "label": "", "metadata": {}, "score": "106.55185"}
{"text": "NCCN Clinical Practice Guidelines in Oncology , Version 1.2015 .Fort Washington , PA : NCCN ; 2015 .National Comprehensive Cancer Network ( NCCN ) .", "label": "", "metadata": {}, "score": "106.70715"}
{"text": "PL performed literature review and wrote the manuscript .FA wrote the manuscript .Both authors read and approved the final manuscript .Authors ' Affiliations .", "label": "", "metadata": {}, "score": "107.37513"}
{"text": "135 , no . 3 , pp .655 - 662 , 2012 .View at Google Scholar .13 , pp .135 - 144 , 2012 .", "label": "", "metadata": {}, "score": "108.33538"}
{"text": "16 , pp .4226 - 4235 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .226 , no . 1 , pp .", "label": "", "metadata": {}, "score": "108.57469"}
{"text": "5 , pp .1507 - 1514 , 1994 .View at Google Scholar \u00b7 View at Scopus .91 , no .4 , pp .", "label": "", "metadata": {}, "score": "108.59778"}
{"text": "116 , no .18 , pp .4227 - 4237 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "108.87235"}
{"text": "Information in the [ brackets ] below has been added for clarification purposes .& nbspCodes requiring a 7th character are represented by \" + \" : .", "label": "", "metadata": {}, "score": "109.13712"}
{"text": "2005 ASCO Annual Meeting Proceedings . 41stAmerican Society of Clinical Oncology Annual Meeting ; 13 - 17 May 2005 ; Orlando , FL .2008 ASCO Annual Meeting Proceedings .", "label": "", "metadata": {}, "score": "109.585266"}
{"text": "PubMed Central PubMed View Article .J Clin Oncol 2013 , 31 : 1947 - 1953 .PubMed View Article .J Clin Oncol 2012 , 30 : 2585 - 2592 .", "label": "", "metadata": {}, "score": "109.7923"}
{"text": "17 , pp .5650 - 5655 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .61 , no .", "label": "", "metadata": {}, "score": "109.865524"}
{"text": "4744 - 4749 , 2001 .View at Google Scholar \u00b7 View at Scopus .16 , no . 2 , pp .234 - 239 , 2005 .", "label": "", "metadata": {}, "score": "111.17156"}
{"text": "10 , pp .2149 - 2157 , 1996 .View at Google Scholar \u00b7 View at Scopus .98 , no .10 , pp .", "label": "", "metadata": {}, "score": "111.57715"}
{"text": "16 , pp .3676 - 3685 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .29 , pp .", "label": "", "metadata": {}, "score": "112.40158"}
{"text": "9 , no .6 , pp .1489 - 1502 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "112.70128"}
{"text": "5 , pp .1706 - 1716 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .100 , p. 3039 , 2006 .", "label": "", "metadata": {}, "score": "112.7906"}
{"text": "6 , no . 2 , pp .667 - 674 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "112.81828"}
{"text": "68 , no .22 , pp .9221 - 9230 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "112.92578"}
{"text": "1124 - 1130 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .30 , pp .2585 - 2592 , 2012 .", "label": "", "metadata": {}, "score": "113.08"}
{"text": "69 , no .24 , pp .9330 - 9336 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "113.25828"}
{"text": "64 , no . 7 , pp .2343 - 2346 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "113.67234"}
{"text": "1090 - 1099 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . 94 , no .21 , pp .", "label": "", "metadata": {}, "score": "114.28975"}
{"text": "515 - 523 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .23 , no .16 , pp .", "label": "", "metadata": {}, "score": "114.292915"}
{"text": "40 , no .4 , pp .488 - 507 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "114.502205"}
{"text": "5 , pp .1629 - 1640 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .103 , no .", "label": "", "metadata": {}, "score": "114.53319"}
{"text": "AETMIS 08 - 03 .Montreal , QC : Agence d'Evaluation des Technologies et des Modes d'Intervention en Sante ( AETMIS ) ; May 2008 .", "label": "", "metadata": {}, "score": "114.709885"}
{"text": "National Comprehensive Cancer Network ( NCCN ) .Central nervous system cancers .NCCN Clinical Practice Guidelines in Oncology , Version 2.2013 .Fort Washington , PA : NCCN ; 2013 .", "label": "", "metadata": {}, "score": "114.752884"}
{"text": "94 , no . 2 , pp .259 - 267 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "115.24347"}
{"text": "91 - 96 , 2010 .View at Google Scholar \u00b7 View at Scopus .106 , no . 8 , pp .1367 - 1373 , 2012 .", "label": "", "metadata": {}, "score": "115.46292"}
{"text": "737 - 744 , 1996 .View at Google Scholar \u00b7 View at Scopus .17 , no . 9 , pp .2639 - 2648 , 1999 .", "label": "", "metadata": {}, "score": "116.14993"}
{"text": "5 , pp .1618 - 1624 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .62 , no .", "label": "", "metadata": {}, "score": "116.370575"}
{"text": "99 , no . 9 , pp .694 - 705 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "116.41113"}
{"text": "Lancet Oncol 2013 , 14 : 1183 - 1192 .PubMed View Article .Lancet 2012 , 379 : 633 - 640 .PubMed View Article .", "label": "", "metadata": {}, "score": "116.86885"}
{"text": "1720 - 1730 , 2002 .View at Google Scholar \u00b7 View at Scopus . 1 , no . 2 , pp .85 - 94 , 2001 .", "label": "", "metadata": {}, "score": "117.16919"}
{"text": "15 , pp .5132 - 5139 , 2011 .View at Google Scholar .29 , 2011 , Abstract 590 .View at Google Scholar .", "label": "", "metadata": {}, "score": "118.21982"}
{"text": "1630 - 1639 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .30 , pp .2585 - 2592 , 2012 .", "label": "", "metadata": {}, "score": "120.50389"}
{"text": "231 - 239 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .29 , 2011 , Abstract 119 .", "label": "", "metadata": {}, "score": "122.46198"}
{"text": "379 , pp .633 - 640 , 2012 .View at Google Scholar .30 , pp .1989 - 1995 , 2012 .View at Google Scholar .", "label": "", "metadata": {}, "score": "123.188"}
{"text": "109 - 119 , 2012 .View at Google Scholar .13 , pp .25 - 32 , 2012 .View at Google Scholar .", "label": "", "metadata": {}, "score": "123.86798"}
{"text": "Academic Editor : Mary Cianfrocca .Copyright \u00a9 2012 Andrea L. A. Wong and Soo - Chin Lee .This is an open access article distributed under the Creative Commons Attribution License , which permits unrestricted use , distribution , and reproduction in any medium , provided the original work is properly cited .", "label": "", "metadata": {}, "score": "124.649994"}
{"text": "All rights reserved .The material on this site is for informational purposes only , and is not a substitute for medical advice , diagnosis or treatment provided by a qualified health care provider .", "label": "", "metadata": {}, "score": "126.26555"}
{"text": "View at Google Scholar .375 , no .9712 , pp .377 - 384 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "128.98544"}
{"text": "View at Google Scholar .29 , no . 2 , pp .166 - 173 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "130.63617"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .24 , no .41 , pp .6213 - 6221 , 2005 .", "label": "", "metadata": {}, "score": "131.16786"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . 13 , no . 1 , pp .228 - 233 , 2007 .", "label": "", "metadata": {}, "score": "132.36024"}
{"text": "Academic Editors : Y. Akiyama , S. Mohanam , and T. T. Trangas .Copyright \u00a9 2012 Rita Nahta .This is an open access article distributed under the Creative Commons Attribution License , which permits unrestricted use , distribution , and reproduction in any medium , provided the original work is properly cited .", "label": "", "metadata": {}, "score": "133.26791"}
{"text": "View at Google Scholar .98 , no . 1 , pp .80 - 85 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "133.65933"}
{"text": "Academic Editor : Gunter Von Minckwitz .Copyright \u00a9 2013 S. Guiu et al .This is an open access article distributed under the Creative Commons Attribution License , which permits unrestricted use , distribution , and reproduction in any medium , provided the original work is properly cited .", "label": "", "metadata": {}, "score": "134.45163"}
